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1.Stroke  
1.1. Definition 
Stroke is a cerebrovascular disease, consequence of the 
alteration of normal cerebral blood flow, which results in a 
transient or permanent deficit of the function of one or more 
parts of the brain. This alteration of normal cerebral blood 
flow induces metabolic or biochemical alterations and would 
lead to cell death, and consequently, the alteration of the 
nervous system. The World Health Organization (WHO) has 
defined stroke as the fast clinical development of focal signs 
of alteration of cerebral function without any other apparent 
origin than the vascular one.1 
1.2. Epidemiology 
Stroke is the major cause of mortality and morbidity 
worldwide. According to the World Health Organization, the 
world average incidence of cerebrovascular disease is around 
200 new cases per 100.000 inhabitants 2. In Europe exist 
differences between northern and southern populations, 
being the most high figures in Nordic countries such as 
Finland (270 per 100.000 in men), and less in others such as 
Italy and Portugal (100 per 100.000 men).3 The incidence of 
Spain is 167 per 100.000 / year (181 for men and 153 for 
women), being higher in Galicia by the aging population.4 
In developed countries, the prevalence of stroke adjusted by 
age in people over 64 years is between 4.6 and 7.3%. It is 
higher in men (5.9 to 9.3%) than females (3.2 to 6.1%) and 
increases with age.5 In Spain, the rate of prevalence 
specifies-age was 4.9% for the total of cerebrovascular 
disease and 3.5% for ischemic stroke.6 Due to the 
progressive aging of Europe's population in general, and the 
Spanish and Galician in particular, the incidence and 
María Pérez Mato  Introduction 
24 
 
prevalence of stroke increase progressively, which will lead to 
a serious social health. 
Therefore, the stroke is a health problem that requires 
establishing better guidelines for prevention and treatment to 
reduce their incidence as the degree of disability that 
originates. Considering that the incidence increases in people 
over 65 years and, based on an improvement in the quality 
of life, is taking a significant increase in life expectancy and a 
progressive aging of the world population, the prevalence of 
this disease increases, and with it, the magnitude of the this 
social problem. 
1.3. Classification of stroke 
Focusing on the nature of the lesion, stroke can be classified 
in two main groups, ischemic and hemorrhagic stroke. 
However, alternative classifications of this cerebrovascular 
disease can be used looking at other parameters such as 
stroke subtype, progression profile, neuroimaging 
characteristics, size and topography of the lesion, nature, 
and the mechanisms of induction and etiology.7, 8 
1.3.1. Ischemic Stroke 
Ischemic stroke is the most common type of stroke, and 
represents about the 80% of all strokes.7, 9-11 Among the 
focal brain ischemia, we can differentiate between transient 
ischemic attack (TIA) and cerebral infarction. TIA is defined 
as the focal or monocular cerebral dysfunction with 
symptoms that last for less than 1h, whose origin is a 
vascular insufficiency caused by an arterial thrombus or 
embolism, associated to arterial, cardiac or hematologic 
disease.12 TIA patients present higher risk of subsequent 
major stroke and other vascular episodes, mainly coronary, 
and the outcome of each individual is extraordinarily 
variable. Cerebral infarction is defined as the lesion caused 
by an intense or prolonged ischemia, which produce 
irreversible loss of cells. 
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In case of cerebral infarction and attending to the etiology, 
different ischemic stroke subtypes can be divided:11  
• Atherothrombotic infarction: (~20%) generally 
middle or large sized infarcts with cortical, 
subcortical, carotid or vertebro-basilar topography, in 
patients with presence of one or several 
cerebrovascular risk factors. It is imperative the 
presence of clinically generalized atherosclerosis, or 
the demonstration of occlusion or stenosis (> 50% 
occlusion or <50% plus two or more vascular risk 
factors) in cerebral arteries, with an established 
correlation to the patient’s clinic. 
• Lacunar infarction or small vessel disease: (~25%) 
small sized infarct (<15 mm of diameter), localized in 
the distribution territory of the penetrating arterioles. 
Although micro-atheromatosis and lipohialinosis of 
penetrating arterioles are the most frequent 
pathologic substrate in lacunar infarcts, other less 
frequent potential causes are cardiac embolism, 
arterial embolism, infectious arthritis or 
prothrombotic state. 
• Cardioembolic infarction: (~20%) generally medium 
(1.5-3 cm of diameter) or large (>3 cm of diameter) 
sized infarcts, with symptoms frequently started 
during awakening. It is mandatory the presence of a 
demonstrated embolic origin, and the absence of 
significant concomitant arterial occlusion or stenosis. 
• Infarction of undetermined etiology: (~30%) brain 
infarcts of medium or large size with more than two 
potential etiologies or unknown origin. 
• Other causes (~5%). 
1.3.2. Hemorrhage stroke 
Among all cerebrovascular diseases, the pathologic group of 
hemorrhages corresponds to approximately 15% of all 
strokes. This percentage excludes those derived from 
cranioencephalic trauma. In essence, it consists in a blood 
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extravasation, secondary to the breakage of a blood vessel, 
either arterial or venous, by diverse mechanisms. 
The most common cause of hemorrhage is arterial 
hypertension. For other causes, except amyloidal angiopathy 
(typical in elderly people and perhaps the most frequent 
cause after hypertension), the list of potential origins in 
infant and young individuals can be summarized in: vascular 
malformations (aneurisms, arteriovenous malformations), 
drugs (antiplatelet, adrenergic stimulants), toxics (alcohol, 
cocaine, poison), hematological diseases (blood dyscrasia, 
coagulopathy), brain vasculopathy, primary or mestastatic 
tumors, and others.13 
1.4. Biochemistry of cerebral ischemia 
The acute obstruction of one of the large brain arteries 
induces an instantaneous reduction of blood flow in the 
corresponding irrigation area (focal ischemia). But that 
reduction of blood supply is not homogeneous in the affected 
area, and can change within min or h, especially if blood 
supply is not reinstated.14 
Two regions can be distinguished: the ischemic core is the 
portion of tissue closest to the affected blood vessel and 
where the ischemia becomes severe, and the so-called 
penumbra, where the reduction of blood flow is less severe, 
due to the blood supply carried out by collateral arteries of 
the non-ischemic neighbor tissue.15 The impact of brain 
ischemia will depend on the level of the artery occlusion and 
duration of the reduction of blood flow, which is why time is a 
very important parameter in this disease. 
After the onset of brain ischemia, a sequence of molecular 
events are triggered in the short and the long term, initiated 
with an energetic failure in cells, related to the interruption of 
oxidative phosphorylation processes and the deficient 
production of adenosine tri-phosphate (ATP) (Figure 1).  
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Figure 1: Sequence of main physiopathological events in cerebral ischemia. 
The cessation of transmembrane ionic gradients due to the 
failure of sodium-potassium-ATPase pumps, and other ATP-
dependent ionic pumps, is the key step of the 
physiopathological mechanisms in stroke, especially of cell 
death in the ischemic core, when the vascular occlusion lasts 
for few min.16 Neurons and glial cells suffer an extreme 
depolarization because of the entrance of sodium, chloride, 
calcium and water into the cytoplasm17 and in addition, 
potassium leaves the cell, inducing a sudden increment of its 
extracellular levels.18 The energetic failure and the associated 
ionic changes, originate an increment in glutamate, a 
hyperexcitability of N-methyl-D-aspartate glutamatergic 
(NMDA) receptors (NMDAr), and of α-amino-3-hydroxy-5-
methyl-4-isoxazol propionic acid (AMPA) receptors (AMPArs), 
which induces an even higher increase of intracellular calcium 
(Figure 2).19-21 
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Figure 2: Role of glutamate on the stimulation of AMPA and NMDA receptors. 
The increase of intracellular calcium does not exclusively 
depend on the activation of glutamate receptors, but also in 
the stimulation of calcium voltage-dependent channels. 
Hyperexcitability causes a depolarization phenomenon in the 
periphery of the infarct, which increases the energetic cost 
while the membrane tries to re-polarize itself.15, 22, 23 Calcium 
increment, together with acidosis and peri-infarct 
depolarization, contributes to initiate the damage, and after 
it, inflammation and activation of apoptotic phenomena 
contribute to increment the lesion.21, 24 During ischemia, and 
particularly during reperfusion, free radicals are generated. 
These are highly reactive species produced at the initial and 
late stages of brain ischemia, following different 
physiopathological mechanisms. In first place, oxygen 
reactive species are produced by the metabolism of 
arachidonic acid and the activity of neuronal Nitric Oxide 
(NO) synthase (nNOS). During intermediate stages, free 
oxygen radicals are provided by the infiltration of neutrophils 
in the ischemic area. At later stages, they are produced via 
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the synthesis and activation of inducible NO synthase 
enzymes (iNOS) and cycloxigenase-2(COX-2).25, 26 Ischemic 
stroke triggers a series of complex molecular events, where 
the activation and the expression of genes are included. 
However, ischemic cellular death can take place in two 
different ways. The most common one is necrosis,27 which is 
the result of the acute energetic failure, mainly located in the 
core region of the lesion zone, and it is characterized by 
morphology changes and, at the end, cellular lysis, which 
also triggers inflammatory processes.28 On the other hand, 
apoptotic or programmed cell death, in the region around the 
core region, can be observed when energy-dependent 
intracellular mechanisms are activated, leading to cell 
degradation.24, 29  
1.5. Therapeutic approaches for the 
treatment of stroke. 
1.5.1. Thrombolysis and neuro-interventionism in 
acute phase of stroke. 
Pharmacological or mechanical (thrombectomy) thrombolysis 
are the strategies that report higher benefits for the patient, 
in terms of neurological outcome. The most common 
thrombolytic agent is the recombinant tissue plasminogen 
activator or rt-PA, and enzyme involve in the clot 
degradatadion of the occluded vessel. The thrombectomy is a 
technique which allows the extraction of the thrombus by a 
mechanical device. Both therapies have pushed for the 
creation of stroke units inside hospitals, which have improved 
the management of stroke patients. Nevertheless only 3-7% 
of stroke patients are currently treated by these procedures 
in most developed countries. Such reduced numbers may be 
due to different factors, including the narrow therapeutic 
window and the high risks of hemorrhage transformation. 
Current neuroprotective strategies are required to work at 
both stages, by widening the therapeutic window and by 
María Pérez Mato  Introduction 
30 
 
reducing the associated risk factors.30-34 The therapeutic 
window associated with intravenous thrombolytic treatment 
is 4.5 h. The extension of this window may be possible by 
selecting candidate patients with a large penumbral area (the 
area of the brain susceptible to damage unless otherwise 
protected within the first 24-48 h).35 
1.5.2. Neuroprotection 
Neuroprotection is a term that conglomerates a variety of 
strategies focused in reducing cell death after an ischemic 
event, without affecting tissue reperfusion. So far, several 
compounds have been proposed to block the pathway leading 
to ischemia-induced cell death at different steps of the 
ischemic cascade. Most of these compounds have shown 
positive effects in experimental studies, although 
unfortunately none of them have shown beneficial effect in 
clinical trials.36 Figure 3 shows clinical trials of 
neuroprotectans in acute ischemic stroke with failed results, 
data provide by the Internet Stroke Center and Stroke Trials 
Registry.37 
Neuroprotective drugs can be classified mainly into different 
groups regarding their action mechanism. 
a. Calcium blockers 
Calcium plays an important role in stroke pathophysiology. 
The blockage of calcium channels stops neuronal calcium 
intake, hence reducing cell death. Nimodipine is an example 
of this family of compounds. Over 250 animal studies of 
nimodipine in cerebral ischemia have been published, but 
only 10 of these studies reported a positive outcome.36 None 
of the members of this family of compounds have 
demonstrated a clear neuroprotective activity on clinical 
trials. Among the reasons for this fact, overall the studies 
that generated positive results, animals were mostly treated 
within the first 15 min post-ischemia, which is not 
translatable to the clinical settings. 
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b. Glutamate antagonists  
It is well established that glutamate, the major excitatory 
CNS neurotransmitter, is also capable of inducing excitotoxic 
neural injury in the setting of cerebral ischemia and other 
disorders. Glutamate and related excitatory amino acids 
interact with several receptor-classes, which are relevant to 
neuroprotection. These include the NMDA and AMPA 
receptors.37 
Antagonists of NMDA receptors reduce infarct size and 
neurological deficit in animal models of focal cerebral 
ischemia, but its clinical use has presented several side 
effects, especially cardiovascular and psychiatric effects. For 
example, selfotel, a competitive antagonist of NMDA 
receptors has shown improve of outcome and no significant 
increase of mortality in a phase III study, but a high 
incidence of psychiatric adverse effects conditioned its 
withdrawal from clinical phases. Likewise, dextromethorphan 
and its metabolites dextrorphan and aptiganel were 
discontinued by an unfavorable relationship between risk and 
benefit and increased adverse effects. Eliprodil reduces the 
action of glutamate by interfere with sensor polyamine site 
on the NMDA receptor, but showed no difference with 
placebo. The gavestinel, antagonist of the NMDA receptor 
glycine, showed excellent tolerance, but no efficacy.38  
On the other hand several AMPA antagonists showed 
neuroprotective efficacy in preclinical studies of both focal 
and global cerebral ischemia, but successful in larger clinical 
trials has not been reported.37  
c. Antioxidants 
Oxidative stress is another mechanism implicated on cell 
death after an ischemic event. Antioxidants could therefore 
play a role as neuroprotective drugs. The most successful 
antioxidant tested has been NXY-059. This drug reduced 
brain infarct by 66% in animal models, when injected even 5 
h after occlusion. The first clinical trial generated positive 
María Pérez Mato  Introduction 
32 
 
results, improving patient’s functional outcome. However a 
second clinical trial showed negative results.39  
Another antioxidant that reached clinical phase is uric acid, 
an antioxidant with neuroprotective effects in experimental 
models of stroke. A recent clinical trial40 assessed whether 
uric acid therapy would improve functional outcomes at 90 
days in patients with acute ischaemic stroke. The results 
showed that uric acid treatment is safe but did not increase 
the proportion of patients who achieved excellent outcome 
after stroke compared with placebo. 
d. Phospholipid precursors: citicoline 
Citicoline or CDP-choline is a precursor on the synthesis of 
phosphate-choline, which is integrated in the membrane of 
neurons. It has been shown that citicoline inhibits 
norepinephrine and dopamine levels on the CNS, and 
restores mitochondrial ATPase activity.41 On animal models, 
citicoline lowered the phospholipase 2 activation after brain 
ischemia, reducing arachidonic acid formation and the 
production of free radicals; therefore lowering the oxidative 
stress. Another effects claimed for this drug are its capacity 
to reduce excitotoxicity and the stimulation of brain 
plasticity.42 In preclinical studies, the treatment with 
citicoline immediately after reperfusion led to an 
improvement on functional deficits after a period of 28 
days.43 A pool-data analysis published in 2002 showed a 33% 
increment in complete recovery after mild or severe stroke 
(NIHSS ≥ 8) when the treatment was started within the first 
24 hours and maintained for 6 weeks,44 however a recent 
clinical trial have demonstrated the lack of protective in 
stroke patients.45 
e. Inhibitors of glutamate release 
Inhibitors of glutamate release work by blocking presynaptic 
channels, preventing membrane depolarization and 
glutamate release. One example of this kind of drugs is 
Lubezol, a compound capable of deregulate the glutamate-
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induced nitric oxide synthase pathway. This compound has 
shown hippocampal neuroprotection from nitric oxide 
toxicity. In experimental studies it has shown a 50 % infarct 
volume reduction upon injecting the drug 3 hours after 
ischemia induction. Nevertheless no clinical trial rendered 
positive results, and one of them was cancelled due to the 
mortality increase experimented in the treated group.46 
f. GABA agonists 
This mechanism of action involves potentiation of the activity 
of GABA, the brain´s major inhibitory neurotransmitter. They 
attempt to counteract cellular depolarization caused by 
ischemia. Clomethiazole, which increases the activity of 
GABA, was negative in the first study and a second study of 
patients with total anterior circulation infarcts. The MaxiPost, 
getting hyperpolarisation of neurons by opening potassium 
channels, also showed no benefit.37 
g. Anti-inflammatory 
The anti-inflammatory compounds act by inhibiting any of 
the mechanisms of extensive inflammatory cascade of 
cerebral ischemia. The enlimomab, a monoclonal antibody 
against ICAM-1, which inhibits leukocyte adhesion and 
migration through the vascular endothelium, able to reduce 
infarct size in animal models of transient focal cerebral 
ischemia; however, in a Phase III, the result has been 
negative with a high number of complications. The 
UK279,276, a recombinant protein inhibitor of the 
CD11b/CD18 receptor, showed a low efficacy in clinical 
trial.36 
h. Others 
Several studies have been performed using other 
neuroprotective agents such as neuronal potassium channel 
activators (BMS-204352), membrane fluidity modifiers 
(Piracetam), opioid antagonists (Namefene), growth factors 
employes as intracellular calcium regulators, and much more. 
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None of them have shown the definitive efficacy of 
pharmacological neuroprotection.37 Figure 3 provides an 
overview of categories of neuroportective strategies that 
have progressed to some stage of clinical trial. 
 
Figure 3: Clinical trials of neuroprotectans in acute ischemic stroke with 
failed results. Internet Stroke Center. Stroke Trials Registry.37 
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1.5.3. Neurorepair 
Neurorepair strategies involve the restoration of brain 
function, either by regeneration of damaged cerebral tissue 
(neurogereneration) or by the establishment of alternative 
neural pathways or synapses (brain plasticity). However, 
therapeutic window for those therapies is wider than for 
thrombolytic or neuroprotective approaches. The aim of the 
treatments for neurological function recovery after stroke is 
not restricted to neurons; it is more focused on the 
neurovascular unit, including procedures that enhance 
synaptogenesis and angiogenesis. Thus, neurorepair 
treatments may use stem cells, pro-neurogenic, pro-
angiogenic and/or pro-synaptogenic drug delivery, among 
others. 
a. Neurogenesis after brain ischemia 
In the adult brain there are niches for the production of 
neural stem cells,47 localized in the subventricular region of 
the lateral ventricles (SVZ) and the dentate gyrus of the 
hippocampus. Under normal physiological conditions, the 
neuroblasts produced in the SVZ migrate to the olfactory 
bulb to differentiate in new neurons. After the induction of 
focal brain ischemia in the rat, an increase in neuroblast 
formation occurs in the ipsilateral hemisphere, and these 
neuroblasts migrate to regions surrounding the lesion.48 This 
effect has been also shown in humans.49 The enhancement of 
endogenous neurorepair mechanisms is one of the main 
goals on new therapies for the treatment of stroke. 
Even though newborn stem cells are recruited after an 
ischemic insult, most of them do not get integrated into 
neuronal circuits. Several strategies have been used to 
enhance endogenous neurogenesis. Thus, a great number of 
newly differentiated neurons would be available, increasing 
the chance of survival and integration in neuronal networks, 
therefore improving functional recovery. Both cellular and 
pharmacological therapies have been used to achieve this 
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goal by activating the phosphatidylinositol-3-kinase (PI3-Akt) 
pathway. This pathway is involved in cell survival, 
proliferation, differentiation and migration.50  
b. Angiogenesis after brain ischemia 
The development of the cerebral vascular system occurs 
mainly due to angiogenic processes. During adult life, 
endothelial cell proliferation ceases under normal 
physiological conditions. However, after an ischemic event 
brain capillaries surrounding the lesion proliferate, and new 
vessels are formed between 2 and 28 days after the onset of 
stroke.51-54 
The angiogenic process involves a multi-step procedure that 
comprises endothelial cell proliferation and migration, tubule 
formation, branching and anastomosis. Vascular Endothelial 
Growth Factor (VEGF) and its receptor (VEGFr2) initiate the 
angiogenic process, being angiopoietin 1 and 2 and their 
receptor (TIE-2) responsible for the maturation, stabilization 
and vascular remodeling.55 VEGF and VEGF2 expression 
promotes vascular ramification, and the newly formed 
vessels are highly permeable. Meanwhile angiopoietins and 
TIE2 expression stimulate vessel maturation leading to the 
formation of fully functional brain blood vessels. VEGF 
treatment or therapies focused in producing VEGF, VEGF2, 
angiopoietin or TIE2 expression could increase the 
angiogenesis in the peri-infarct region. 
The angiogenic process is essential for brain recovery after 
cerebral ischemia. In experimental studies both cellular and 
pharmacological therapies have been used to increase 
angiogenesis, promoting the functional recovery of ischemic 
animals.56 
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c. Neurogenesis & angiogenesis 
Neurogenesis and angiogenesis after cerebral ischemia are 
not separated processes. Neurogenesis in the peri-infarct 
region cannot occur without angiogenesis, since the ultimate 
is responsible for restoring the oxygen and nutrient supply. 
Furthermore, endothelial cells produce growth factors that 
allow the neurons to survive, and that regulate metabolic 
activity of neural precursors. Endothelial cells secrete 
Stromal Cell-Derived Factor-1 (SDF-1), VEGF and Matrix 
Metalloproteinases (MMPs) that induce and facilitate neural 
progenitor cell migration to the injured site. On the other 
hand, neural progenitor cells overexpress angiopoietin 2 and 
VEGFR2 leading to an increase in angiogenesis.57 
Several in vitro and in vivo studies have shown the 
relationship between angiogenesis and neurogenesis.57, 58 In 
animal models of ischemia, Tie2 inhibitors not only reduce 
angiogenesis, but also neuroblast migration to the peri-
infarct area. On the other hand, neural progenitor cell grafted 
in the infarct region have demonstrated the induction of 
angiogenesis. These and other studies have reported that 
neurogenesis and angiogenesis are highly connected, and 
both promote neural remodeling and improve neurologic 
function after brain ischemia.59, 60 
d. The role of oligodendrocytes, astrocytes and axons in 
neurorepair 
In the brain parenchyma there are not only neurons, but 
other cellular components as well oligodendrocytes, 
astrocytes and the development of functional axons are also 
involved on neurorepair. After an ischemic event, astrocytes 
proliferate forming a glial scar that surrounds the lesion and 
release proteoglycans that inhibit axonal growth. Hence there 
should be mechanisms for reducing glial scar formation, and 
also to stimulate axonal growth, leading to an efficient 
neurorepair.61 
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2.Glutamate  
2.1. Glutamate  
The glutamate is considered to be the major mediator of 
excitatory signals in the mammalian central nervous system 
and is probably involved in most aspects of normal brain 
function including cognition, memory and learning. 
Glutamate also plays major roles in the development of the 
central nervous system, including synapse induction. 
Glutamate plays a signaling role also in peripheral organs 
and tissue as well as a in endocrine cells.62 
The brain contains huge amounts of glutamate (about 5-15 
mM per kg wet weight depending on the region),63 but only a 
tiny fraction of this glutamate is normally present 
extracellular space. In fact, the glutamate in the brain is 
primarily maintained intracellular.64 The concentrations in the 
extracellular fluids and plasma are normally around 1-10 µM 
and around 40-60 µM, respectively.65, 66 It should be noted 
that the distribution of glutamate is in a dynamic equilibrium 
which is highly sensitive to changes in the energy supply. 
2.2. Compartmentalization of glutamate 
In the brain, glutamate exists as a free amino acid divided 
between two separate metabolic compartments located in 
astrocytes and neurons.67 In this sense, different studies 
reveal the existence of one separate pool in astrocytes, which 
containing a small glutamate pool that is rapidly metabolized 
to glutamine. While the neuronal glutamate is contained in 
≥2 pools, one composed of neuronal soma and dendrites and 
the one of nerve terminals (vesicles). Nerve impulses trigger 
the release of glutamate from the presynaptic cell, which in 
turn binds to the glutamate receptors on the opposing 
postsynaptic cell. Neurotransmission is terminated by 
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astrocytes and neurons that take up glutamate. Very little 
glutamate is believed to diffuse away from the synapse.68-70 
2.3. Gutamate transporters 
2.3.1. Excitatory amino acid transporters (EAATs) 
EAATs (to date described 5 subtypes) are polypeptides in the 
range of 500-600 amino acid residues and exhibit 50-60% 
amino acid homology. The transmembrane topology of EAATs 
is thought to consist of six to eight putative transmembrane 
domains, one to two re-entrant loops, and cytoplasmic N- 
and C-terminal.71 EAATs action involves the transport of 
glutamate across the cellular membrane couples to the 
inwardly directed electrochemical potential gradients of 
sodium and one H+, and the outwardly directed potassium 
gradient. The initiation of this process involves the 
recruitment of glutamate and three sodium and one H+ from 
the extracellular space to an outward-facing conformation of 
the transporter. The binding of these substrates triggers a 
conformational change, which adopts an inward-facing 
conformation of EAATs, followed by cargo release into the 
cytoplasm of the cell. The subsequent step involves the 
recruitment of potassium ions to an EAAT transporter from 
the cytoplasm, which evokes the return to an outward-facing 
conformation and release outside the cell.72 
a. Location in the brain 
EAAT (1-3) are widely distributes in the CNS, while EAAT4 
and EAAT5 are predominantly expresses in the cerebellum 
and retina, respectively.72 EAAT1 and EAAT2 are in the 
astrocyte membranes, being the highest densities of both in 
the astrocytes membrane facing neuropil. EAAT1 is selective 
for astrocytes, while EAAT2 is predominantly expressed in 
astrocytes, but there is also some (about 10%) in 
hippocampal nerve terminals. EAAT3 is selective for neurons, 
but is expressed at levels two orders of magnitude lower 
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than EAAT2 and is targeted to dendrites and cell bodies.73 
Besides of the location describe above, different studies 
indicate that EAATs are present in brain capillary endothelial 
cells,74 where participate in cellular mechanism for brain 
glutamate efflux. 
b. Function of EAATs 
The general function of EAATs (Figure 4) is to regulate the 
extracellular glutamate concentration and maintain the 
concentration of glutamate at low physiological levels to 
avoid toxic effects. After release into the synaptic cleft, 
glutamate is rapidly removed through EAATs into glial cells 
and neurons. The major transporter is the EAAT2, which is 
responsible for more than 90% of total glutamate uptake.75 
The role of the EAAT4 is to regulate neuronal excitability 
through counteracting the depolarization of neurons. Both 
EAAT4 and EAAT5 possess a thermodynamically uncouple 
chlorine flux, which involves high chloride conductance with 
relatively low glutamate uptake.72 
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Figure 4: EAATs regulate the extracellular glutamate concentration and 
maintain it at low physiological levels to avoid toxic effects.  
c. Potential aplicactions of EAATs. 
Regulation of extracellular glutamate levels in the brain is 
crucial for maintenance of its normal functions. Abnormalities 
in this process are implicated in several neurodegenerative 
diseases including Alzheimer’s disease, Huntington’s disease, 
and amyotrophic lateral sclerosis. Since the major regulator 
of extracellular glutamate levels in the brain is the EAAT2 
promoter, proper expression and regulation of this promoter 
is critical for maintaining brain homeostasis and survival of 
neurons. The critical role of EAAT2 and glutamate in 
neurodegeneration, suggest that this transporter can be use 
for developing screening protocols to identify molecules 
capable of physiologically and safely regulating glutamate 
levels in vitro and in vivo in animals, with ultimate 
applications in humans. Thus, it has identified β-lactam 
antibiotics, as transcriptional activators of EAAT2 that are 
capable of providing neuronal protection through facilitating 
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glutamate uptake by astroglial cells. This finding suggests 
potential applications for these types of drugs as therapeutic 
agents to limit and prevent glutamate excitotoxicity. A 
thorough understanding of the mechanism(s) underlying 
transcriptional activation of EAAT2 may help identify 
potentially new molecules and targets for drug discovery 
leading to compounds that can ameliorate and potentially 
prevent neurodegeneration. Through chemical modeling, it 
may be possible to develop new derivatives of β-lactam 
antibiotics with enhanced pharmacological and bioactivity 
properties that can be orally delivered and pass more readily 
through the blood brain barrier to decrease the severity and 
progression of specific neurodegenerative diseases. Use of 
the EAAT2 promoter as a screening paradigm also provides 
an entry point for identifying potentially new classes of 
neuroprotective drugs that function by controlling glutamate 
levels in the synaptic region of neurons.76 
2.3.2. Vesicular glutamate transporters (VGLUSTs) 
a. Function of VGLUST 
VGLUTs are responsible for transport of glutamate into the 
synaptic vesicles. The vesicular uptake is dependent on a 
proton gradient that they created by hydrolyzing ATP with 
H+-ATPase. This enables the flow of H+ into the interior of the 
synaptic vesicle making it more acidic and generating a pH 
gradient across the vesicle membrane.72 
The vesicular glutamate transporters are polypeptides 
consisting of about 600 amino acid residues. Three subtypes 
of VGLUTs (1, 2 and 3) have been identified and appear to 
share more than 70% homology with one another. The 
transmembrane topology of VGLUTs is thought to consist of 
8-10 putative transmembrane domains. A highly conserved 
glycosylation site between transmembrane domains 1 and 2, 
and numerous consensus sequences for phosphorylation by 
various protein kinases are also predicted.71 
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b. Localization in the brain 
The isoforms VGLUT1 and VGLUT2 are expressed mainly in 
glutamatergic neurons and their expression in CNS seems to 
be largely complementary with only a limited overlap. 
VGLUT1 is localized in the neocortex, hippocampus and 
amygdale. VGLUT2 can be observed in olfactory bulb, 
cerebral cortex, dentate gyrus, thalamus and hypothalamus. 
VGLUT3 is localized in a limited number of glutamatergic 
neurons in multiple brain regions: neocortex, hippocampus, 
olfactory bulb, hypothalamus, sustantia nigra. Additionally, 
VGLUT3 has been found in hippocampal and cortical 
GABAergic neurons.72 
2.4. Glutamate metabolism and cycling 
There are a few ways for the body to produce glutamate 
molecules:  
a. Glu-glutamine cycle  
b. Synthesis in neurons and astrocytes from glucose 
c. Synthesis inside neurons from lactate delivered from 
astrocytes 
A fraction of glutamate present in the brain participates in 
the glutamate-glutamine cycle in neurons and astrocytes. 
However, de novo synthesis is necessary because glutamate 
can be oxidized and cannot be entirely regenerated through 
this cycle. Glutamate also does not cross the blood brain 
barrier and hence is not delivered to the CNS through the 
ingestion of food. 
Glucose is the major substrate for glutamate synthesis in 
astrocytes and neurons,77 and the influx of sodium stimulates 
glucose uptake in astrocytes and neurons by GLUT1 and 
GLUT3, respectively. Glucose is metabolized via glycolysis to 
pyruvate, which can be reduced to lactate or enters the 
tricarboxylic acids cycle (TCA cycle) and provides α-
ketoglutarate (α-KG) as a carbon backbone of glutamate. 
María Pérez Mato  Introduction 
44 
 
Glutamate in neurons can also be synthesized from lactate 
delivered from astrocytes. In some neurons, glutamate might 
be converted to gamma-aminobutyric acid (GABA) through 
the action of glutamate decarboxylase. Glutamate is released 
from presynaptic neurons into the synaptic cleft, where this 
compound binds to specific ionotropic (iGluR) or 
metabotropic receptors (mGluR) located on postsynaptic and 
presynaptic neurons. Besides, EAATs start uptake glutamate 
direct into astrocytes (EAAT1 and EAAT2) and neurons 
(EAAT3),78 to maintain adequate extracellular glutamate 
concentrations. Through EAAT1 and EAAT2, glutamate is 
taken up through the inward co-transport of three sodium 
molecules, one H+ molecule and the counter transport of one 
K+.79, 80 The sodium-dependent neuronal glutamate 
transporters include EAAT3, which exhibits a similar 
mechanism of action. In astrocytes, glutamate is converted 
to glutamine through glutamine synthetase (a specific 
enzyme in astrocytes and oligodendrocytes) in an ATP-
dependent process. Notably, not every molecule of glutamate 
is converted to glutamine, as a small fraction of glutamate is 
degraded to α-KG and enters the TCA cycle. The glutamine 
produced from astrocytes is released through the glutamine 
transporter system N transporter 1 (SN1) and reaches 
neurons via system A transporter (SAT1) (Figure 5). Here, 
glutamine is converted to glutamate through phosphate-
activated glutaminase.81 Subsequently, transmitter is loaded 
into vesicles through VGLUTs, and after interaction with 
soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (SNAREs), glutamate is released into the synaptic 
cleft where it binds to glutamate receptors and EAATs. There 
is demonstrated mechanism of action cysteine/glutamate 
antiporter (Xc-), which by means of this transporter L-cystine 
is uptaken from synaptic space to astrocyte where is 
converted to L-cysteine which may be transporter to neurons 
and serve as a substrate to glutathione synthesis, or this 
synthesis may take place in astrocytes.82 
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Figure 5: Glutamate cycling and metabolism. 
It seems evident that uptake of extracellular glutamate into 
endothelial cells (EC) via EAATs is an important step in the 
glutamate metabolism. The presence of EAATs in the 
abluminal membrane of EC in the brain, indicates that EC are 
able to accumulate glutamate. The following fate of 
accumulated glutamate may involve both transport of intact 
glutamate, metabolism of glutamate and transport of 
resulting metabolites or a combination of the two.80 The 
transport of intact glutamate is supported in vivo studies, 
which indicate the presence of a facilitative glutamate 
transporter at the luminal membrane of the Scathe 
transporter was named XG- and has been shown to be sodium 
independent.83 As regards the metabolism of glutamate in 
the EC, studies demonstrated a high mitochondria density in 
brain endothelial cells. It has been suggested that endothelial 
cells may utilize glutamate as an energy substrate to fuel the 
ABC-transporters.84 Furthermore, endothelial cells express 
branched chain aminotransferases, which may catalyze the 
conversion of glutamate to α-KG, this go through the Krebs 
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cycle in the mitochondria. From there, the α-KG can appear 
on pyruvate, which may be converted to lactate in the 
cytosol and transported through MCT-1 in the luminal 
membrane to the blood.74 Besides, in the abluminal size of 
EC there are transporters capable of pumping glutamine from 
the extracellular fluid into endothelial cells and glutaminase 
within EC may also hydrolyze glutamine to glutamate and 
NH4+(Figure 3).67  
2.5. Mechanism of glutamate excitotoxicity 
The mechanisms of glutamate excitotoxicity have been well 
studied in both animals and humans. Though the precise 
genes and proteins involved are still being elucidated, it is 
well known some of the major pathways that glutamate 
contributes to neuronal damage.85, 86 The disruption of 
glutamate homeostasis is implicates in both acute central 
nervous system (CNS) injuries such as stroke,87-90 trauma, in 
chronic neurodegenerative disorders including multiple 
sclerosis, amyotrophic lateral sclerosis and Parkinson´s 
disease88, 91-93 as well as in surgery interventions that 
produce brief period of cerebral blood flow interruption.94 
In the event of CNS injury such as stroke, cell membrane 
depolarization from ATP break down increases the release of 
glutamate, while also blocking the reuptake of the 
neurotransmitter due to the consumption of the energy 
source.95 The massive release of glutamate overwhelms 
regulating mechanisms leading to a buildup of the 
neurotransmitter in the extracellular milieu. The excess 
glutamate in turn activates a series of downstream mediators 
in the affected tissue that ultimately leads to 
neuroexcitotoxicity. Cellular death causes also more increase 
in extracellular glutamate, which feeds into the cycle of 
further cellular death.96  
Ionotropic glutamate receptors include the NMDA, AMPA, and 
kainite types. The major receptor involve in glutamate 
mediated neuronal damage is NMDAr, an important tri-
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subunit-receptor essential to neuronal plasticity (i.e. learning 
and memory formation).97 Studies have shown that increase 
of activation of NMDAr by high levels of glutamate plays a 
significant role in neuronal excitotoxicity by receptor-
mediated influx of calcium.98 The increased intracellular 
calcium, may then lead to the activation of other 
mechanisms including NOS and mitochondrial toxicity.64, 99, 
100 
Nitric oxide production plays also a significant role in 
glutamate-mediated neuronal damage. Neuron injuries have 
been show to induce translocation of nNOS from the cytosol 
to the cell membrane where it can interact with NMDAr.100 
Studies have demonstrated that NMDAr are spatially linked 
with nitric oxide synthase via the postsynaptic density 
protein of 95kDa (PSD-95).101-103 During the glutamate 
binding to NMDAr, the influx of calcium leads to the 
activation of the nearby NOS resulting in the production of 
NO.64, 86 NO can in turn lead to formation of harmful 
oxidants, causing protein nitration, protein oxidation, lipid 
peroxidation, direct DNA damage and Glyceraldehyde 3-
phosphate deshydrogenase (GAPDH) depletion.103 Neuron 
degeneration can also arise from formation of free radicals 
via damage of mitochondrial after massive NMDAr mediate 
glutamate insult. Again, increase in calcium is implicated.86, 
104 Studies by Dykens et al. demonstrated that the increase 
in calcium concentrations after NMDA activation leads to 
increase in the mitochondria sequestration through high 
capacity sodium/calcium exchangers.105 The elevated 
utilization of these exchanges, however, can result in 
metabolic acidosis as well as the activation of superoxide and 
other free radical production. Mitochondrial injury also 
initiates calpain cleavage of key regulatory proteins and 
activation of pro-apoptotic genes leading to cell death.96 
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2.6. Pharmacological findings to combat 
glutamate excitotoxity 
The elucidation of the mechanisms behind glutamate 
excitotoxicity ushered in a wave of pharmacological advances 
aimed to exploit this newfound knowledge. In the beginning, 
the major focus of research centered on NMDAr antagonism. 
NMDAr provided a logical target for drug design as it 
represented a major gateway for the myriad of other 
downstream effects of glutamate excitotoxicity. Moreover, 
during this period, progress in protein biochemistry and small 
molecule design yielded a wealth of information regarding 
the structure and function of these receptors.106 
Several classes of NMDAr antagonists with different sites of 
action were developed, namely the competitive NMDAr 
antagonists acting on glutamate or glycine binding sites; 
noncompetitive allosteric inhibitors acting at other 
extracellular sites; and NMDAr channel blockers, which acted 
on sites in the receptor channel pore.107 Though showing 
promise in animal studies, antagonist drugs such as Selfotel, 
Gavestinel and Traxoprodil have largely failed in randomized, 
controlled clinical trials in humans. A variety of reasons have 
postulated in explaining the lack of success for these NMDAr-
targeting therapies. Many of these compounds lack sufficient 
brain penetrance while exhibiting significant dose-limiting 
side effects.37, 107 The adverse events profile included 
hallucinations, agitations, catatonia, peripheral sensory loss, 
nausea, and elevation in blood pressure.108 Moreover, in the 
setting of acute CNS insults, such as strokes or traumatic 
brain injuries, glutamate excitotoxicity is thought to cause 
harm within a narrow time frame after which the 
neurotransmitter reassumes its normal function. Therefore, 
the use of agents acting on NMDAr, a major receptor of 
glutamate, may have not only missed the window for 
therapeutic efficacy but also led to undesired side effects 
from prolonged receptor blockade.109  
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Research has continued on NMDAr antagonism despite initial 
disappointments. Agents such as Amantadine and Memantine 
have proved to be valuable in Parkinson’s disease and 
Alzeheimer’s diseased.103 However, studies in the last two 
decades have expanded beyond the NMDAr with newer 
experiments seeking ways to control the upstream glutamate 
concentration as well as downstream protein signals. 
2.7. Blood glutamate grabbing: new 
potential agents against glutamate 
excitotoxicity 
Blood to brain homeostasis of glutamate is mediated by 
several glutamate transporters as previously has mentioned. 
Danbolt et al. suggested that high glutamate concentration at 
the synaptic cleft are rapidly (up to 1000 fold) reduced by 
the action of glutamate transporters present on both nerve 
terminal and surrounding astrocytes to prevent glutamate 
excitotoxicity.110 There is an unfavorable gradient between 
brain (1-10µM) and blood (40-60µM) glutamate 
concentration into the EC95 and when endothelial glutamate 
concentration becomes higher than the blood glutamate 
concentration, glutamate is transported into the blood by 
mechanism that facilitates blood excretion of glutamate from 
the brain of glutamate. The presence of EAATs in the blood-
brain barrier and their ability to accumulate large intracellular 
glutamate concentrations started the hypothesis that 
lowering blood-glutamate levels could increase the 
concentration gradient from endothelium to blood and 
thereby increase elimination of glutamate from the brain, 
known as blood glutamate grabbing hypothesis (Figure 6). To 
demonstrate this glutamate grabbing hypothesis, the blood 
resident enzyme glutamate-oxaloacetate transaminase 
(GOT), which transforms glutamate into α-ketoglutarate and 
aspartate in the presence of oxaloacetate, was used. This 
enzyme, when oxaloacetate is artificially increased shifts the 
equilibrium of the reaction to the right side, thereby 
decreasing glutamate levels in blood (Figure 7). In this 
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sense, Gottlied et al. demonstrated when radioactive 
glutamate were injected into the lateral ventricles in 
experimental animals and the effect of oxaloacetate were 
studied, the results of the study showed that oxaloacetate 
induced a decrease in blood glutamate levels followed by an 
increase of the diffusion of radioactive brain glutamate into 
the blood. Similar effects were observed in other studies 
using two microdialysis probes, where the first one infusing, 
and the other collecting glutamate; oxaloacetate treatment 
reduced the rate of radioactive glutamate collection by the 
second probe. 
 
Figure 6: Mechanism of glutamate diffusion between brain and blood 
circulation through endothelial cells. (A) Under physiological conditions the 
brain blood barrier (BBB) acts as a semi-permeable membrane preventing 
the diffusion of glutamate from blood to brain. (B) During ischemia, 
glutamate concentrations in brain rise to levels 10 times above normal, 
leading to increased blood levels. (C) Oxaloacetate administration reduces 
blood glutamate levels facilitating the lowering of extracellular levels in 
brain. 
Alternatively, malate pretreatment, a GOT blocker, has also 
demonstrated inhibition of the oxaloacetate-dependent 
lowering of blood glutamate, confirming that the effect of 
oxaloacetate on blood glutamate levels was mediated by 
blood glutamate lowering. 
These studies inspired several investigations of the effects of 
blood glutamate grabbing during pathological conditions such 
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as ischemia, subarachnoid hemorrhage, closed head injury, 
traumatic brain injury and paraoxon intoxication. The studies 
utilized different approaches to reduce blood glutamate 
levels. All these studies came to the same general conclusion 
that lowering blood glutamate levels decreases the morbidity 
of the disease states, for instance through better recovery, 
better neuron survival or smaller stroke volumes.74 The blood 
glutamate grabbers show potential for the development of 
novel, effective and safe therapeutic agents. Whereas NMDAr 
antagonists were ineffective or potentially harmful, blood 
glutamate grabbers do not act on glutamate receptors nor do 
they interfere with normal cellular signaling processes. Their 
action is only in the blood, and they accelerate a 
physiological mechanism of removing glutamate only from 
areas in which glutamate is pathologically elevated.64  
 
Figure 7: Blood resident enzyme glutamate-oxaloacetate transaminase 
(GOT) transforms glutamate into α-ketoglutarate and aspartate in the 
presence of oxaloacetate. 
María Pérez Mato  Introduction 
52 
 
2.8. Therapeutics applications of blood 
brain glutamate grabbers 
2.8.1. Ischemic stroke 
It is well established that during brain ischemia, glutamate 
plays an important role in mediating neuronal damage,111 
and higher glutamate concentration in the blood and CSF are 
associated with an increased neurological deterioration after 
stroke in humans.88, 89 Castillo et al. had described in clinical 
patients that glutamate acted as a critical key in the neuronal 
damage after ischemic stroke.87-90, 112 Thus, the ischemic 
patients presented higher blood and CFS glutamate levels 
than control subjects at admission,112suggesting that, 
glutamate concentrations above of 200µM in plasma acted an 
import predictor of neuronal damage progression at 48 h, 
with a sensitivity of 85% and a specificity of 97%.89 
This studies have also demonstrated that high levels of 
glutamate in plasma for at least 24 h was associated with 
early neurological deterioration, while in patients with stable 
ischemic stroke, glutamate levels dropped to normal values 
in less than 6 h from onset.89 All these clinical data 
demonstrated for first time the critical role of glutamate in 
stroke pathology, and suggested a source of new strategies 
for the research of new protective therapies based on the 
inhibition of glutamate toxicity. 
The central role of glutamate on ischemic pathology and the 
failure of glutamate antagonists, opened in 2009 a new line 
of investigation focused on blood glutamate grabbing 
hypothesis, that purpose the lowering of blood glutamate as 
new strategy to reduce the excitotoxic effect of glutamate 
after stroke, by means of the used of blood glutamate 
grabbers (Figure 8). 
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Figure 8: (A) Under ischemic conditions happens an accumulation of 
glutamate in the extracelluar space. (B) The increase of glutamate gradients 
between brain and blood facilitates the dumpling of glutamate from the 
extracellular space to circulating blood. 
Based on this mechanism, when glutamate levels in brain 
fluids are elevated, oxaloacetate treatment causes a 
decrease in blood glutamate levels; this leads to a larger 
glutamate gradient between the brain and blood, which 
facilitates a decrease in extracellular levels of brain 
glutamate reflected in a reduction of ischemic damage. 
The first evidence of the protective effect with oxaloacetate 
in ischemia was observed in rats submitted to 
photothrombotic lesion.113,114 In this study, rats were 
subjected to a photothrombotic lesion and treated with a 
single 30-min-long administration of oxaloacetate (1.2 
mg/100g, i.v.). Following induction of the lesion, the infarct 
size was measured and the amplitudes of the somatosensory 
evoked potentials (SEPs). The photothrombotic lesion 
resulted in appreciably decreased amplitudes of the evoked 
potentials, but oxaloacetate administration significantly 
attenuated this reduction, and also the infarct size assessed 
histologically. Oxaloacetate further prevented the long-term 
potentiation impairment in the rat CA1 hippocampal region 
induced by 2-vessel occlusion.115 In the same way, Campos 
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et al. under the STAIR guidelines (Philip et al., 2009), 
demonstrated that a bolus intravenous injection of 
oxaloacetate (3.5 mg/100g), 90 min after occlusion, 
decreased blood glutamate levels, inducing an 60% decrease 
in infarct volume at 7 days after ischemia; edema was also 
reduced. These effects were associated with reduced motor 
deficit. To confirm that the neuroprotective effect was due to 
decreased brain glutamate levels, we performed magnetic 
resonance spectroscopy (MRS) in the infarct region. 
Spectroscopic analysis revealed that the increase in brain 
glutamate seen in control animals after MCAO was clearly 
reduced in animals treated with oxaloacetate, demonstrating 
its mechanism of action.116 Similarly, infusion of peripheral 
pyruvate (with or without GPT) after MCAO resulted in 
reduced blood glutamate concentrations, smaller volume of 
infarction, reduced brain edema, improved neurological 
outcome, and reduced mortality compared with controls.117 
In patients with ischemic stroke, Campos et al. also reported 
an association between higher concentrations of GOT and 
GPT in the blood and good outcomes (GOT having a stronger 
association than GPT levels).118 In fact, patients with lower 
GOT levels and higher blood glutamate levels were 
independently associated with a worsened neurological 
outcome at 3 months and a higher infarct volume, which 
emphasizes the role that GOT plays in blood glutamate 
regulation.114, 119 However the therapeutic effect of GOT 
administration in ischemic model animals have not been 
tested so far. 
Godino et al120 has reported another alternative method to 
decrease blood glutamate levels by peritoneal dialysis. In a 
rat model of cerebral ischemia, peritoneal dialysis was able to 
reduce the transient increase of glutamate levels induced by 
ischemia, decreasing the size of the infarct area and 
preventing the functional deficit. Nonetheless, more 
preclinical and clinical studies are needed in order to 
demonstrate that peritoneal dialysis is an effective and safe 
procedure for treating acute ischemic stroke patients. 
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• Limitations of glutamate grabbers in stroke 
From a clinical point of view, glutamate grabbers may have 
some important limitations for their use as stroke therapy, 
as, glutamate increases immediately after neuronal damage, 
inducing a rapid effect, and therefore exhibits a short 
therapeutic window. Oxaloacetate showed a therapeutic 
window of no longer than 2 h after insult; therefore, the 
efficacy of this protective mechanism depends of the time-
point of drug administration. However, in a recently 
published model of brain hemorrhage, oxaloacetate 
decreased the blood glutamate levels but did not affect the 
hemorrhagic hematoma, suggesting that this treatment can 
be given as early as possible, without neuroimaging, in case 
of suspected stroke, which may potentially increases the 
number of patients treated within the therapeutic window.121 
2.8.2. Traumatic brain injury 
Traumatic brain injury (TBI) is caused by a blow or jolt to the 
head or a penetrating head injury that disrupts the normal 
function of the brain. It is one of the most important cause of 
death and disability in the US and Europe and constitutes a 
major health and socioeconomic problem throughout the 
world.122, 123 According to a report from the Centers for 
Disease Control and Prevention, an average of 1.7 million 
TBIs occurred annually from 2002 to 2006 in the US, with 
the majority of these cases being considered mild TBIs. 
Approximately 275,000 patients with TBI are hospitalized per 
year in the US, including 52,000 deaths. The leading causes 
of TBI include falls, struck by/against events, motor-vehicle 
traffic crashes, and assaults. In addition, a large population 
of military personnel has suffered some degree of TBI, and 
blast injury is a major cause of TBI for soldiers in modern 
wars.124For example, according to the Joint Theater Trauma 
Registry, compiled by the US Army Institute of Surgical 
Research, soldiers with head or neck injuries, including 
severe brain trauma, accounted for one quarter of total 
service members who have been evacuated from Iraq and 
Afghanistan.124, 125 The long-term effect of mild traumatic 
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brain injury among soldiers deployed in Iraq is strongly 
associated with post-traumatic stress disorder and 
depression after soldiers return home, which may also induce 
physical health problems.126 Moreover, the economic and 
social burden of traumatic brain injury has implications on a 
global scale, particularly with increasing motor-vehicle use in 
developed and developing countries.127  
TBI can manifest clinically from concussion to coma and 
death depending on the extent of brain damage. Two major 
pathophysiological processes contribute to brain injury after 
trauma: primary injury, in which damage is caused as a 
direct result of the mechanical impact; and secondary injury, 
which is initiated immediately after trauma due to further 
cellular damage from the effects of primary injuries and 
continues to develop over a period of h or days following the 
initial traumatic assault.128The primary injury is usually 
irreversible since neural cell death occurs at the moment of 
injury. On the contrary, the secondary injury is likely a 
reversible process because delayed neural cell death is a 
protracted event that can be regulated at many points in the 
death pathway. Therefore, intervention in the program of 
delayed neural cell death has become a therapeutic target for 
the treatment of Tibia present, neurotransmitter release, 
calcium over-load, free radical-mediated damage, 
proapoptotic gene activation, mitochondrial dysfunction, and 
inflammatory responses are the major known mechanisms of 
secondary injury pathogenesis.129, 130 These mechanisms are 
all induced via synaptic transmission and subsequent 
activation of postsynaptic receptors. Several proteins on the 
postsynaptic membrane are believed to form a special 
postsynaptic structure known as the postsynaptic density 
that serves as a multi-protein complex that mediates a 
molecular network among neural cells after injury. 
Is well described that following TBI, brain CSF concentrations 
of glutamate increase in humans131, 132 and rats.133 Within 
min after TBI, experimental and clinical studies have found 
the extracellular glutamate levels to rise sharply.131-133 This 
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increase in extracellular glutamate is mainly a consequence 
of massive neuron depolarization due to the traumatism and 
the associated energy failure commented above. Similar than 
stroke pathology, excess of glutamate in turn induces 
increased sodium and calcium influx to the cell, and the 
resulting intracellular calcium overload triggers cell damage 
mechanisms that finally lead to apoptosis through caspase 
activation.134 
The importance of glutamate in TBI led to test the potential 
application of blood glutamate reduction as therapy of this 
brain lesion. The results observed showed that peripheral 
administration of oxaloacetoate,91, 135, 136 60 min after TBI in 
rats caused a significant reduction in blood glutamate 
concentrations and concomitant improvement in neurological 
outcome. 
Interestingly, results from TBI model animals135 (rats) 
demonstrated that the blood glutamate-reducing effect of 
oxaloacetate was dose-dependent, and that the 
administration of very low doses (5 mM) of oxaloacetate did 
not result in a reduction of blood glutamate. However, when 
low doses of oxaloacetate were administered with rGOT, the 
blood glutamate-lowering effects were restored. Seeing as 
rGOT is too large to penetrate the blood brain barrier, this 
finding suggested that the therapeutic effects of oxaloacetate 
was mediated by blood glutamate grabbing and not by direct 
effects in the brain. In line with previous data, in recent 
studies, oxaloacetate treatment resulted in an increased 
number of surviving neurons in five different regions of the 
hippocampus, with preserved cellularity, 30 days after Trico-
administration of oxaloacetate with maleate, a GOT-blocker, 
was shown to prevent this glutamate reduction and 
improvement neurological outcome. Again, this provided 
strong evidence that the neuroprotective properties of 
oxaloacetate and GOT are primarily the result of blood 
glutamate grabbing, and not by some other mechanism.91, 114 
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2.8.3. Subarachnoid hemorrhage (SAH) 
SAH is a common condition that is associated with significant 
mortality and morbidity. The mortality rate for SAH 
approaches 45 % at 30 days, and 10 to 15 % of cases are 
fatal before hospitalization.137-140 At the time of the initial 
bleed, there is a critical reduction in cerebral blood flow as 
the regional intracranial pressure increases and approaches 
the systemic arterial pressure. The persistent lack of blood 
flow results in cerebral vasospasm and subsequent swelling 
of perivascular astrocytes, neuronal cells, and capillary 
endothelium.64 Although a great deal of knowledge exists 
regarding the delayed effects of SAH, the pathophysiology of 
early brain injury has yet to be fully understood and essential 
early treatment remains to be a challenge.141 Previously it 
has been described that elevated glutamate levels in the 
interstitial fluid and cerebrospinal fluid (CSF) of the brain 
may play a significant role in the mechanism for various 
acute brain insults.85, 88,89, 142 
In agreement with these studies, later investigations also 
confirmed that after SAH, there is a massive release of 
glutamate that leads to overstimulation of NMDArs.143, 144  
The level of glutamate concentration correlates with patients’ 
neurological status after SAH.145 A significant loss of blood–
brain barrier (BBB) integrity after SAH has also been 
described to cause cerebral swelling and disturbance of 
intracranial hemodynamics,146 which may in turn disrupt the 
BBB, causing a vicious cycle. A number of studies have 
demonstrated that the NO pathway is pathologically altered 
after SAH, contributing to early ischemic injury.147 The NO 
produced from L-arginine by NOS through its three isozymes, 
nNOS, endothelial NOS, and inducible NOS, plays an 
important role in maintaining cerebrovascular tone and CBF. 
It is known that a calcium sensitive nNOS enzyme is 
physically associated with NMDAr and is activated after SAH 
causes glutamate excitotoxicity and subsequent neuronal 
death.147, 148 Based on the excitotoxicity theory, NMDAr 
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antagonists may provide neuroprotection to limit secondary 
neuronal damage in different animal models of brain disease. 
However, the clinical potential of most NMDA antagonists 
demonstrated to be limited due to their indiscriminate 
blocking of the physiologic effects of NMDAr activation, as 
well as undesirable side effects like neuro-psychotic 
symptoms and memory deficits. 
In line with our previous evidences in stroke and TBI, recent 
experiments suggested that glutamate grabbers also may be 
therapeutically useful in the treatment of SAH. Thus, in a rat 
model of SAH, oxaloacetate (250 mg/kg) was infused for 30, 
60 min after induction of SAH,64, 117 observing that infusion of 
the treatment was associated with a significant reduction in 
blood and CSF glutamate. Furthermore, there was an 
improvement in neurological outcome 24 h after SAH 
demonstrated by blood brain barrier disruption, neurological 
severity score, and brain edema.64, 117 
2.8.4. Epilepsy 
One of the most severe acute neurological conditions, 
associated with excessive glutamate release, is the status 
epilepticus (SE). SE is defined as an epileptic seizure lasting 
more than 30 min or as intermittent seizures, lasting for 
more than 30 min, during which the patient does not recover 
consciousness between repeated episodes.149 SE is one of the 
most common neurological emergencies and several 
prospective studies have reported an incidence of 10– 
20/100,000 amongst whites in Europe and the US.150 
Convulsive SE is the commonest form, representing 40–60% 
of all SE cases. Mortality is high, with one out of five dying in 
the first 30 days.150 The main neurological sequels of SE 
reported in the literature are cognitive impairment, brain 
damage-related deficits, and long-term development of 
recurrent seizures.149  
There is much evidence that abnormally elevated glutamate 
is present in the brain of patients with medically refractory 
María Pérez Mato  Introduction 
60 
 
temporal lobe epilepsy.151, 152 As such, treatment with 
glutamate grabbers may provide a novel therapeutic 
modality in the treatment of such medically refractory 
seizures. With such purpose, rats submitted to a single 
injection of peripheral oxaloacetate 30 min after being 
subjected to pilocarpine-induced SE resulted in complete 
prevention of SE-induced neuronal loss in the CA1 region of 
the hippocampus with a significant reduction in apoptosis.153 
Despite evidence for neuroprotection, a reduction in seizure 
severity was not observed in that study. This concluded that 
the acute neuronal cell loss in the hippocampus (CA1 
subfield) induced by SE was completely prevented in rats 
treated with oxaloacetate. 
Moreover, the late caspase-1 activation was significantly 
reduced when rats were treated with oxaloacetate. These 
data supported the idea that the treatment with oxaloacetate 
causes a neuroprotective effect in rats subjected to 
pilocarpine-induced SE.153 
2.8.5. Migraine headache 
Migraine is a neurobiological disorder that affects 14.7 % of 
Europeans and its attacks manifest themselves from 
childhood to old age, with a decline among women during the 
postmenopausal years.154 Although the molecular 
mechanisms of migraine are not completely understood, it 
has been suggested that glutamatergic homeostasis is 
involved.112, 155-157 An excessive glutamatergic signal induces 
an over-activation of NMDAr, which seems to be implicated in 
the triggering, propagation and duration of cortical spreading 
depression (CSD).157 Furthermore, NMDA-mediated 
glutamatergic transmission is probably implicated in the 
activation of the trigemino-vascular system158 and may cause 
the clinical symptoms of migraine attack and central 
sensitization.159 In this regard, NMDAr antagonists have been 
used as the most effective compounds for CSD suppression 
in experimental models160, however their use in humans has 
failed mainly, because of unacceptable side effects.161  
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The role of glutamate in migraine suggested that systemic 
modifications of blood glutamate levels could reduce the 
excessive glutamatergic signal in brain and therefore to be 
used as a potential prophylactic treatment against migraine 
attacks.155  
To test this hypothesis, the association of GOT activity in 
blood with serum glutamate levels and clinical parameters in 
patients with migraine99 was performed. The results exhibited 
that migraine patients showed increased glutamate levels 
and lower GOT activity than control subjects. Furthermore, 
GOT activity was inversely associated with glutamate levels 
during interictal period, while increased glutamate levels was 
associated with the duration of the pain during ictal period, 
but not relationship was found for GOT activity levels and 
clinical parameters in patients with migraine.99 
This has led to suggest that new therapeutic modalities in 
migraine prophylaxis may involve blood glutamate 
reduction.155 Thus far, however, there are no experimental 
studies that demonstrate the use of blood glutamate 
grabbers in the treatment or prophylaxis of migraine 
headaches. 
2.8.6. Glioma 
In the last few years, it has been suggested that glutamate 
plays a crucial role in the growth of malignant gliomas, and 
may play an important role in the development of seizures 
that often accompany gliomas.162-166 Studies with glioma cells 
in culture have shown that the cells release massive amounts 
of glutamate resulting in elevations of the extracellular 
concentrations higher than 100 μM within h in a space that is 
1,000-fold larger than the cellular volume.166 Significant 
increases were also demonstrated in the peritumoral space 
surrounding experimental brain tumors in rats167 and in 
malignant gliomas and oligodendrogliomas in human 
patients.168, 169 Since gliomas appear release glutamate, this 
pathology can be added to the long list of neurological 
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diseases in which glutamate excitotoxicity is the common 
destructive pathway, and therefore susceptible to be treated 
with blood glutamate grabbers. 
In fact, a recent study demonstrated that rats and mice 
subjected to oxaloacetate treatment displayed a smaller 
tumor volume, reduced tumor invasiveness, and prolonged 
survival.170 Suggesting the use of glutamate grabbers as a 
new treatment against gliomas. 
2.8.7. Organophosphate intoxication 
Organophosphate compounds are highly toxic chemicals 
widely used as pesticides [e.g. malathion and paraoxon (PO)] 
and as chemical warfare nerve agents (e.g. soman, sarin). 
Pesticide poisoning is one of the most common poisonings 
worldwide, estimated at one million cases each year with 
several hundred thousand deaths.171 Organophosphates 
inactivate the enzyme acetylcholine esterase, a serine 
protease that hydrolyzes the neurotransmitter acetylcholine. 
Exposure to organophosphates leads to acetylcholine 
accumulation that causes the overstimulation of cholinergic 
receptors, which consequently results in the rapid and 
profound excitotoxicity and dysfunction of cholinergic 
neurons.172 
Exposure to organophosphates damages several brain areas 
including the entorhinal and piriform cortex, amygdale, and 
hippocampus CA1/CA3.173 Much of the brain damage does 
not typically occur at the time of the initial lesion, making 
secondary neuronal damage a major contributor to the 
neuronal loss. The degree of brain damage depends on the 
severity of the convulsions and is in direct relation to the 
increase in peripheral benzodiazepine receptors density.174 
The density of PBRs increases when microglia is activated in 
response to tissue damage such as organophosphates 
exposure.175 
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Glutamate has a substantial role in the propagation and 
maintenance of organophosphate-induced seizures, thus 
contributing to the secondary brain damage.176 Gutamate 
was shown to be releases in excess in the brain under some 
intoxication and has prominent role during seizures.177 
Furthermore, glutamate receptor antagonists in general, 
NMDA blockers in particular, were proposes as potential 
antidotes against organophophates intoxication.177 The 
standard treatment for organophophates intoxication consists 
of pretreatment with pyridostigmine, a reversible inhibitor of 
AChE and anticholinergic agents such as atropine sulfate.178 
In addition, it was reported that benactyzine (combined with 
anticholinergic and anti-NMDA properties), or 
benzodiazepines, could reduce some of the brain damage if 
administered early enough.179  
Based on the important role of glutamate on 
organophosphate toxicity and the efficacy of blood glutamate 
grabbers, in a recent study Ruban et al.180 showed that 10 
min after paraoxon exposure in rats, followed by 
oxaloacetate and GOT infusion significantly reduced neuronal 
damage and prevented the peripheral benzodiazepine 
receptor density elevation. This study showed promise that 
glutamate grabbers may be useful in the treatment of 
secondary brain damage in the setting of organophosphate 
toxicity. 
2.8.8. Fetal hypoxic–ischemic asphyxia 
Fetal asphyxia or hypoxic–ischemic encephalopathy remains 
an important cause of perinatal death and long-term 
developmental disability. Among the different biochemical 
mechanisms that can damage the neuronal tissue after fetal 
asphyxia, it has been established that the release of 
excessive amounts of glutamate into the cerebral 
extracellular space plays as well a central role in pathology. 
In this regard, glutamate antagonists have been proposed as 
potential therapeutic agents to reduce the effects of asphyxia 
in the affected infants.181 However, their use has important 
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limitations in newborn infants because of the critical role of 
the glutamatergic system during brain development. In this 
line, previous clinical studies reported that GOT was 
presented in higher concentration in fetal blood than 
maternal blood.182 In addition, it was also observed that 
elevated concentration of GOT in fetal blood was directly 
correlated with the concentration of blood glutamate. These 
findings led to hypothesize that mechanisms such as GOT 
activity could participate in maintenance of non-toxic 
concentrations of glutamate during brain development, 
suggesting that GOT could be used as a potential treatment 
for the increased concentration of glutamate after fetal 
asphyxia. To test this hypothesis, and based on the well-
known increase of glutamate after fetal asphyxia, it was 
studied the relationship between GOT and glutamate levels in 
arterial umbilical cord blood samples from control newborn 
infants and newborn infants with symptoms of hypoxia–
ischemia. The results demonstrated that glutamate 
concentration and GOT activity in umbilical blood samples 
were higher in newborn infants with symptoms of hypoxia-
ischemia compared to newborn infants without fetal distress. 
Analysis of Apgar scores and blood pH values (markers of 
perinatal distress) exhibited that conditions of severe distress 
were associated with higher glutamate and GOT levels. Then, 
this study suggested that during fetal development, based on 
the ability of GOT to metabolize glutamate this enzyme can 
act as an endogenous protective mechanism in the control of 
glutamate homeostasis.183  
2.8.9. Amyotrophic Lateral Sclerosis (ALS) 
The role of glutamate excitotoxicity in ALS has been 
extensively documented and remains one of the prominent 
hypotheses of ALS pathogenesis. In light of this evidence, 
the availability of a method to remove excess glutamate from 
brain and spinal cord extracellular fluids without the need to 
deliver drugs across the blood-brain barrier and with minimal 
or no adverse effects may provide a major therapeutic asset. 
Ruban et al.184 demonstrated the therapeutic efficacy of the 
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combined treatment with recombinant glutamate-
oxaloacetate-transaminase (rGOT) and its co-factor 
oxaloacetic acid in an animal model of sporadic ALS. This 
study showed that oxaloacetic acid/rGOT treatment provides 
significant neuroprotection to spinal cord motor neurons. 
3.Stem cells in stroke 
3.1. Classification of stem cells 
Stem cells represent the building blocks of our bodies, 
functioning as the natural units of embryonic generation 
during development, and adult regeneration following tissue 
damage. They are defined by two distinct characteristics: the 
ability to maintain themselves through cell division, 
sometimes after long periods of inactivity (self-renewal), and 
the ability to give rise to more specialized cell types 
(differentiation). Stem cells are broadly classified as 
embryonic and adult stem cells.185 Recently, there has been 
an exciting development in generation of a new class of 
pluripotent stem cells, induced pluripotent cells (iPSCs).186 
3.1.1. Embryonic stem cells 
The functional definition of embryonic stem cells (ESCs) 
includes four criteria: origin from a pluripotent cell 
population, capable of self-renewal indefinitely in the 
undifferentiated state, capable of maintaining normal 
karyotype during growth and clonally derived cells capable of 
differentiation in to all three embryonic germ layers in vitro 
or in to teratomas in vivo.187 
In culture, ESCs appears as tightly packed colonies with 
distinct borders. Within the colonies, individual stem cells 
have a high nucleus and the cytoplasm with distinctive 
nucleoli. The pluripotent ESCs express transcription factors 
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Oct 4, Nanog and Sox 2 as well as tumor rejection antigens 
Tra–1–81 and Tra–1–60. It is important that any newly 
derived ESCs line be rigorously tested to unequivocally 
identify it as pluripotent. This should also include 
demonstration of differentiation capability and positive 
identification of all three germ layers in embryoid bodies 
formed in vitro or by teratoma formation in vivo. Karyotypic 
stability during culture needs also to be established.188 
Human embryonic stem cells (hESCs) have emerged as 
exciting candidates for cell therapies in regenerative 
medicine due to their capacity to self-renew and differentiate 
into lineages of all three embryonic germ layers. Studies 
have demonstrated the ability of hESCs to differentiate into a 
number of pathologically relevant cell types, including 
insulin-producing cells, neural precursor cells, 
cardiomyocytes and hepatocyte-like cells189189, highlighting 
their potential to be used as a renewable cell source to treat 
major diseases such as type I diabetes, Parkinson’s disease, 
cardiovascular disease and liver diseases, among many 
others. Thus holding a high potencial for biomedical research 
and clinical applications as an allogeneic cell source.188 
However, the broader differentiation potential also presents a 
challenge in directing/ controlling the cell fate, and a higher 
risk of tumor formation after transplantation of ESCs derived 
tissue progenitors compared to adult stem cells.189 Another 
controversial point of the application of ESCs in translational 
medicine it is difficult to suppress immunologic rejection in 
ESCs-based therapies.190  
3.1.2. Induced pluripotent stem cells  
The ethical controversies involving isolation of ESCs and the 
need for an autologous pluripotent stem cell source have 
fueled intense investigations into cellular reprogramming, 
leading to the generation (iPSCs). 
Two groups (Yamanaka group in Kyoto University and 
Thomson group in University of Wisconsin) separately 
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reported that somatic cells can be successfully 
reprogrammed into iPSCs, marking a major landmark in stem 
cell research.191, 192 In each study, four transcription factors 
were used for induction. Yamanaka’s group selected Oct3/ 4, 
Sox2, Klf, and c-Myc191, while Thomson’s group used Oct3/4, 
Sox2, Nanog, and Lin28.192 This allowed researches to 
reprogram mature somatic cells harvested from patients and 
generate an unlimited supply of iPSCs which in turn could be 
differentiated into various cell types needed such as neurons, 
cardiac cells, pancreatic cells, liver cells, blood cells or 
enterocytes for disease modeling, drug screening and cell 
therapy. 
iPSCs cells have a couple of key advantages: they avoid the 
ethical concerns that have plagued the embryonic stem cell 
field, and they are patient-specific, thus providing a powerful 
tool for translational medicine.193 
3.1.3. Adult stem cell 
Adult stem cells, also called somatic stem cells, prompt 
tissue homeostasis throughout life and ensure tissue 
regeneration following damage. They reside in specific 
anatomic locations “stem cell niches” and are regulated by a 
combination of cellular, molecular and physical signals. 
Numerous types of adult stem cells have been identified, 
including hematopoietic, mesenchymal, endothelial, intestinal 
and neuronal stem cells, each displaying different properties 
and potency. 
3.2. Cell therapies in stroke 
Research on stem cell therapies has been increasing from the 
last 40 years. These kinds of therapies are especially 
attractive because stem cells interact directly to brain 
parenchyma cells whereas classical or pharmacological 
treatments depend on their pharmacokinetic profiles.194 In 
this way, stem cells have emerged with a double role, not 
only as the key for revealing the insights of the neuroscience 
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as well as new promising therapies for stroke, due to their 
self-renewal and multipotentiality properties.195 However, the 
mechanisms mediating ischemic stroke recovery using stem 
cells are still poorly understood.196 
One of the potential mechanisms of stem cell therapy is cell 
replacement. Early studies have reported that after stem cell 
transplantation the number of grafted cells differentiated into 
mature neurons formed can vary. The origin of this variation 
lies in the source of the stem cell and also in the injection 
site. In this way, in recent preclinical studies, 34-60% of the 
injected cells were Neural Stem Cells (NSCs),197 30% ESCs198 
or 2-20% for Mesenchymal Stem Cells (MSCs).199, 200 But 
sometimes, grafted cells remain undifferentiated close to the 
injury site, releasing growth and trophic factors201, 202 or even 
without entering the Cerebral Nervous System (CNS) 
inducing also benefits after stroke.203 Regardless of this 
effect, this systemic cell administration can provoke that 
administered cells stay also in other organs, like spleen or 
liver, interacting with other cells from the immune system 
and leading into modulatory functions,204 reducing at the 
same time, the post-ischemic inflammatory damage in 
stroke.205-207 Nevertheless, apart from cell replacement, 
enhanced trophic support and immunomodulatory response, 
there are endogenous brain repair processes that stem cell 
can stimulate, such as angiogenesis, neurogenesis, 
synaptogenesis and white matter remodeling48, 208-211 
inducing neurorestorative effects after ischemia. 
In contrast to other pathologies, in stroke there is affected 
more than one brain cell population, involving also vascular 
cells in the ischemic region. This heterogeneity means that 
not only functional neuronal connections have to be 
reestablished; the vascular system has to be restored as 
well. In consequence, there is not an unique type of stem 
cells for stroke therapy, many of them have been tested 
demonstrating beneficial effects: ESCs,212-214 Neural Stem 
Cells (NSCs),209, 215, 216 iPSCs217, 218 Human Umbilical Cord 
Blood Cells (HUCBCs)219, 220 and MSCs.200, 221, 222 Recent 
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studies with iPSCs have shown powerful new opportunities 
for modeling human diseases offering hope for personalized 
regenerative cell therapies. However, the field is racing 
ahead, and some researchers are pausing to evaluate 
whether induced pluripotent stem cells are indeed the true 
equivalents of ESCs and whether subtle differences between 
these cells might affect their research applications and 
therapeutic potential.223, 224 
But, there are several parameters to take into account to 
elucidate the effective time point for stem cell therapy in 
preclinical or even clinical studies. An important factor to be 
considered is the use of autologous versus allogenic stem 
cells. In spite of this, the less lineage specific the cells are, 
the less chances to have an immune response,225 in fact, for 
example MSCs which can be harvested from a variety of 
mesenchymal tissues have different immune response 
depending on their origin.226  
Very few preclinical studies have compared different routes 
of administration, and the choice among them depends on 
the organ target. First studies for cerebrovascular diseases 
explored the intraparechymal route with the main goal of 
determine the feasibility of replacing lost neurons and 
rebuilding neural circuits,227 meanwhile later studies showed 
that stem cells were not only able to survive after injection, 
as well as proliferate, differentiate and even migrate to the 
site of the injury.228, 229 However, intraparenchymal cell 
delivery normally is not the first choice because the injection 
is focused in one region and to reach that point it is 
necessary to damage brain tissue. On the other hand, 
vascular routes, intravenous (i.v.) and intra-arterial (i.a.) 
solve these pitfalls and they are becoming the most common 
cell delivery method. Tail vein, femoral and jugular veins are 
the most common ones for stem cell administration. Several 
groups have demonstrated that i.v. administration can 
reduce infarct size or induce functional recovery 200, 219 when 
administrated 24h after stroke. Later studies also studied the 
biodistribution after i.v. injection and found out that depend 
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on the cell type, between 1-5% of the injected cells reached 
arterial circulation.230 One of the most interesting i.v. 
applications was for NSCs delivery. It’s known that this kind 
of stem cells has the ability to differentiate into neurons, 
astrocytes and oligodendrocytes. At the early beginning of 
stem cell therapies their repairing mechanisms were 
assumed to be related to rebuild the neural structure, but in 
recent years it has been observed that the injured brain 
environment is not optimal for cell integration, so the 
recovery works through growth factor mediation or anti-
inflammatory processes.231 Nevertheless, it seems that if the 
brain is the target, it would be desirable to reach it with the 
most of the injected cells, and to achieve it the best delivery 
route is the i.e. administration. The first study showed that 
21% of the injected Bone Marrow Stem Cells (BMSCs) were 
observed in the affected hemisphere, and this was also 
related with functional recovery in behavioral tests but not as 
an infarct volume reduction in the treated group. However, 
administration route efficiency is also conditioned by the 
safety of the procedure and attending to this, i.a. 
administration has shown higher mortality than i.v. delivery. 
In a recent study, 41% of the animals died after an i.a. 
injection compared to 8% for i.v. delivery.232 That’s why this 
delivery route has been more explored recently and many 
studies have developed different injection strategies to 
minimize the risks.233-236 
All these promising preclinical results progressed into early 
clinical trials of stem cell therapy in stroke. The effectiveness 
of different types of stem cells and delivery routes is also 
reflected in clinical studies which are exploring different 
combinations. So far, there is four published clinical trials of 
intracerebral cell therapy for stroke and one that is still 
ongoing,237-239 one of intravenously administration231, 240-242 
and three following intra-arterial delivery.243-245 The main 
goals of these clinical trials were to demonstrate the safety 
and feasibility of stem cell therapy using different types of 
stem cells and routes of administration. Published results 
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have reported that there were not enough patients enrolled 
in these studies to show benefits in terms of functional 
recovery after the treatment, but all of them demonstrated 
that stem cells are a promising, feasible and safe therapy for 
stroke. 
However, the optimal conditions for applying stem cell 
therapies are still under discussion, fundamental questions 
related to cell type, characterization and dosage, therapeutic 
timing versus toxicity, or the relationship between 
biodistribution, fate and outcome are still on the bench, and 
preclinical studies should answer it first. 
3.3. Mesenchymal stem cells 
In 1970, Friedenstein et al.246 demonstrated that bone 
marrow contains a population of hematopoietic stem cells 
(HSCs) and a rare population of plasti-adherent stromal cells 
(1 in 10000 nucleated cells in BM). These plastic adherent 
cells, initially referred to as stromal cells and now commonly 
called MSCs, were capable of forming single-cell colonies. 
No exist an unique cell surface marker unequivocally 
distinguishes MSC from other HSC, which makes a uniform 
definition difficult. The International Society for Cell Therapy 
proposed criteria247 that comprise: adherence to plastic in 
standard culture conditions, expression of the surface 
molecules CD73, CD90 and CD105 in the absence of CD 34, 
CD 45, HLA-DR, CD 14 or CD 11b, CD 79a or CD19 surface 
molecules as assessed by fluorescences-activated cell sorter 
analysis and a capacity for differentiation to mesodermal 
lineages (adipocytes, chondrocytes, osteocytes, fibroblasts 
and myocytes)248. Besides this lineage, according to 
environmental factors such as growth factors, hypoxia and 
the extracellular three-dimensional environment, MSCs may 
differentiate into other different cell types. 
MSCs have been isolated from multiple tissues: skeletal 
muscle, adipose tissue, synovial membranes, dental pulp, 
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periodontal ligaments, cervical tissue, menstrual blood, 
Wharton´s jelly (WJ), umbilical cord (UC), umbilical cord 
blood (UCB), amniotic fluid, placenta and fetal tissues such 
as blood, liver and bone marrow (BM). In most cases, 
isolated MSCs are heterogeneous in proliferation and 
differentiation, although all express the characteristic MSC 
marker profile.246  
Numerous reports have described therapeutic benefits in 
various disease models after administration of the MSCs. The 
therapeutic benefits of MSCs were initially associated by their 
migration, engraftment, and differentiation into target 
tissues.249 However, remarkable anatomical structural repairs 
and functional improvements were increasingly observed 
with a small number or even no MSCs in the injured tissues. 
This suggests that most beneficial effects are largely due to 
secretory factors (neurotrophins, chemokines, cytokines) 
which mediate paracrine action and effects involving 
modulation of inflammatory and immune responses.250 
Studies has shown that the therapeutic effects of MSC 
depend on their potency to secrete various factors to 
enhance tissue regeneration, modulate the local environment 
and stimulate the proliferation, migration, differentiation, 
survival and functional recovery of resident cells.251 The MSC 
transplantation had a dual role, decreases the expression of 
factors deleterious to tissue and upregulate the beneficial 
lead to tissue regeneration a few days later. Angiogenesis 
process252 and endothelial cell proliferation251251 are related 
with the secretion of epidermal growth factor (EGF), 
fibroblast growth factor (FGF), platelet-derived growth factor 
(HGF), insulin-like growth factor-1 (IGF-1) and VEGF. 
Another variety of cytokines, like transforming growth factor 
beta (TGF-β), tumor necrosis factor-stimulated gene-6 (TSG-
6), prostaglandin E2 (PGE2), galectin 1 and 9, interleukin 10 
(IL10), indoleamine-1,3, dioxygenase (IDO), intercellular 
adhesion molecule (ICAM-1) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF), are implicated in the 
paracrine action of MSC.253, 254 Besides of the mechanism 
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described above, a large number of studies have indicated 
that MSCs have low inherent immunogenicity and possess an 
immunomodulation and immunosuppression function, which 
makes them attractive candidates for autologous and 
allogeneic transplantation.255, 256255, 256 MSCs affect immune 
response through their interactions with the cellular 
components of the innate and adaptive immune system, 
which can occur through cellular contact and the secretion of 
diverse factors.255-257 In response to pro-inflammatory 
stimuli, MSC develop an anti-inflammatory profile through 
the secretion of soluble factors (Table 1) these licensed cells 
can act on numerous innate immune cells. 
Cytokines secreted by MSCs Target cells 
IL-10 Mph,Neu,DCs,Th1,Tregs,Tr1, tumor cells 
IL-6 Neu,Mo,DCs,Th2,Tregs,Th17,CD8+FoxP3+ 
TGFβ Mph,NK,DCs,B,T,Tregs 
Chemokines Neu,Mo,NK,Eo,Baso,DCs,Ly 
CCL-2/MCP-1 Mph,EC,PL,Th2,Th17 
CCL-5/RANTES Neu,Mo,DCs,Th1,Tregs,CD8+FoxP3+ 
IDO Mo,DCs,B,T,Tregs 
VEGF DCs,EC,Th1,Th17,Tregs 
ICAM T,MSCs 
PGE2 Mph,Mo,NK,DCs,T,Tr1 
Table 1: Cytokines secreted by MSCs and the corresponding target cells 
So is that, MSC secretion of IL-6, IL-8, IFNβ, MIF and GM-
CSF increase neutrophil migration to the site of injury, 
enhancing their activation and phagocytosis whilst promoting 
their survival. The cytokines CCL2, CCL3 and CCL12 recruits 
monocytes to the site of injury where they differentiate into 
M1 pro-inflammatory macrophages. In Figure 9 is 
summarized molecules secreted by the MSC and the innate 
immune cells that are involved. MSC exert different effects, 
quite so MSC produce an inhibitory effect on natural killers 
(NK) cells, affecting different aspects of NK cell function such 
as proliferation, cytotoxic activity and cytokine production. 
Relating to dendritic (DC) cells (DC), MSC have been 
demonstrated to interfere with DC differentiation, maturation 
and function. Another affected cells are the mast (MC) cells, 
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the MSC can effectively suppress MC activation both in vitro 
and in vivo.258 
 
Figure 9: The multi-faceted anti-inflammatory actions of mesenchymal stem 
cells (Adapted from 291). 
But the activation of the immunoregulatory properties of MSC 
requires the presence of proinflammatory cytokines derived 
from T lymphocytes, macrophages and NK cells, thus 
indicating that there are bidirectional regulatory mechanisms 
between MSCs and immune cells. Cytokines, such as IFNγ, 
are necessary in this process, either alone or in combination 
with TNFα, IL-1α, IL-1β or IL-17. The expression of toll-like 
receptors (TLRs) in MSC has led to the involvement of TLRs 
in the activation of the MSC. The studies suggested that the 
activated MSC by TLR is getting a proinflammatory or anti-
inflammatory phenotypes depending on TLR which is 
enabled. The importance of an inflammatory environment for 
MSC immunosuppressive capacity has been shown both in 
vitro and vivo.257 
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3.4. The use of mesenchymal stem cells in 
stroke  
3.4.1. Route and time of transplantation of MSCs  
Preclinical studies addresses questions related to route of 
transplantation and optimum time administration. 
Different routes of administration, like intracerebral, intra-
arterial (IA), intravenous (IV), intranasal, intrathecal and 
intraventricular were tested.259, 260 The IA and IV 
transplantation presents the advantages of safety and wide 
distribution of stem cells within the ischemic penumbra as 
compared to other method. Experimentally, IA administration 
was superior to intravenous IV due to lower cell trapping by 
systemic organs such as lung, liver and spleen. 
The optimal time of transplantation depends on the 
dynamically changed environment in injured brain. Early 
delivery of MSCs probably plays neuroprotective roles 
because of it are counteract against increased toxicity and 
inflammatory response. Transplantation of cells at 2-3 weeks 
after ischemia probably is superior in enhancing endogenous 
neuronal repair such as plasticity, angiogenesis and 
neurogeneis. In order to determine the optimal time for 
MSCs administration, Ishikaza et al.261 infused IA human 
MSCs at 1,4 and 7 days after stroke and observed that MSCs 
were distributed both in peri-infarct and core area in 1 days 
group and dominantly in peri-infarct area in 4 days group 
and very few cells were observed on 7 days group. 
3.4.2. Mechanism of action of MSCs in stroke 
The mechanisms of action of MSCs have been explored on 
two levels: a peripheral level accounting for reduction of 
inflammation and immunomodulation and a central level 
expressed by the effects on neurogenesis, astrocytes, 
oligondendrocytes, axons and angiogenesis. 
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a. Immunomodulation and effect on inflammation in 
stroke 
The current state of knowledge regarding activation of the 
immune response to focal cerebral ischemia is not complete 
even if it is known that immune responses play a pivotal role 
in the pathogenesis of ischemic stroke. 
In settings of transient or focal cerebral ischemia the immune 
system is activated in response to damage of components of 
the neurovascular unit. Immediately after stroke the innate 
immune response that leads to inflammation is activated. 
The inflammatory mediators in turn lead to recruitment of 
inflammatory cells and the production of more inflammatory 
mediators that result in activation of the adaptive immune 
response. In the ischemic brain, inflammation acts as a 
“double edge sword”: gives way to tissue repair and attempts 
at regeneration but also, due to “bystander toxicity” and scar 
formation, is a major impediment of regeneration and 
plasticity.262, 263 
MSCs have been found capable of attenuating both innate 
and adaptive immune responses in vitro studies. Studies on 
neuronal cells subjected to oxygen-glucose deprivation and 
on animal models of ischemic stroke, showed that MSCs 
generate reduction of tumor necrosis factor-α (TNFα) through 
a mechanism involving interleukin (IL)-6 and VEGF signaling 
and inhibit NF-κB, finally producing an anti-inflammatory and 
anti-apoptotic effect.264 
Human cord blood MSCs significantly decrease expression of 
IL-2 mRNA and IL-6 mRNA, attenuate IL-23 and IL-17 
expression both in serum and around infarct lesion, reduce 
infarct size and improve functional deficits in a rat model of 
middle cerebral artery occlusion.265  
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b. Increased neurogenesis 
It is now widely accepted that neural stem cells (NSCs) 
residing in the subventricular zone (SVZ) of the lateral 
ventricle and the subgranular zone (SGZ) of the hippocampal 
dentate gyrus are capable of producing new neurons in the 
adult brain. In addition it has been suggested the existence 
of an adult human neurogenic system that rises from the 
circumventricular organs (CVOs) and follows, at minimum, 
the circuitry of the hypothalamus and limbic system.261, 
266Ischemic stroke injury triggers a dramatic and long-lasting 
(14 days) up regulation in NSC proliferation, inducing 
neurogenesis and gliogenesis in the SVZ and CVOs.267-269 
Although neurogenesis in stroke has been characterized in 
detail, its role in recovery is mostly unknown. Only a very 
small fraction of newly formed cells in fact integrate into the 
lesioned tissue, so that the prevailing idea is that newly 
formed cells support the lesioned tissue.270, 271 
Cell-based therapies activate the phosphatidylinositol-3-
kinase (PI3K)/Akt pathway in neural progenitor cells that 
influence cell survival, proliferation, differentiation and 
migration. BM-MSCs stimulate the brain parenchyma cells to 
produce neurotrophic factors such as the fibroblast growth 
factor (bFGF) and the brain-derived neurotrophic factor 
(BNDF).272, 273 
c. Effects on astrocytes, microglia, oligodendrocytes and 
axons 
In the acute phase after ischemic stroke, the glial reaction to 
injury results in recruitment of microglia, olygodendrocyte 
precursors, meningeal cells and astrocytes to the lesion site. 
Some of these responses have beneficial effects, isolating the 
injury site and minimizing the area of inflammation and 
cellular degeneration, whereas other mechanisms inhibit 
axonal regeneration by participating in the formation of the 
glial scar.274 
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After ischemic stroke astrocytes become “reactive” and 
certain astrocytes release inhibitory extracellular matrix 
molecules known as chondroitin sulfate proteoglycans 
(CSPGs), a major barrier against axonal regeneration and 
produce a variety of proinflammatory cytokines. Other 
populations of astrocytes have important roles in 
neuroprotection and neurorestoration. They protect spared 
tissue from further damage, rebuild the blood–brain barrier 
(BBB), take up excess glutamate and produce neurotrophic 
factors. Astrocytes have also prominent roles in modifying 
synaptic plasticity and formation of new synapses.275, 276 
In the setting of brain ischemia, the administration of MSCs 
stimulates astrocytes to release neurotrophins and growth 
factors including VEGF, vFGF and BDNF. MSCs reduce 
astrocyte apoptosis and inhibit ischemia-induced aquaporin-4 
upregulation contributing to maintenance of BBB integrity 
after cerebral ischemia.277 
MSCs decrease TGFβ1 expression in microglia/macrophages 
from the ischemic border zone (IBZ) contributing to the 
regulation of plasminogen activator inhibitor 1 (PAI-1) level 
in astrocytes. PAI-1 is associated with neurite remodeling 
after stroke.278 
Oligodendrogenesis and remyelination play a crucial role in 
behavior and functional restoration post-ischemia. 
Oligodendrocyte progenitor cells (OPCs) present in the 
corpus callosum, striatum and SVZ of the adult mouse brain 
differentiate into mature oligodendrocytes. Oligodendrocytes 
are highly vulnerable to ischemic stress. Mature 
oligodendrocytes form myelin sheaths for sprouting axons in 
ischemic tissue. Transplantation of BM-MSCs increases both 
the number of oligodendrocyte progenitors in these areas of 
the ischemic stroke hemisphere and the number of mature 
oligodendrocytes at the periphery of the lesion.279 
In the induced experimental stroke, BM-MSCs increase axon 
density in the perilesional zone, this phenomenon continuing 
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for at least 1 year after the stroke. MSCs reduce the 
expression of a protein called reticulon (Rtn4 or Nogo) and 
the production of a proteoglican named neurocan (Ncan), 
identified as axonal growth inhibitors.280 
d. Increased angiogenesis 
Angiogenesis is a process which involves endothelial cell 
proliferation, migration, tube formation, branching and 
anastomosis. The VEGF and VEGFr initiate the angiogenesis 
and angiopoietin 1 and 2 and their receptor Tie2 are involved 
in vessel maturation, stabilization and remodeling. 
Angiogenesis is essential for ischemic brain repair because it 
stimulates the blood flow and the metabolism in the ischemic 
boundary zone.281  
Intravenous administration of BM-MSCs leads to a time 
dependent release of neurotrophins and angiogenic growth 
factors such BDNF, VEGF, bFGF, NGF, hepatocyte growth 
factor (HGF) and glial cell derived neurotrophic factor (GDNF) 
which stimulates angiogenesis and neurogenesis after stroke. 
These cytokines and growth factors have both autocrine and 
paracrine effects, regulating differentiation, proliferation and 
cell survival. Several studies showed that BM-MSCs increase 
the expression of SDF-1, VEGF, angiopoietin 1, Tie2, tight 
junction proteins and BDNF in the peri-infarct region.282  
Other studies compared different routes of administration as 
well as various sources of MSCs in terms of bioactive 
molecules secretion, effects on angiogenesis and functional 
recovery after experimental stroke. In a rat stroke model, 
intra-arterial and intravenous delivery of BM-MSCs improved 
brain perfusion and metabolism as evaluated by SPECT and 
PET. Especially in rats treated with cells delivered via intra-
arterial infusion, promoted angiogenesis and improved 
functional recovery. No micro-strokes were detected after 
intra-arterial injection. Another study reported that adipose 
tissue-derived from MSCs were found to be as effective as 
BM-MSCs in promoting functional recovery, reducing cell 
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death, as well as increasing cellular proliferation, 
neurogenesis and the expression of angiogenesis markers 
(such as VEGF) at 14 days post-infarction in a rat stroke 
model.283  
In order to enhance growth factor delivery, certain groups 
used genetically modified MSCs to express growth factors 
known to stimulate differentiation and survival of host 
neurons. Miki et al.284 uses the genetically modified MSC with 
herpes simplex virus Type 1 (HSV-1) vector to carry VEGF 
and obtained a 10% reduction of the infarct volume and 
improved functional deficit. Onda et al.285 employed MSCs 
modified with adenoviral vector containing angiopoietin 1, 
which reduced by 30% the infarct size and improved motor 
deficit. 
3.4.3. Safety in preclinical studies 
The use of MSCs on animal stroke models was generally safe 
and showed favorable effects on behavioral outcome, yet 
several studies reported adverse events such as 
embolization, infection and tumorigenesis, as well as 
accumulation of amyloid β and calcium in the thalamus.286 
3.4.4. Clinical experience with MSCs 
In order to evaluate the safety profile of MSCs, Lalu et al. 
conducted a meta-analysis of prospective clinical trials, 
published in MEDLINE, EMBASE and the Cocrane Central 
Register of Controlled Trials, regarding trials using 
intravascular administration of MSC in adult or mixed 
populations (adult and pediatric population). The meta-
analysis of the randomized controlled trials did not detect 
any association between the administration of MSC and acute 
infusional toxicity, systemic organ complications, infection, 
malignancy or death. Only a significant association between 
the administration of MSCs and transient fever syndrome was 
detected.287 
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Lalu et al. described a total of 9 clinical trials, which used 
autologous MSCs administered once or twice mostly 
systemically in a dose ranging from 50x106 to 159x106. The 
maximum follow-up period was 1 year and no significant side 
effects were reported.286 The only three trials (NCT01678534, 
NCT01297413, NCT01091701) employing allogeneic MSCs 
are still ongoing and no partial results are published yet. 
4.Expression of exogenous genes 
in cells 
Due to in the present study, experimental procedures of 
trasnsfection and viral infection were used, a previous 
explanation of transfection categories, viral biology and 
infection were included in this section, with the aim to clarify 
the protocols described in Material and Methods section. 
4.1. Transfection  
Transfection, the delivery of DNA or RNA into eukaryotic 
cells, is a powerful tool used to study and control gene 
expression. Cloned genes can be transfected into cells for 
biochemical characterization, mutational analyses, 
investigation of the effects of gene expression on cell growth, 
investigation of gene regulatory elements, and to produce a 
specific protein. There are two types of transfection: 
transient and stable. 
When cells are transiently transfected with plasmids, the 
DNA is introduced into the nucleus of the cell, but does not 
integrate into the chromosome. This means that many copies 
of the gene of interest are present, leading to high levels of 
expressed protein. Transcription of the transfected gene can 
be analyzed within 24–96 h after introduction of the DNA 
depending on the construct used. Transient transfection is 
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most efficient when supercoiled plasmid DNA is used. siRNAs 
miRNAs and mRNAs can be used for transient transfection 
and are effective in the cytoplasm, without the need to be 
transferred to the nucleus. 
In the stable or permanent transfection, the transfected DNA 
is either integrated into the chromosomal DNA or maintained 
as an episome. Stably transfected cells can be selected by an 
antibiotic-resistance gene. 
Several transfection methods have been employed and it can 
be classified in chemical methods and physical methods. 
• Chemical transfection 
Chemical transfection methods are the most widely used 
methods in contemporary research and were the first to be 
used to introduce foreign genes into mammalian cells. 
Chemical methods commonly use cationic polymer (one of 
the oldest chemicals used), calcium phosphate, cationic lipid 
and cationic amino acid.288-290 The underlying principle of 
chemical methods is similar. Positively charged chemicals 
make nucleic acid/ chemical complexes with negatively 
charged nucleic acids. These positively charged nucleic 
acid/chemical complexes are attracted to the negatively 
charged cell membrane. The exact mechanism of how nucleic 
acid/chemical complexes pass through the cell membrane is 
unknown but it is believed that endocytosis and phagocytosis 
are involved in the process. Transfected DNA must be 
delivered to the nucleus to be expressed and again the 
translocation mechanism to the nucleus is not known. The 
transfection efficiency of chemical methods is largely 
dependent on factors such as nucleic acid/chemical ratio, 
solution pH, and cell membrane conditions, so the process 
results in low transfection efficiency, especially in vivo, 
compared with virus-mediated methods. However, these 
methods have merits of relatively low cytotoxicity, no 
mutagenesis, no extra-carrying DNA, and no size limitation 
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on the packaged nucleic acid. Chemical transfection efficiency 
also varies depending on cell type. 
• Physical methods 
The physical transfection291 methods are the most recent 
methods and use diverse physical tools to deliver nucleic 
acids. The methods include direct micro injection, biolistic 
particle delivery, electroporation, and laser-based 
transfection.291291 In brief, the micro injection method directly 
injects nucleic acid into the cytoplasm or nucleus.292, 293 This 
method deliver nucleic acids into cells but demands skill, 
often causes cell death, and is very labor-intensive. Biolistic 
particle delivery employs gold particles that conjugate with 
nucleic acids. The nucleic acid/particle conjugates are then 
shot into recipient cells at a high velocity (“gene gun”). This 
method is straightforward and reliable but it requires 
expensive instruments and causes physical damage to 
samples. Electroporation is the most widely used physical 
method. The exact mechanism is unknown but it is supposed 
that a short electrical pulse disturbs cell membranes and 
makes holes in the membrane through which nucleic acids 
can pass.294 Because electroporation is easy and rapid, it is 
able to transfect a large number of cells in a short time once 
optimum electroporation conditions are determined. Laser-
mediated transfection (also known as optoporation or 
phototransfection) uses a pulse laser to irradiate a cell 
membrane to form a transient pore.295-298 When the laser 
induces a pore in the membrane, nucleic acids in the medium 
are transferred into the cell because of the osmotic difference 
between the medium and the cytosol. The laser method 
enables one to observe the transfecting cell and to make 
pores at any location on the cell. This method can be applied 
to very small cells, because it uses a laser, but it requires an 
expensive laser-microscope system. In addition to those 
mentioned above, there are other physical methods using 
ultrasound (sonoporation) and magnetic field 
(magnetofection).299-301 
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4.2. Viral Vectors 
Viral vectors is the most effective means of gene transfer to 
modify specific cell type or tissue and can be manipulated to 
express the therapeutic genes. Several virus types are 
currently being investigated for use to deliver genes to cells 
to provide either transient or permanent transgene 
expression. These include adenoviruses (Ads), retroviruses 
(γ-retroviruses and lentiviruses), poxviruses, adeno-
associated viruses, baculoviruses and herpes simplex viruses. 
• Adenoviruses  
This virus has since been classified into six species that infect 
humans, and these species are subdivided into over 50 
infective serotypes. The Ad capsid is a non-enveloped, 
icosahedral protein shell (70-100 nm in diameter) that 
surrounds the inner DNA-containing core. The genome of the 
Ad is a linear, double-stranded DNA (dsDNA) ranging from 26 
to 40 kb in length. This linear form is organized into a 
compact, nucleosome-like structure within the viral capsid 
and is known to have inverted terminal repeat (ITR) 
sequences. 
• Retroviruses 
Retroviruses are known for their ability to reverse the 
transcription of their single-stranded RNA genome, thus 
creating dsDNA to replicate after infecting host cells. These 
viruses are most generally categorized as either simple 
(oncogenic retroviruses) or complex (lentiviruses and 
spumaviruses). The retroviral capsid is an enveloped protein 
shell that is 80-100 nm in diameter and contains the viral 
genome. The envelope structure surrounding the capsid is 
actually a lipid bilayer that originates from the host cell and 
contains both virus-encoded surface glycoproteins and 
transmembrane glycoproteins. The genome of the retrovirus 
is a linear, non-segmented, single-stranded RNA, 7-12kb in 
length. 
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• Lentiviruses 
Lentiviruses, a subcategory of the retrovirus family, are 
known as complex retroviruses based on the details of the 
viral genome. The most common example of a lentivirus is 
the human immune-deficiency virus type 1 (HIV-1). The 
lentiviral capsid is the same as that of the simple retroviruses 
describe above. The lentiviral genome, like other 
retroviruses, contains a single-stranded RNA, 7-12 kb in 
length. 
• Baculoviruses 
The most commonly studied baculovirus is known as the 
Autographa californica multiple nucleoplyhedrovirus 
(AcMNPV). It was originally thought that virus was incapable 
of infecting mammalian cells; however, in 1983 several 
studies showed that baculovirus could be internalized by 
mammalian cells, and they were used for the expression of 
human interferon β. The baculoviral capsid is a rod-shaped 
protein shell (40-50nm in diameter and 200-400nm in 
length) that is naturally protected by a polyhedron coat. 
• Herpes simplex viruses (HSV) 
Actually, many different varieties of the HSV have been 
discovered. The most common of these, known as HSV-1, is 
well known by the average person as the viral cause for cold 
sores. The HSV has an icosohedral protein shell that is 
covered by a viral envelope. Embedded within the envelope 
are a variety of glycoproteins important for the viral 
attachment to host cellular receptors. The HSV genome 
consists of a dsDNA (152kb in length) that code for up to 90 
different proteins important for viral attachment and 
replication. 
• Recombinant adeno associated viral (rAAV) vectors 
AAV is a small (25-nm), non-enveloped virus that packages a 
linear single-stranded DNA genome. It belongs to the family 
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Parvoviridae and is placed in the genus Dependovirus, 
because productive infection by AAV occurs only in the 
presence of a helper virus, either adenovirus or herpesvirus. 
In the absence of helper virus, AAV (serotype 2) can set up 
latency by integrating into chromosome 19q13.4, 
establishing itself as the only mammalian DNA virus know to 
be capable of site-specific integration.302 
The rAAV genome is a linear, single-stranded DNA of 4.7 kb. 
Both sense and antisense strands of AAV DNA are packaged 
into AAV capsids with equal frequency. The genome is 
structurally characterized by 145-bp ITRs that flank two open 
reading frames (ORFs).303 
The AAV life cycle have two stages after a successful 
infection, a lytic stage (Figure 10) and a lysogenic stage. 
During the lytic stage in the presence of helper virus 
(adenovirus or herpesvirus), AAV undergoes productive 
infection characterized by genome replication, viral gene 
expression and virion production. However, the lysogenic 
stage is characterized by the absence of adenovirus or 
herpesvirus, there is limited AAV replication, viral gene 
expression is repressed and the AAV genome can establish 
latency by integration into a 4-kb region on chromosome 19, 
termed AAVS1.304 
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Figure 10: AAV life cycle (Adapted from 302). 
AAV entry into target cells by using the cellular receptor 
heparin sulfate proteoglycan. Internalization is enhanced by 
interactions with one or more of at least six known co-
receptores including integrins, fibroblast growth factor 
receptor 1, hepatocyte growth factor receptor and laminin 
receptor. Cell defective for this receptors, the AAV infection is 
produced by endocytosed into clathrin-coated vesicles. The 
AAV trafficking postentry and AAV enters the nucleus are not 
completely characterized.302 
AAV has become increasingly common as a vector for use in 
human clinical trials; as of now, 38 protocols have been 
approved by the Recombinant DNA Advisory Committee and 
the Food and Drug Administration (FDA). The factors that 
have played a role in encouraging the use of AAV vectors 
include the low pathogenicity of the virus, the persistence of 
the virus and the many available serotypes. In Table 2 are 
summarized some trials, some of the them have been 
concluded or are in progress.302 
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Condition Gene product(s) Phase 
Monogenic disease CFTR I/II 
Canavan´s disease Aspartoacylase I 
Parkinson´s disease GAD65,AADC,neurturin I 
Alzheimer´s disease Beta nerve growth factor I 
Alpha-1-antitrypsin deficiency AAT I 
Arthritis TNFR:Fc I 
Leber congenital amaurosis RPE65 I 
Hemophilia B Factor IX I 
Late infantile neuronal 
lipofuscinosis CLN2 I 
Muscular dystrophy Minidystrophin, sarcolycan I 
Heart failure SERCA-2a I 
Prostate cancer GMCSF I/II/III 
Epilepsy Neuropeptide Y I 
Table 2: Clinical trials involving rAAV vectors. 
  
María Pérez Mato  Hypothesis 
89 
 
 
 
 
 
 
 
 
 
 
Hypothesis 
  
María Pérez Mato  Hypothesis 
90 
 
  
María Pérez Mato  Hypothesis 
91 
 
 
 
After cerebral ischemia, there is a rapid but transient raise of 
glutamate into the extracellular space mediating 
excitotoxicity mechanisms. Therefore, several therapies have 
been tested in order to mitigate the deleterious effects of 
glutamate. Unfortunately, all of them have failed by lack of 
efficacy or displayed severe side effects in clinical trials. In 
this regard, the decrease of brain glutamate levels by 
lowering blood glutamate have been described as a new an 
effective protective mechanism against cerebral ischemia; 
therefore, blood glutamate grabbers may establish a novel 
and attractive therapeutic strategy for acute ischemic stroke. 
Based on this mechanism, previous studies by our group 
have demonstrated that oxaloacetate treatment mediated a 
decrease of blood glutamate levels, which reflected in the 
lowering of extracellular levels of brain glutamate and a 
reduction of brain injury. However, oxaloacetate interferes in 
Krebs cycle and the large dose required may lead to side 
effects in human clinical practice. Therefore, new alternatives 
of blood glutamate grabbers are necessary. We hypothesized 
the following: 
o The use of recombinant GOT1 as a new blood glutamate 
grabber 
o The use of cell line transfected with EAAT2 able to act as 
novel glutamate grabbers cells. 
o Mesenchymal Stem Cells transfected with EAAT2 that 
could have a dual role: a) neuroprotective effect due to 
their role of blood glutamate grabber through EAAT2 
expression; and b) neurorepair effect associated with 
their endogenous features of stem cell. 
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The present work will be structured in 2 sections, and the 
main objectives are the following: 
1. Analysis of protective effect of rGOT1 in ischemia 
o Analyze the protective effect of human rGOT1 
administrated alone and in combination with a low dose 
(non-effective dose) of oxaloacetate in the rat model of 
ischemia. 
 
2. Test the effect of glutamate grabbers cells on ischemic 
damage. 
o Induce the exogenous expression of EAAT2 in 
mesenchymal stem cells and other types of cells. 
o Characterization of EAAT2 expression in transfected 
cells. 
o Validate the functionality of the EAAT2 in cells 
transfected. 
o Demonstrate in healthy animals that transfected cells 
with EAAT2 have capacity for uptaking plasma 
glutamate. 
o Confirm that the transfected cells with EAAT2 induce 
neuroprotection in an animal model of cerebral 
ischemia. 
o Determinate the additional beneficial effect of EAAT2 
expression on mesenchymal stem cells. 
  
María Pérez Mato  Materials & Methods 
96 
 
  
María Pérez Mato  Materials & Methods 
97 
 
 
  
 
 
 
 
 
Materials & 
Methods 
María Pérez Mato  Materials & Methods 
98 
 
  
María Pérez Mato  Materials & Methods 
99 
 
5. Section I. Analysis of protective 
effect of rGOT in ischemia 
The purpose of this study was to test the efficacy of GOT 
administration on blood and brain glutamate lowering and 
the subsequent potential protective effect on cerebral 
ischemic damage. For that, recombinant GOT1 (rGOT1) were 
administered in ischemic animal model and their effect were 
compared with oxaloacetate,116 used as a positive control of 
blood glutamate reduction. 
This study was divided into two steps: a dose-response study 
and therapeutic study. 
5.1. rGOT1 dose-response study 
In the first place, a dose-response study was performed in 
healthy animals, with the aim to determine the highest 
effective dose of rGOT1 on blood glutamate reduction. As 
glutamate is metabolized by GOT in combination with 
oxaloacetate, the effect of rGOT1 supplemented with a non-
effective oxaloacetate was also tested in with healthy 
animals. 
With this purpose, healthy rats were first subjected to an 
artificial increase in serum glutamate concentration in order 
to determine the effective dose of rGOT1 able to induce a 
reduction in glutamate concentration (n=6 per dose). The 
artificial increase in serum glutamate concentration was 
induced by means of the administration of glutamate 15 mM 
(1 ml per 300 g weight of the animal). This procedure was 
used to mimic the increase in serum glutamate observed 
after an ischemic insult116. Glutamate 15 mM was injected in 
jugular at the beginning of the experiment (after animal 
anesthesia induction), and 30 min later rGOT1 was given. 
Serum samples (500 ml) were taken (from vein tail) under 
basal conditions (before glutamate injection), and 1, 2, 4, 6 
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and 24 h after glutamate injection. Glutamate 15mM and 
treatments were administered through the jugular vein in a 
bolus form. All rGOT1 doses were dissolved in saline (0.9% 
of NaCl) and the concentration was adjusted to inject 1ml per 
animal. pH was adjusted to 7.4. Pure human rGOT1 (stock 
5800 U/l)) was provided by Professor David Mirelman from 
Weizmann Institute, Israel. 
The following experimental groups were designed: 
a) Group 1 (n=6): rats treated with saline (1mL). 
b) Group 2 (n=6): rats treated with glutamate 15mM 
(1mL). 
c) Group 3 (n=6): rats treated with oxaloacetate 
1.5mg/100g (1mL). 
d) Group 4 (n=6): rats treated with glutamate 15mM + 
rGOT1 6.44 µg/100g (1mL). 
e) Group 5 (n=6): rats treated with glutamate 15mM + 
rGOT1 12.88 µg/100g (1mL). 
f) Group 6 (n=6): rats treated with glutamate 15mM + 
rGOT1 25.76 µg/100g (1mL). 
g) Group 7 (n=6): rats treated with glutamate 15mM + 
rGOT1 12.88 µg/100g supplemented with oxaloacetate 
1.5mg/100g (1mL). 
The dose of rGOT that induces a greater decrease in blood 
glutamate in healthy animals will be selected for use in the 
protective study. 
5.2. Protective study 
In this phase, the protective optimal dose selected in 
previous the dose–response study was tested in an ischemic 
model. Four experimental groups were studied: 
a) Group 1(n=11): animals treated with saline (1mL). 
b) Group 2 (n=11): animals treated with oxaloacetate 3.5 
mg/100g (1mL). 
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c) Group 3 (n=11): animals treated with rGOT1 12.88 
µg/100g (1mL). 
d) Group 4 (n=11): animals treated with rGOT 12.88 
µg/100g supplemented with oxaloacetate 1.5 mg/100g 
(1mL). 
To determine the capacity of the treatments to induce a 
blood and brain glutamate reduction and a protective effect, 
two different studies were performed. On one hand serum 
glutamate determination through ELISA (Figure 11) and on 
the other hand, brain glutamate determination through MRS 
(Figure 12). Moreover, other parameters as serum GOT 
activity, infarct volume and functional deficit were also 
measured. Treatments were administered immediately after 
reperfusion (80 min after occlusion) or 1 hour after 
reperfusion (140 min after occlusion). 
 
Figure 11: Protocol used to determinate the effect of the treatments used on 
serum glutamate. Serum glutamate levels were measured before tCMAO 
surgery, after artery reperfusion (80 min) and 1, 2, 3 and 24 h after artery 
reperfusion. 
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Figure 12: Protocol used to determinate the effect of the treatments on brain 
glutamate levels. 
Serum glutamate concentration were determined under basal 
conditions (before surgery), immediately after reperfusion 
(80 min after occlusion) and 1, 2 and 3 h after reperfusion. 
GOT activity was measured under basal conditions (before 
surgery) and 1, 3 and 24 h after reperfusion. Brain glutamate 
levels were measured during occlusion (80 min) and during 
reperfusion (180 min) using the Magnetic Resonance 
Spectroscopy (MRS) technique (Figure 12). As it was not 
technically accurate to measure the serum and brain 
glutamate levels after reperfusion at the same time in the 
same animal, treatments were tested in two independent 
groups of animals (n=6 each). 
One group (Figure 12) was used to measure brain glutamate 
levels and in the other group (Figure 11) to determine the 
serum glutamate concentration and GOT activity. Infarct 
volume was determined during occlusion (only in those 
animals subjected to spectroscopy analysis), 24 h and 7 days 
after ischemia. Sensorimotor test was performed under basal 
conditions (1 day before surgery) and 7 days after ischemia. 
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5.3. Animal procedures 
5.3.1. Animal management 
In this study we have used 119 male Sprague Dawley rats 
(Harlan Laboratories, Barcelona, Spain) with a weight of 
275±25g. Animals were kept at controlled conditions of 
temperature (22±1ºC) and humidity (60±5%), with a 12/12 
h light/ dark cycle for a period of one week prior to surgery 
and up to 14 days after surgery. The rats were granted free 
access to food (commercial chow pellets) and tap water. For 
surgery and MRI, rats were anesthetized with sevoflurane 
(3% in 70% N2O and 30% O2). Rectal temperature was 
monitored and maintained at 37±0.5ºC with a feedback 
controlled heating system (1025 system, SA Instruments). At 
the end of the procedures animals were sacrificed under deep 
anesthesia (8% sevoflurane). Experimental protocols were 
approved by the local Animal Care Committee according to 
the Spanish and European Union (EU) rules (86/609/CEE, 
2003/65/CE, 2010/63/EU, RD 1201/2005 and RD53/2013). 
5.3.2. Model of focal transient ischemia in rat 
Transient focal ischemia was induced in rats by intraluminal 
occlusion of the middle cerebral artery (MCAO), performed as 
previously described305 with several modifications. In order to 
monitor the relative cerebral blood flow (CBF) during the 
surgery, a laser-Doppler flow probe (tip diameter 1mm) 
attached to a flow meter (PeriFlux 5000; Perimed AB) was 
located over the thinned skull, and over the middle cerebral 
artery territory (approximately 4mm lateral to bregma). 
Under a surgical microscope, common carotid, external 
carotid, and the internal carotid arteries of the left side were 
dissected from connective tissue through a midline neck 
incision. Left external carotid and pterygopalatine arteries 
were separated and tied with 6-0 silk sutures. A silicon 
rubber-coated monofilament (403512PK5Re; Doccol 
Corporation, USA) was inserted through the external carotid 
into the left common carotid artery and advanced into the 
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internal carotid from the bifurcation to occlude the origin of 
the Macbeth vertebral arteries remained intact in all surgical 
procedures. In those animals subjected to spectroscopy 
analysis, once the artery was occluded, determined by 
Doppler signal reduction, the animals were carefully moved 
from the surgical bench to a Magnetic Resonance (MR), with 
the aim to determine the basal ischemic lesion by means of 
apparent diffusion coefficient (ADC) maps. Angiography 
imaging was also performed to confirm the artery remained 
occluded over the MR study, and finally brain glutamate by 
MRS was analyzed. After basal MR analysis, animals were 
returned to the surgical bench and Doppler probe was 
repositioned. Reperfusion was performed 80 min after the 
occlusion onset. Animals were subsequently randomized in 
experimental groups performed, by using computer-
generated random numbers. 
5.3.3. Inclusion criteria 
Only animals with a cerebral serum flow reduction of over 
70% and with reperfusion after occlusion were included in 
the study. 
5.4. Treatment administration 
Animals were intravenously injected into the jugular vein. 
First, animals were anesthetized with sevoflurane 3% in 
O2:N2O/30:70. Then a 0.5 cm incision was made in the 
animal´s neck just above the clavicle 1cm to both left and 
right of the midline. Subcutaneous fat was cut out, and the 
jugular vein was exposed. A 30g needle was used for every 
injection after withdrawal, the puncture is rapidly closed to 
preventing bleeding. 
5.5. Blood glutamate analysis 
Venous blood was collected from the tail vein at different 
times specified in 5.1. Blood samples were collected in test 
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tubes and centrifuged at 3,000 rpm for 7 min. Serum was 
removed and immediately frozen and stored at 80 °C. Serum 
glutamate concentration was determined by means of 
Glutamate Assay Kit (Abnova, Taiwan) following the 
manufacturer´s technical specifications. 
5.6. GOT activity analysis 
GOT activity was determined by means of Reflotron GOT 
(AST). Tests followed the manufacturer´s technical 
specifications (Roche, Basel, Swizerland). 
5.7. Functional test 
In all animals, cylinder test306 was performed before MCAO 
and 7 days after MCAO by a researcher who was blinded to 
the experimental groups. 
The Cylinder test is designed to evaluate locomotor 
asymmetry in rodent models of CNS disorders. In this test 
while the animal moves within a clear plastic cylinder, its 
forelimb activity is recorded. Forelimb use is defined by the 
placement of the whole palm on the wall of the arena, which 
indicates its use for body support. Forelimb contacts while 
rearing are scored with a total of 10 contacts recorded for 
each animal. The number of impaired and non-impaired 
forelimb contacts is calculated as a percentage of total 
contacts. 
5.8. Magnetic resonance studies 
5.8.1. MR equipment 
Magnetic resonance imaging studies were conducted on a 9.4 
T horizontal bore magnet (Bruker BioSpin, Germany) with 20 
cm wide actively shielded gradient coils (440mT/m). Radio-
frequency transmission was achieved with a birdcage volume 
resonator; signal was detected using a four-element surface 
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coil, positioned over the head of the animal, which was fixed 
with a teeth bar, earplugs, and adhesive tape. Transmission 
and reception coils were actively decoupled from each other. 
Gradient-echo pilot scans were performed at the beginning of 
each imaging session for accurate positioning of the animal 
inside the magnet bore. 
5.8.2. Imaging protocol 
• Magnetic resonance angiography  
Magnetic resonance angiography (MRA) was used to identify 
the circle of Willis and to evaluate the relative blood flow 
during tMCAO. Axial MRA images of rat brain are a stack of 
58 slices where all brain is mapped. In Figure 13A and Figure 
13B it is shown a MRA Z-projection of a healthy and a tMCAO 
rat respectively. The parameters used for TOF-MRA 3D Flash 
sequence were FOV 30.72 x 30.72 x 14 mm3, image matrix 
256 x 256 x 58 (in plane resolution 120 mm/pixel x 120 
mm/pixel x 241 mm/pixel), repetition time 15 ms, 2 
averages and echo time 2.5 ms. 
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Figure 13: Z-projection of MRA. (A) Healthy animal. (B) Animal under 
tMCAO. 
• Diffusion weighted images & Apparent diffusion 
coefficients maps 
In order to evaluate the extent and localization of the 
hypoperfunded brain region during the occlusion, MR 
Diffusion Weighted images (DWI) were performed. It is 
important to note that in clinical practice MR DWI infarct 
region are displayed as hyperintense signal in MRI while 
preclinical displays are normally hypoinense. This is because 
clinical MR images normally present the image for the higher 
“b” value of the sequence (DWI) while preclinical images are 
normally maps (Apparent diffusion coefficient, ADC), resulted 
from the adjustment of all “b” values to an exponential 
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decay. So, for the previous animal, ADC maps are shown in 
grayscale in Figure 14A and color scale in Figure 14B. 
Attending to these maps, tMCAO is affecting to MCA territory 
where a reduction of the cerebral blood flow (CBF) can be 
noted in cortex and striatum (dark in grayscale, black-
purple-blue in color scale). During tMCAO the Apparent 
diffusion coefficient maps were acquired using a spin-echo 
echo-planar imaging sequences with the following acquisition 
parameters: FOV 24 x 16 mm2, image matrix 96 x 64 (in 
plane resolution 200mm/pixel x 200mm/pixel), 14 
consecutive slices of 1mm thickness, repetition time 4 s, 4 
averages, echo time 26.91 ms, spectral bandwidth 200.000 
Hz and 7 diffusion b values: 0; 300; 600; 900; 1200; 1600 
and 2000. Diffusion-weighted images were acquired during 
the ACM occlusion. 
 
Figure 14: ADC of an rat during tMCAO. Coefficient diffusion values (0.3-
2.0·10-3 mm2/s. (A) Grayscale. (B) Color scale.  
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• MR T2 
In order to evaluate the efficacy of the treatments studied in 
this work, MRI T2 weighted images were acquired and T2 
maps were calculated to quantify the infarct volume over 
time. MRI T2-weighted images were acquired using a 
multislice multiecho spin-echo sequence with the following 
acquisition parameters: FOV 19.2 x 19.2 mm2, image matrix 
192 x 192 (isotropic in-plane resolution of 100 μm/pixel x 
100 μm/pixel), 14 consecutive slices of 1mm thickness, 
repetition time of 3 s, and 16 echoes with 9 ms of echo time. 
T2-weighted images were acquired at different timepoints 
(normally, 24h, 1, 3, 7 and 14 days) after the onset of the 
ischemia. 
5.8.3. Magnetic resonance spectroscopy  
Magnetic resonance spectroscopy (MRS) was acquired to 
compare the metabolite change in the ischemic region during 
and after tMCAO by comparing the obtained spectrum over 
time and also with the non ischemic brain region. Technically, 
MRS was acquired as previously described.307, 308 Briefly, local 
shimming was performed by manual adjustment of first- and 
second-order shim coil currents using a proton-stimulated-
echo acquisition mode (STEAM)-waterline sequence. The field 
homogeneity in a 3-mm3 voxel typically (FIG XX) resulted in 
signal line widths of 10-20 Hz for the water signal. Water 
signal was suppressed by variable power RF pulses with 
optimized relaxation delays (VAPOR). In vivo 1 hour 
magnetic resonance spectra of the rat brain were acquired by 
using a STEAM sequence with echo time=3ms, mixing time 
(TM)= 5ms, repetition time= 2500ms, 176 averages, cubic 
voxel=3x3x3 mm3 (27 µl). Spectra were processed using 
MNOVA 7 (Mestrelab Research, Santiago de Compostela, 
Spain). For the quantitative analysis, glutamate signals were 
normalized to the creatine peak areas for each single 
spectrum. MRS was acquired during the occlusion (80min) 
and during 180 min after reperfusion in different part of the 
brain, cortex and striatum from the ischemic and non 
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ischemic region to compare metabolite differences between 
them. 
 
Figure 15: Schematic view of the MRS acquisition procedure. Here, 27µL 
voxel in the ischemic hemisphere is studied and for it the areas of Cr+PCr 
and Glu peaks (noted as blue in the spectrum) are determined and 
compared. 
5.8.4. Image analysis 
All images were processed using ImageJ (Rasband WS, 
ImageJ, NIH, http://rsb.info.nih.gov/ij). Infarct volumes 
were determined from ADC maps and T2 maps by manually 
selecting areas of reduced ADC values or hyperintense T2 
signal by a researcher blinded to the animal protocol. 
5.9. Statistical analysis. 
All data are presented as the mean and standard error of the 
mean (mean ± SEM). One-way or two-way analysis of 
variance (ANOVA) followed by post-hoc Bonferroni evaluation 
was used for multiple groups to determine significant 
differences. Student’s t-test was used to test the differences 
between two groups. Statistical significance was set at 
*p<0.05, **p<0.01 and ***p<0.001. The statistical analysis 
was conducted using PASW Statistics 18 for MAC (SPSS Inc., 
Chicago, CA, USA). 
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6.Section II: Effect of glutamate 
grabbers cells on ischemic 
damage. 
In this section it is described all in vitro protocols used to 
induce the artificial expression of EAATs in the cells, and the 
in vivo procedures to test the protective effect of these 
transgenic cells in ischemic model animals. 
6.1. In vitro studies 
6.1.1. Cell culture 
Four types of cell cultures were used in this experimental 
section, rat astrocytes, rat neurons, HEK and MSC. HEK (KEK 
293) and MSC were used to induce the expression of EAATs 
while astrocytes and neurons for additional experiments. 
a. Rat astrocytes isolation and culture 
Astrocytes were obtained as described before309 with minimal 
modifications. Briefly, brains were removed, meninges were 
separated and cortical area was dissected from one-day old 
Sprague–Dawley rat pups. The digestion of cortices was 
performed with 0.25% trypsin-EDTA (Gibco-Invitrogen, 
USA). Cells were mechanically dissociated in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 25 mM glucose, 2 
mM glutamine, 10% (v/v) horse serum, 10% (v/v) penicillin 
and 100 mg/ml streptomycin (all from Gibco-Invitrogen, 
USA). Dissociated cells were seeded in 75 cm2 flasks 
(Corning, USA) and maintained in an incubator at 37ºC with 
a humidified atmosphere containing 95% air and 5% CO2. 
Medium was replaced every 3 days to fresh growth medium 
until cells reached confluence. 
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b. Rat neuron isolation and culture 
Cortical neurons were obtained from embryos (E16-17) 
(Sprague Dawley rats). Embryos rats were decapitated and 
the brains were removed, the meninges were separated and 
the cortical area was dissected and collected. The digestion 
of cortices was performed with 0.25% trypsin-EDTA (Gibco-
Invitrogen, USA) for 10 min at 37ºC. The tissues were 
mechanically dissociated in Dulbecco´s Modified Eagle 
Medium (DMEM) containing 25 mM glucose, 2 mM glutamine, 
10% horse serum, 10% fetal bovine serum, 1% antibiotic 
solution (penicillin/streptomycin) all from Gibco-Invitrogen, 
USA. Afterwards, the tissue was treated with 0.4 mM DNAase 
(Sigma-Aldrich, USA) for 10 min at 37ºC and centrifuged for 
10 min at 800 rpm. Neurons were resuspended in Neurobasal 
medium supplemented with 0.5% B27, 1% 
penicillin/streptomycin, 1% L-glutamine (all from Gibco-
Invitrogen, USA). After counting, neurons were seeded at a 
density of 2x105 cells/cm2 in the previously described 
medium supplemented with cytosine arabinoside 10 mM 
(Sigma-Aldrich, USA) to prevent the astroglial proliferation. 
All procedures were conformed to the Committee of Animal 
Care of the Hospital Clínico Universitario of Santiago de 
Compostela, according to E.U. rules (86/609/EEC, 
2003/65/EC and RD 1201/2005). 
c. Rat Mesenchymal Stem Cells (rMCSs) culture and 
expansion 
rMSCs were purchased from Trevigen (Cultrex, USA). These 
cells were plated in 75 cm2 flasks at a density of 1x106 per 
dish. The culture medium used was Iscovec Dulbecco 
modified medium (1x) (IMDM, Gibco-Invitrogen, USA) and 
supplemented with 10% Fetal Bovine Serum (FBS, Gibco-
Invitrogen, USA), 10% Horse Serum (HS, Gibco-Invitrogen, 
USA), 1% antibiotic solution (penicillin/streptomycin; Gibco-
Invitrogen) and 1% antimycotic solution (amphotericin; 
Sigma-Aldrich, USA). The cells were incubated at 37°C in a 
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humidified atmosphere of 95% air and 5% CO2. Medium was 
replaced every 3 days. When MSCs reached to 80-90% of 
confluence, they were trypsinized (0.25% trypsin-EDTA; 
Gibco-Invitrogen, USA). Cell passage numbers between 7 
and 18 were used in the experiments. 
d. HEK cell line cultivation 
HEK cells were obtained from the Institute of Zelluläre 
Biophysik of Forschungszentrum (Jülich, Germany). Cells 
were cultured in Minimun Essential Medium GlutaMAX I 
(Gibco-Invitrogen, USA) supplemented with 10% Fetal 
Bovine Serum (FBS, Gibco-Invitrogen, USA), 1% MEM Non 
Essential Amino Acids (Gibco-Invitrogen, USA), 1% antibiotic 
solution (penicillin/streptomycin; Gibco-Invitrogen, USA) and 
1% antimycotic solution (amphotericin; Sigma-Aldrich, USA). 
The cells were maintained at 37ºC in a humidified 
atmosphere of 95% air and 5% CO2, changing the medium 
every 2-3 days. When the cells achieved the 80-90% 
confluence, these were detached with 0.25% trypsin-EDTA 
(Gibco-Invitrogen, USA). Cell passage numbers between 7 
and 25 were used in these experiments. 
6.2. Exogenous expression of EAATs on 
cells 
To induce the exogenous expression of EAATs on cells, two 
molecular procedures were probed, transfection and virus 
infection. 
6.2.1. Cellular in vitro transfection 
To induce the EAATs expression in cells, a plasmid containing 
the EAAT2 sequence was used. Previous to explain the 
transfection protocol, an explanation about the plasmid DNA 
expansion will be described. 
Plasmid DNA pRcCMVmYFPEAAT2 (Figure 16) encoding the 
constructs YFP-EAAT2 was obtained from the Institute of 
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Zelluläre Biophysik of Forschungszentrum (Jülich, Germany) 
and was propagated in competent Escherichia Coli. Ultrapure, 
endotoxin free plasmid DNA was prepared using a QIA filter 
kit (Qiagen, Germany) according to the manufacturer´s 
instructions. Purified plasmid was resuspended in sterile TE 
buffer (Tris/HCL 10mM, EDTA 1mM, pH 7.6). For analysis of 
the fractions at each stage of the plasmid purification 
procedure, the plasmid was restricted with the enzyme EcoRI 
(New England BioLabs, UK) and checked by gel 
electrophoresis. The plasmid concentration and its purity 
were measured by ultraviolet (UV) absorbance at 280 and 
260 nm on a Nanodrop (Thermo Scientific, USA) 
 
Figure 16: Plasmid DNA pRcCMVmYFPEAAT2 
Three different transfection protocols were probed to induce 
the plasmid expression: calcium phosphate transfection, 
electroporation transfection and lipofectamine transfection. 
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a. Calcium phosphate transfection 
This method requires the preparation of the transfection 
buffers. For that, N, N-bis (2-hydroxethyl)-2- 
aminoethanesulfonic acid (BES) was obtained from 
Calbiochem-Behring, German; CaCl2 was purchased from 
Sigma-Aldrich, USA. Stock solutions of 1 M CaCl2 was 
prepared, filter through a polyethersulfone filter with a 
0.22µm pore size (Millipore, Germany) and stored at room 
temperature. Then 2xBES-buffered saline (2xBBS) containing 
50 mM BES, 280 mM NaCl and 1.5 mM Na2HPO4 was 
prepared, filter again and stored at room temperature. The 
pH was adjusted at 6.95 with HCl at room temperature. 
The day before of the transfection, cells were seeded at a 
density of 5x104 cells per cm2 and incubated overnight in the 
suitable medium and conditions. Then 124 µl of H2O, which 
contained 15 µg of plasmid DNA, was mixed with 41 µl of 1M 
CaCl2 and 165 µl 2xBBS and the mixture was incubated for 
20 min at room temperature. Calcium phosphate-DNA 
solution was added dropwise to the plate of cells, and the 
mixtures were swirled gently and incubated for 15 to 24 h at 
35ºC under 4% CO2. After this time, the medium was 
removed and the cells were rinsed twice with PBS and once 
with PBS-EDTA and split with trypsin (0.25% trypsin-
EDTA).310  
A little percentage of transfected cells with this method can 
integrate the gen properly. To select the stably transfected 
cells, the gentamicin (G418) (Gibco-Invitrogen, USA) was 
used. Then, the transfected cells were split and planted at 
density (1x104) into 10cm2 dishes 24 h prior to selection. 
Cells were selected for 2 to 3 weeks in growth medium 
containing 1 mg/ml of G418, except the second day of 
selection, in which G418 concentration was 1.2 mg/ml. 
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b. Electroporation transfection 
Electroporation of cells were performed according to the 
optimized protocols provided by the manufacturer (Amaxa 
Biosystem, Germany). Cells were detached by incubation in 
0.25% trypsin-EDTA (Gibco-Invitrogen, USA) and centrifuged 
at 800 rpm for 5 Minford electroporation, the cells were 
counted and resuspended in 100 µl of Human MSC 
Nucleofector Solution (Amaxa Biosystem, Germany) at a 
concentration of 1x106 cells/lathe cell suspension was mixed 
with 4 µg of plasmid DNA in a sterile electroporation cuvette 
(Amaxa Biosystem, Germany) and pulsed with the U-23 
program. Immediately after, the cells were transferred into 
pre-warmed fresh medium in 6-well plates preteated with 
poly-D-lysine hydrobromide (Sigma-Aldrich, USA). 
c. Lipofectamine transfection 
Lipofectamine 2000 (Gibco by Life Technologies, USA) was 
used as the lipid vehicle. For harvesting transfected cells with 
high efficiency and low cytotoxicity, different concentration of 
DNA, cell density and lipofectamine was tested in order to 
optimize transfection protocol. For this purpose, 24 h before 
transfection, the cells were planted at a density of 0.5–2×105 
cells per cm2 on 24 well plates and maintained in growth 
medium, which was replaced with medium without antibiotics 
and antimycotics before of the transfection. Different 
amounts of reagent Lipofectamine (1-5 µl) and plasmid DNA 
(1-5 µg) were tested. Each amount of Lipofectamine was 
dissolved in Opti-MEM (Gibco-Life Technologies, USA) without 
serum to a final volume of 50 µlathe same procedure was 
done for the plasmid DNA (pDNA). The pDNA-Lipofectamine 
complexes were prepared by combining the 50 µl of the 
Lipofectamine 2000 solution with the 50 µl of pDNA solution. 
The mix was left to stand at room temperature for 20 min. 
The solution was stable for 6 h at room temperature. 
Meanwhile, the medium antibiotics and antimycotics in each 
well of the cells cultures were changed to Opti-MEM (without 
serum). The 100 µl complex solution was added to each well 
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and mixed gently by rocking the plate back and forth. The 
cells were incubated for 18-48 h at 37°C under 5% CO2. 
After lipofection, the medium was replaced with growth 
medium. 
6.2.2. Viral infection: rAAV 
In addition to transfection, the cell-induction EAATs 
expression was tried with recombinant adeno-associated 
virus (rAAV) as well. 
The first step in the production of rAAV is the design of the 
constructs. For that, we must take into account that rAAV 
has a packaging capacity of ~4.7Kb. The length of two ITRs 
(inverted terminal repeat sequences) of rAAV is about 0.2-
0.3Kb in total and the foreign DNA that could be introduced 
between these ITRs should be <4.4Kb. In addition, when the 
length of inserted DNA between the ITRs is close to the 
maximal allowed, i.e., 4-4.4Kb, the packaging efficiency 
decreases significantly. For instance, for gene over-
expression from cDNA, since the CMV-poly(A) element is 
about 1 Kb, therefore the maximal allowable cDNA length is 
about 3Kb. Considering this, it is expected to be package the 
YFP-EAAT2 construct, whose length is 2.5Kb, to a size which 
is very close to the limit of packaging. Due to this, another 
short construct was also designed. The short construct 
consisted of the EAAT2 sequence and a region encoding the 
Ha-tag sequence, thus the size of this construct being shorter 
and therefore providing an expected better efficiency of 
packaging. 
1. Long construct rAAV: YFP-EAAT2 
We used the plasmid pRcCMVmYFPEAAT2 contain the gen 
EAAT2 linked in tandem to the gen YFP. The plasmid was 
digested by EcoRI (New England BioLabs, UK) to create two 
fragments: the YFP-EAAT2 sequence (2500 bp) and the 
backbone of the vector (5500 bp). Equal amounts of digested 
DNA were electrophoresed on 0.75% agarose gels to test the 
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digestion was successful. The gel was stained with SYBR Safe 
DNA (Life Technologies, USA) gel stain (1:10,000 dilution) 
for 15 min, and then viewed using the blue-light 
transilluminator (Bio-Rad, USA). The insert DNA YFP-EAAT2 
were excised from the gels and purified using the Nucleospin 
Gel and PCR clean up (Macherey-Nagel, Germany) according 
to the optimized protocols provided by the manufacture. The 
insert was cloned in the vector viral ccCMVm (kindly donated 
by Prof. A. Baumann), which in the multiple cloning site 
contained restriction sites as XabI, HindIII, EcoRV, EcoRI, 
BamHI. The ccCMVm was linearized by digestion with the 
enzyme EcoRI (New England BioLabs, UK). The linearized 
vector was subjected to an electrophoresis process similar to 
that performed in the fragment YFP-EAAT2. Likewise, the 
vector ccCMVm was excised from the gel and purified with 
the same protocol mentioned above. Besides the vector was 
submitted to dephosphorylate using the Rapid DNA Dephos & 
Ligation Kit (Roche, Switzerland), thereby preventing the 
viral vector becoming circular by binding of sticky ends. After 
that, the ligation of insert into linearized vector ccCMVm was 
done with the Rapid DNA Dephos & Ligation Kit (Roche, 
Switzerland) following the protocol provided by the 
manufacture. Competent cells were transformed with the mix 
of ligation (Table 3) and planted on a selective medium for 
growth. Only cells containing the insert cloned in the vector 
ccCMVm formed colonies, which were picked and grown in 
liquid culture. The purification of the DNA from the culture 
was performed following the protocol described in the kit 
NucleoSpin Plasmid (Macherey-Nagel, Germany). The 
purified DNA was digested with the enzymes EcoRI (New 
England BioLabs, UK) to verify that the insert had the 
expected size and with Sami (New England BioLabs, UK) and 
Audi (New England BioLabs, UK) to corroborate that cloning 
of the insert into the viral vector was performed in the right 
direction. 
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Ligation 1 Ligation 2 Ligation 3 
0 µl DNA insert 4 µl DNA insert 4 µl DNA insert 
2 µl DNA vector 0 µl DNA vector 2 µl DNA vector 
2 µl DNA dilution Buffer 
5x 
2 µl DNA dilution Buffer 
5x 
2 µl DNA dilution Buffer 
5x 
6 µl Water 4 µl Water 2 µl Water 
10 µl T4 DNA ligation 
buffer 
10 µl T4 DNA ligation 
buffer 
10 µl T4 DNA ligation 
buffer 
1 µl DNA lipase 1 µl DNA lipase 1 µl DNA lipase 
Table 3: Mix of ligation 
2. Short construct rAAV: Ha-tag-EAAT2 
The fragment YFP-EAAT2 was obtained with the same 
procedure as previously was described. Due to the design of 
this construct, only the gen EAAT2 was necessary, which was 
linked to the gen Ha-tag. For that, EAAT2 amplification was 
carried out using 2 primers: 
5´accatctagaccaccatggcatctacggaaggtgc 3´ (contains a 
Kozak sequence, a recognition sequence of the enzyme XbaI 
and free sequence) and 
3´accagaattcggcatagtcggggacgtcatagggatatttatcacgttccaaggt
ttc 5´include the Ha-tag sequence, a recognition sequence of 
the enzyme EcoRI and a free sequence ended in cytosine, 
both of them were acquired from Applied Biosystems, USA. 
Amplification process was performed using the kit T4 DNA 
Polymerase (New Englands BioLabs, UK) and according to the 
following protocol: (1) polymerase activation for 2 min at 
T=95ºC, (2) denature for 20s at T=95ºC, (3) annealing for 
10s at T=56ºC and (4) extension for 4s at T=70ºC, the steps 
2-4 were repeated in 30 cycles. The PCR product was 
submitted to an electrophoresis, excision and purification 
process similar to that described above. The purified PCR 
fragment was digested with the restriction enzymes XbaI 
(New Englands BioLabs, UK) and EcoRI (New Englands 
BioLabs, UK), electrophoresed, excised and purified 
according to the previously described protocols. 
The PCR fragment was cloned into the viral vector scCMVm 
(Figure 17), which was necessary linearized. For that, the 
viral vector was digested with EcoRI (New Englands BioLabs, 
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UK) and XbaI (New Englands BioLabs, UK) enzymes. The 
product of the digestion was subjected to electrophoresis, 
excised and purified following the same protocol as in the 
previous section. 
 
Figure 17: Viral vector scCMVm 
The ligation of construct into the vector, the transformation 
of competent cells, the selection of a clone and purification of 
DNA was performed following the protocol described in 
previous section. To verify that insertion of the sequence 
EAAT2-HaTag in the vector was successful, the following 
controls of restriction were conducted: EcoRI, XbaI, SmaI 
and AhdI (New Englands BioLabs, UK). 
• Production and purification of recombinant adeno-
associated viruses (rAAVs) 
The most commonly used method for production of AAV 
vectors in research laboratories consists of a 2 or 3 plasmid 
transfection of adherent HEK cells. The triple transfection 
method described below uses the plasmid with the gene of 
interest, plasmids of different serotypes and helper plasmid 
providing the adenoviral gene products necessary for 
replication and packaging. The protocol includes the 
processes for transfecting of cells with the 3 plasmids, 
harvesting the crude cells lysate, preparing the lysate for 
viral vector purification by iodixanol gradient and the titration 
by real-time PCR of the viral genome. 
• Production of AAV vector by transient transfection 
The day before the transfection, 1x107 HEK cells per 14.5 
cm2 dish were seeded out in a total volume of 25 ml 
complete medium. At a time point of 2 h before transfection, 
the medium was replaced with fresh complete medium. The 
HEK cells were transfected using the calcium phosphate-
transfection method310 and the next transfection cocktail: 1 
ITR CMV ITR AmpR
1 181
SaII
205
PstI
793
XbaI
799 807
EcoRV
811
EcoRI
817
BamHI
2153 5030
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ml CaCl2 (250mM), 7,5 µg helper plasmid pRC, 22,5 µg 
adeno helper plasmid pXX (both plasmid were kindly 
provided by Prof. Dr. A. Baumann), 7.5 µg virus plasmid 
(pAAV-YFP-EAAT2 or pAAV-Ha-Tag-EEAT2) and 1ml HBS 2x 
(50mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.12). 
After 24 h of the transfection, the medium was changed and 
HEK cells were maintained at 37ºC, 5% CO2 and 95% of 
humidified atmosphere for 48h. At this point, the cells were 
harvested. To do this, the medium was removed and 10 ml 
PBS M/K (sterile PBS, substituted with 1mM MgCl2 and, 2.5 
mM KCl) was placed per dish. The cells were collected by 
scraping and the cell suspension was transferred to a falcon 
tube, which was centrifuged at 300g for 5 menthe 
supernatant was removed and the pellet was resuspended in 
a lysis buffer (NaCl 150 mM, Tris/HCl 50 mM, pH 8.5) and 
incubated at room temperature for 10 min. Immediately, the 
cell lysate was subjected to three cycles of freezing in liquid 
nitrogen and thawing at 37ºC. Finally, 2 µl benzonase (25 
kU/µl/ml) was added to the cell lysate and incubated at 37ºC 
for at least 30 menthe, the cell homogenate was centrifuged 
for 30min at 5000g and the clarified supernatant was 
collected. 
• Purification of rAAV vectors by iodixanol gradient 
sedimentation 
In order to purificate the rAAV suspension, a iodixanol 
gradient was performed by filling the volume of each 
iodixanol solution (15%, 25%, 40% and 60%) in a ultra-
centrifugation tube (Polycarbonate, 26.3 ml, Beckmann 
Coulter) with a peristaltic pump. The supernatant obtained in 
the previous section formed the uppermost layer of the 
iodixanol gradient until the tube was filled to the top. The 
tube was ultracentrifuged 120 min at 60,000 rpm in a 
Beckman 70 Ti Rotor. To complete the process, the 40% 
iodixanol solution (clear band, contains the virus particles) 
was transferred with a syringe connected to a 40 mm canula 
to a fresh tube and was frozen at -80ºC. 
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• Determination of rAAV titers by real-time PCR 
Viral genomes were isolated from purified virus for titer 
determination. The genetic material was isolated using the 
Dneasy Blood & Tissue Kit (Qiagen, Germany), according to 
the manufacturer instructions. The titer values were 
determined via qPCR analysis. For this, the QuantiTect SYBR 
Green PCR (Qiagen, Germany) was used for qPCR reactions. 
The qPCR reaction mixture, a total of 18 µl was composed as 
indicated Table 4. 
Table 4: qPCR reaction mixture 
 
The qPCR running protocol is summarized in Table 5. 
 
Program Step Tª Duration Cycles Detection 
Pre 
incubation Denaturing 95ºC 10min 1 - 
 Denaturing 95ºC 10 sec  - 
Amplification Annealing 62ºC 15 sec 50-80 - 
 Synthesis 72ºC 15 sec  Single 
 Denaturing 95ºC 1 sec  - 
Melting curve Annealing 62ºC 15 sec 1 - 
 Melting 65-95ºC 0.1ºC/sec  Continuous 
Cooling - 40ºC 30 sec 1 - 
Table 5: qPCR running protocol. 
 
Component Volume  
SYBR Green 10 µl  
Primer 1 (10pmol/ µl) 1 µl To 18 µl qPCR reaction 
Primer 2(10pmol/ µl) 1 µl mixture:add 2 µl of sample 
H2O 6 µl in LightCycler capillary 
Total 18 µl  
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6.2.3. Infection of cells 
a. Transduction with rAAV-GFP of different serotypes in 
cells and the best MOI (multiplication of infection) 
determination 
Cells were plated at 5x104 cells/well onto a 24 well plate and 
cultured at 37ºC in an atmosphere containing 5% CO2 for 24 
h before rAAV infection. A total of 7 serotypes was tested 
(rAAV1, rAAV2, rAAV4, rAAV5, rAAV6, rAAV8 and rAAV9), all 
of them donated by Prof. A. Baumann (Germany). The viral 
stocks were used at 3 MOI gradients: 5x105, 2.5x105 and 
4x104vp/cell. Each dilution was performed in triplicate. A no-
viral well and iodixanol 40% well were included as negative 
controls. Two days later, after infection, the medium was 
replaced with complete medium. The YFP expression was 
analyzed 5 days after infection using fluorescence microscopy 
and FACS analysis. 
b. Infection with rAAV-YFP-EAAT2 (serotypes 2, 6) and 
rAAV-Ha-tag-EAAT2 (serotypes 2, 6) in MSC and HEK 
cells 
Cells (5x104cells/well) were seeded onto a 24 well plate for 
24 h before rAAV infection. The cells were transduced with 
the next MOI gradients: 1x1010, 5x109, 1x109 vp/cell of 
rAAV2YFP-EAAT2, rAAV2Ha-tag-EAAT2, rAAV6YFP-EAAT2 and 
rAAV6Ha-tag-EAAT2 in triplicate. Uninfected cells were used 
as a negative control. Virus infection was performed for 48 h 
and the medium was changed. Seven days after infection, 
YFP and Ha-tag expression was analyzed by fluorescence 
microscopy and FACS analysis. 
6.3. Analysis of YFP and Ha-tag expression 
To confirm the integration and the expression of the EAAT2 
used in the transfection and viral infection, YFP and Ha-tag 
(used as gene expression reporters) were analyzed by flow 
cytometry and fluorescence microscopy. 
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6.3.1. Flow cytometry  
We used flow cytometry techniques for the analysis of the 
YFP expression in transfected and infected cells. Cells were 
dissociated with 0.25% Trypsin-EDTA (Sigma-Aldrich, USA) 
and centrifuged at 800 rpm during 5 min to remove the 
Trypsin-EDTA. Subsequently, cells were washed with PBS 
(Life Technologies, USA) and centrifuged at 800 rpm during 5 
min to form a cell pellet, which was finally resuspended at 
concentration of 1x105 cells per 100µl. For the analysis, 
30000 gated events (cells) were collected. A cell was counted 
as positive for YFP expression when its fluorescence was 
higher than the threshold settings of the negative control 
sample (non-fluorescing cells). For the cytometry analysis we 
used a FACSAria IIu analyzer (BD, USA), and the PC 
FACSDiva software program (BD, USA). Cell counts were 
always expressed as percentage. 
 
In case of the Ha-tag-EAAT2 infected cells, 1x106 cells, 
infected which the virus Ha-tag-EAAT2 (serotypes 2, 6) were 
detached whit 0.25% Trypsin-EDTA and centrifuged at 800 
rpm for 5 min the cells were washed and stained by 
incubation (30 min) with Anti-Ha-tag-Fluorescein clone 3F10 
(20 µl per 1x106 cells, Roche, Switzerland) antibody at 2-8ºC 
during 30min. Then, cells were suspended in 200 µl of PBS 
and the analysis was performed. The unlabelled cells were 
used as a negative control. The analysis was done using a BD 
FACS Aria I (BD Bioscience, USA) and data were analyzed 
with the use of FACSDiva software (BD Biosciences, USA). 
6.3.2. Fluorescence microscopy 
The cells were observed under inverted microscope (Olympus 
IX51) during the infection and the efficiency of YFP 
expression was detected using a fluorescence microscopy. 
For analysis of the Ha-tag sequence by fluorescence 
microscopy, cells were planted at a density of 2x104 cells on 
glass coverslips, which were previously treated with 0.1 
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mg/ml poly-D-lysine hydrobromide (Sigma-Aldrich, USA). 
The next day, the medium was removed and the cells were 
rinsed in PBS 3 times. Following on, the cells were fixed in 
4% PFA solution methanol free (Thermo Scientific, USA) for 5 
min at room temperature. After that, the washing process 
described above was repeated. Then, the cells were 
incubated with 0.5% BSA (GE Healthcare, UK) in PBS for 30 
min, in order to block unspecific antibody binding sites. Then, 
the washing process was repeated and a rat monoclonal 
antibody (Roche, Switzerland) against the sequence Ha-tag 
was used at a dilution 5 µg/ml in 0.5% BSA and PBS for 24 h 
at 4ºC. After this time, the washing process was performed 
and cells were incubated with 1:6000 Hoescht (Invitrogen, 
USA) for 5 min. Afterwards a coverslip was mounted. For this 
purpose, the coverslip was removed from the well and the 
edge of the coverslip was touched with a paper to aspirate as 
much buffer as possible. Then, ensuring that the place 
coverslip with the cells were side down, a drop of Aqua 
Polymount (Polysciences, USA) was added and kept in the 
dark at room temperature for 2 h and after the samples were 
stored at 4ºC for further analysis. 
Images were captured randomly using Nikon digital camera. 
6.4. Analysis of EAAT2 expression in cells  
6.4.1. Immunostaining of EAAT2 in MSCs and HEK 
cells 
Cells were planted at a density of 2x104 on glass coverslips, 
which were previously treated with 0.1 mg/ml poly-D-lysine 
hydrobromide (Sigma-Aldrich, USA). The next day, the 
medium was removed and the cells were rinsed in PBS 3 
times. Following on, the cells were fixed in 4% PFA solution 
methanol free (Thermo Scientific, USA) for 5 min at room 
temperature. After that, the washing process described 
above was repeated. Then the cells were incubated with 
0.5% BSA (GE Healthcare UK) in PBS for 30 min, in order to 
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block unspecific antibody binding sites. Then, the washing 
process was repeated and a mouse primary monoclonal 
antibody (Millipore, USA) against the protein EAAT2 
(Millipore, USA) was used at a dilution 1:100 in 0.5% BSA 
and PBS for 24h at 4ºC. After this time, the washing process 
was performed and incubation with a biotinylated horse anti-
mouse IgG antibody rat adsorbed (1:200, Vector 
Laboratories, USA) was done, followed again by a 10 minute 
wash, applied 3 times. Next, a 1:100 dilution of both avidin 
and biotin (Vector Laboratories) in PBS was made and used 
for incubation for 30 min. After, 3 washes of 10 min with 
PBS, samples were incubated with dylight 594 streptavidin 
1:500 (Vector Laboratories, USA) for 30 min. After another 3 
step washes of 10 min, cells were incubated with 1:6000 
Hoescht (Invitrogen, USA) for 5 min. Afterwards a coverslip 
was mounted to determine whether EAAT2 expression 
colocalize with the transfected cells with YFP, the 
colocalization was analyzed by means of a confocal 
microscope (LEICA AOBS-SP5X). 
6.5. Characterization of transfected MSCs 
The infection and transfection processes described above 
could induce chances in MSC phenotype, as well as the 
capacity associated with MSCs to secrete growth factors and 
their angiogenic ability. Because of this, the following 
experiments in order to verify that MSCs maintains their 
characteristics were realized. 
6.5.1. Flow cytometry of MSCs 
To confirm that transfected MSCs (cells which were 
expressed YFP) did not lose the MSC phenotype after the 
experimental procedure, cells were analyzed by flow 
cytometry analysis. For that, specific membrane makers of 
rMCSs as CD90, CD73 and CD45 were analyzed. 
Cells (1x105) were washed and stained by incubation (15 
min) with CD90-PerCP-Cy5 (5 µl per 1x105 cells, 
María Pérez Mato  Materials & Methods 
127 
 
Immunostep, Spain), CD73-APC (1 µl per 1x105 cells, 
Immunostep, Spain) and CD45-PE (2.5 µl per 1x105 cells, BD 
Pharmigen, USA) antibodies. Then, cells were suspended in 
100 µl of PBS and the analysis was performed. The 
unlabelled MSCs were used as a negative control and the 
phenotype of MSC was characterized as 
CD90+/CD73+/CD45-. The analysis was performed using a 
BD FACS Aria I (BD Bioscience, USA) and data were analyzed 
with the use of FACSDiva software (BD Biosciences, USA). 
6.5.2. In vitro matrigel angiogenesis assay. 
To determine the angiogenic capacity of the transfected 
MSCs (a specific characteristic of these cells), a tube 
formation assay was performed in transfected and non-
trasnfected cells. 
Matrigel reduced growth factor (BD Biosciences, USA) was 
used as a substrate to assess tube formation capacity as an 
in vitro measurement of functional angiogenesis, in MSC 
control and transfected MSC. Standard 24-well plates were 
coated with 200 µl of cold Matrigel and allowed to solidify at 
37ºC for 30 min. Afterwards, outgrown MSC were added onto 
matrigel-coated wells at seeding of 1x104 per well in IMDM 
(Gibco-Invitrogen, USA) supplemented with 5% Fetal Bovine 
Serum (FBS, Gibco-Invitrogen, USA), 1% antibiotic solution 
(penicillin/streptomycin; Gibco-Invitrogen, USA) and 1% 
antimycotic solution. Cells were incubated for 12 h at 37ºC, 
5% CO2 and in a humidified atmosphere of 95%. After 
removal of the medium, the cells were fixed in 4% PFA and 
images were captured using an inverted microscope 
(Olumpus IX51). The tube formation was assessed by 
counting the number of circular structures (rings) and 
number of branching points (tube joints). Five random fields 
were measured for each well. 
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6.5.3. Vascular endothelial growth factor (VEGF) 
determination:  
VEGF, a specific growth factor produced by MSCs was also 
analyzed to determine that artificial EAAT2 expression does 
not affect to the MSCs properties. 
VEGF concentrations of MSC control and transfected MSC 
were measured with a Quantikine VEGF ELISA kit (R&D 
Systems, USA) following the manufacturer’s protocol. VEGF 
values are corrected for the amount of total cell protein 
calculated by Bradford (Bio-Rad, USA) techniques. 
6.6. In vitro test of toxicity 
For assessing the cellular mortality caused in cells after 
transfection and infection, the LDH assay and proliferation 
rate were performed. 
6.6.1. Lactate dehydrogenase (LDH) assay 
Supernatants from last 24 h (fresh medium incubation) were 
collected in Eppendorf tubes. A negative control of lysated 
cells was also included (death control) following 
manufacturer protocol. After a mild centrifugation of the 
supernatants, 75 µl were mixed in a 96 well plate with 150 µl 
LDH reagents following the manufacturer protocol (Lactate 
Dehydrogenase Assay Kit Sigma-Aldrich, USA). After 20 min 
incubation, the plate was read on Synergy2 (Biotek, USA) at 
490 nm. To calculate the viability rate respect to control, 
next equation was applied. 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦[𝑐𝑜𝑛𝑡𝑟𝑜𝑙] =
𝐿𝐷𝐻𝑙𝑦𝑠𝑒𝑑 − 𝐿𝐷𝐻𝑒𝑥𝑝𝑜𝑠𝑒𝑑
𝐿𝐷𝐻𝑙𝑦𝑠𝑒𝑑 − 𝐿𝐷𝐻𝑐𝑜𝑛𝑡𝑟𝑜𝑙
· 100 
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6.6.2. Proliferation rate 
To determine the proliferation rate, total cell count was 
performed with Trypan Blue staining and a Neubauer 
chamber. 
6.7. Characterization the functionality of 
the EAAT2 
To determine the functionality of the EAAT2-induced 
expression, a glutamate uptake assay was performed in both 
types of cells used, HEK and MSCs. 
6.7.1. Glutamate uptake assay 
Uptake of radiolabeled glutamate was performed using a 
competitivity assay. Transfected cells (HEK and MSCs) with 
EAAT2 were planted in triplicate at 1.5x105 on 24-well tissue 
culture plates treated with poly-D-lysine hydrobromide 
(Sigma-Aldrich, USA). Non-transfected cells were used as 
negative control and astrocytes were employed as positive 
control. After 24h, the medium was aspirated and cells were 
washed 3 times with 250 µl PBS buffer at room temperature. 
Then 500 µl PBS buffer, supplemented with 13 nM L-[3H] 
glutamate (1 µCi/ µl; Sigma-Aldrich USA; specific 
activity=51.1 Ci/mmol) and various concentrations of 
glutamate (1µM, 10 µM, 50 µM, 100 µM, 250 µM, 500 µM, 1 
mM and 10 mM) was added to each well, and the plate was 
incubated at 37ºC for 10min. After this time, the plates were 
placed on ice and cells were washed 3 times with ice-cold 
PBS. Through microscopy it was verified that the cells 
continued to be fixed to the bottom of the well, and the cells 
were lysed with 200 µl of 0.2 M NaOH for 4 h in shaking. 
After four h, 50 µl of cell lysate was transferred to a 96-well 
multiplex plate and 150 µl of Optiphase buffer were added to 
each well. The multiplex plate was shaken for 30min at RT. 
Cell-associated radioactivity was determined in cell lysates by 
scintillation counting (PerkinElmer, Germany) and the total 
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protein content in lysates was determined by the Bradfor 
assay (Bio-Rad, USA). The results were expressed in DPM per 
µg of cellular protein. 
To determine the specificity of glutamate uptake, two 
selective inhibitors of EAAT2, DHK and TFB-TBOA, (Tocris, 
Bioscience, USA) were employed. Both inhibitors were used 
individually and jointly at the next concentrations: 300µM 
(DHK) and 500µM (TFB-TBOA)311. For doing the assay, the 
cells were prepared as described above and the medium was 
removed. Three washes were performed with PBS and the 
cells were incubated with inhibitors for 10 min at 37ºC. After 
this time, the labeled and unlabeled glutamates, at the same 
concentrations described above, were added. The protocol 
employed was the same as that made in the previous 
section. 
6.8. In vivo experiments 
With the aim to test the efficacy of EAAT2 transfected cells on 
blood glutamate lowering and their protective effect on 
ischemic damage, cells were administered in ischemic animal 
model and their effect were compared with non-transfected 
cells and with oxaloacetate, used a positive control of blood 
glutamate reduction. Control group was treated with saline. 
6.8.1. Timeline of the study 
This study was divided into two steps: a dose-response study 
and protective study. 
a. Dose-response study 
Previously a dose-response study was performed in healthy 
animals, with the aim to determine the optimal cell dose able 
to induce a reduction in serum glutamate levels. For that, the 
following experimental groups were done: 
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a) Control group (n=3): treated (i.v.) with 1ml of 
PBS.  
b) Oxaloacetate group (n=3): treated (i.v.) with 1ml 
of 3.5 mg/100g. 
c) 3x106 HEK cells non-transfected cells (n=3), 
defined as HEK- (1 mL). 
d) 3x106 HEK cells transfected with EAAT2 (n=3), 
defined as HEK+ (1 mL). 
e) 3x106 and 9x106 MSCs non-transfected (n=3), 
defined as MSCs- (1mL). 
f) 3x106 and 9x106 MSCs transfected with the EAAT2 
(n=3), defined as MSCs+ (1 mL). 
To determine the effect of the treatments on blood 
glutamate, blood samples (500 µl) were taken (from vein 
tail) under basal conditions (before treatment injection), and 
1, 2, 3, 5, 4, 6 and 24 h after treatment injection. 
Treatments were administered through the jugular vein in a 
bolus during 10 wingover treatment administration, the 
animals were maintained under sevoflurane 1% in 
O2:N2O/30:70. 
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b. Protective study 
In order to evaluate the protective properties of the cellular 
treatments in an animal model of ischemic stroke, 8 groups 
were studied:  
a) Control group (n=6): treated (i.v.) with 1ml of 
PBS. 
b) Oxaloacetate group (n=6): treated (i.v.) with 1ml 
of 3.5mg/100g. 
c) HEK- group (n=6): treated (i.v.) with 1ml of 3x106 
control HEK- cells. 
d) HEK+ group (n=6): treated (i.v.) with 1ml of 
3x106 HEK+ cells. 
e) MSC- group (n=6): treated (i.v.) with 1ml of 
3x106 HEK- cells. 
f) HEK+ group (n=6): treated (i.v.) with 1ml of 
9x106 HEK+ cells. 
g) MSC- group (n=6): treated (i.v.) with 1ml of 
9x106 HEK- cells. 
To determine the capacity of the treatments to induce a 
blood glutamate reduction and a protective effect, serum 
glutamate levels, infarct volume and functional deficit were 
measured in the experimental animals. Treatments were 
administered immediately after reperfusion (45 min after 
occlusion). Serum glutamate concentration was determined 
under basal conditions (before surgery), and 1, 2, 3, 4, 5, 6 
h after treatment administration and 1, 7 and 14 days after 
ischemia for further glutamate determinations. Infarct 
volume was determined during occlusion (to determine the 
basal lesion before treatment administration), 1, 7 and 14 
days after ischemia. Sensorimotor test (Cylinder test and 
Modified Neurological Severity Scores; mNSS) was performed 
under basal conditions (1 day before surgery) and 14 days 
after ischemia. Finally, on the 14th day, animals were 
transcardially perfused and their brains processed as 
described previously for future histology analysis. 
Experimental protocol can be observed in Figure 18. 
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Figure 18: Timeline evaluation of the therapeutic benefits of the different 
treatments in an animal model of ischemic stroke. 
6.8.2. Animal procedures 
a. Animal management 
In this study we have used 202 male Wistar rats (Harlan 
Laboratories, Barcelona, Spain) with a weight of 300±25 g. 
Of the total number of Wistar animals, 72 animals were 
discarded for not meeting the inclusion criteria and 11 
animals died. Animals were kept at controlled conditions of 
temperature (22±1ºC) and humidity (60±5%), with a 12/12 
h light/ dark cycle for a period of one week prior to surgery 
and up to 14 days after surgery. The rats were granted free 
access to food (commercial chow pellets) and tap water. For 
surgery and MRI, rats were anesthetize with sevoflurane (3% 
in 70% N2O and 30% O2). Rectal temperature was monitored 
and maintained at 37±0.5ºC with a feedback controlled 
heating system (1025 system, SA Instruments). At the end 
of the procedures animals were sacrificed under deep 
anesthesia (8% sevoflurane). Experimental protocols were 
approved by the local Animal Care Committee according to 
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the Spanish and European Union (EU) rules (86/609/CEE, 
2003/65/CE, 2010/63/EU, RD 1201/2005 and RD53/2013). 
b. Model of focal transient ischemia in rat 
Transient focal ischemia was induced in rats by intraluminal 
occlusion of the middle cerebral artery (tMCAO), performed 
as previously described305 with several modifications. In 
order to monitor the relative cerebral blood flow (CBF) during 
the surgery, a laser-Doppler flow probe (tip diameter 1mm) 
attached to a flow meter (PeriFlux 5000; Perimed AB) was 
located over the thinned skull, and over the middle cerebral 
artery territory (approximately 4mm lateral to bregma). 
Under a surgical microscope, common carotid, external 
carotid, and the internal carotid arteries of the left side were 
dissected from connective tissue through a midline neck 
incision. Left external carotid and pterygopalatine arteries 
were separated and tied with 6-0 silk sutures, showing a CBF 
reduction of 20%, measured by laser Doppler. A silicon 
rubber-coated monofilament (403512PK5Re; Doccol 
Corporation, USA) was inserted through the external carotid 
into the left common carotid artery and advanced into the 
internal carotid from the bifurcation to occlude the origin of 
the Macbeth vertebral arteries remained intact in all surgical 
procedures. Once the artery was occluded, determined by 
Doppler signal reduction, the animals were carefully moved 
from the surgical bench to a Magnetic Resonance (MR), with 
the aim to determine the basal ischemic lesion by means of 
apparent diffusion coefficient (ADC) maps. Angiography 
imaging was also performed to confirm the artery remained 
occluded over the MR study. After basal MR analysis, animals 
were returned to the surgical bench and Doppler probe was 
repositioned. Reperfusion was performed 45 min after the 
occlusion onset. Animals were subsequently randomized in 
experimental groups performed, by using computer-
generated random numbers. 
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c. Inclusion criteria 
Only animals with a cerebral blood reduction (CBR) higher 
than 60% and with reperfusion after occlusion, MCA occluded 
on MR angiography and an infarct volume during the 
occlusion between 35-45% of the hemisphere were included 
in this study. 
6.8.3. Blood serum determinations: glutamate 
analysis 
Venous blood was collected from the tail vein at different 
times which are specified in the section 6.8.1. Blood samples 
were collected in test tubes (BD Microtainer), centrifuged at 
3,000 rpm for 7 min; serum was removed and immediately 
frozen and stored at –80°C. Serum glutamate concentration 
was determined by means of Glutamate Assay Kit (Abnova, 
Taiwan) following the manufacturer's technical specifications. 
6.8.4. Treatment administration  
Animals were intravenously injected into the jugular vein. 
First, animals were anesthetized with sevoflurane 3% in 
O2:N2O/30:70. Then a 0.5 cm incision was made in the 
animal´s neck just above the clavicle 1cm to both left and 
right of the midline. Subcutaneous fat was cut out, and the 
jugular vein was exposed. A 30g needle was used for every 
injection after withdrawal, the puncture is rapidly closed to 
preventing bleeding. 
6.8.5. Functional test 
In all animals, a battery of behavioral tests was performed 
before MCAO and 7, 14 days after MCAO by a researcher, 
who was blinded to the experimental groups. The battery of 
tests consisted of the Cylinder test and the Modified 
Neurological Severity Score (mNSS)306. 
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a. Cylinder test 
The Cylinder test was performed as described in the 
section.5.7. 
b. Modified Neurological Severity Scores (mNSS) 
One of the most common neurological scales used in animal 
studies of stroke is the modified neurological severity scores 
(mNSS Neurological function was graded on a scale of 0 to 
12 (normal score, 0; maximal deficits core, 12). The mNSS is 
a composite of motor, sensory, reflex, and balance tests. In 
the severity scores of injury, 1 score point is awarded for the 
inability to perform the test or for the lack of a tested reflex; 
thus, the higher the score, the more severe is the injury. 
Table shows a set of the mNSS. 
Placing rat on floor  
Normal walk 3 
Inability to walk straight 1 
Circling toward paretic side 1 
Falls down to paretic side 1 
  
Proprioceptive test (deep sensation, pushing paw against table edge 
to stimulate limb muscles) 
Posterior limb 
 
1 
Anterior limb 1 
  
Raising rat by tail  
No flexion of forelimb 1 
Head moved 10º to vertical axis within 30s 1 
Lack of visual placing 1 
  
Suspension of the half posterior of the body  
Turn to the side of the lesion 1 
  
Maximum points 12 
Table 6: One point is awarded for inability to perform the tasks or for lack of 
a tested reflex: 1-3, mild injury; 6-9, moderate injury; 9-12, severe injury. 
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6.8.6. Magnetic resonance studies 
Magnetic resonance imaging studies were conducted on a 9.4 
T horizontal bore magnet (Bruker BioSpin, Ettligen, 
Germany) with 20 cm wide actively shielded gradient coils 
(440mT/m). Radio-frequency transmission was achieved with 
a birdcage volume resonator; signal was detected using a 
four-element surface coil, positioned over the head of the 
animal, which was fixed with a teeth bar, earplugs, and 
adhesive tape. Transmission and reception coils were actively 
decoupled from each other. Gradient-echo pilot scans were 
performed at the beginning of each imaging session for 
accurate positioning of the animal inside the magnet bore. 
a. Imaging protocol 
Infarct size and angiography were assessed by magnetic 
resonance imaging. For this purpose, MRA and DWI-ADC 
during the occlusion, and MR T2 on the 1st, 7th and 30th 
days after the ischemia described in 5.8.2 were employed. 
b. Image analysis 
All images were processed using ImageJ (Rasband WS, 
ImageJ, NIH, http://rsb.info.nih.gov/ij). Infarct volumes 
were determined from ADC maps and T2 maps by manually 
selecting areas of reduced ADC values or hyperintense T2 
signal by a researcher blinded to the animal protocol. 
6.9. Statistical analysis 
All data are presented as the mean and standard error of the 
mean (mean ± SEM). One-way or two-way analysis of 
variance (ANOVA) followed by post-hoc Bonferroni evaluation 
was used for multiple groups to determine significant 
differences. Student’s t-test was used to test the differences 
between two groups. Statistical significance was set at 
*p<0.05, **p<0.01 and ***p<0.001. The statistical analysis 
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was conducted using PASW Statistics 18 for MAC (SPSS Inc., 
Chicago, CA, USA). 
6.10. Summary procedure 
In Figure 19 is described all experimental procedures 
necessary to obtain and characterize EAAT2-cells used to test 
their effect on blood glutamate reduction and protection on 
ischemic animal model. 
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Figure 19: Summary of the experimental procedure. 
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7.Section I: Analysis of protective 
effect of rGOT in ischemia 
7.1. Animals included in the study. 
A total of 119 animals were used in this study. Thirty-six 
animals were used in the rGOT1 dose–response study, six 
animals per group (six groups of treatments). In this study, 
no animal deaths were observed within the first 24 h after 
treatments administration. In the protective study, 60 
animals were included, six animals/group (four groups in the 
spectroscopic study and other six groups in the non-
spectroscopic study). Eighteen animals were excluded, 16 of 
them were not included because of unsuccessful MCA 
occlusion or reperfusion and 2 animals died 24 h after 
surgery (1 treated with saline and 1 treated with rGOT1). 
Finally, 5 animals were used as sham-operated control rats 
(sham) without MCAO. 
7.2. rGOT1 dose-response study 
7.2.1. Dose-response effect of oxaloacetate and 
rGOT1 treatments on serum glutamate 
concentration in healthy animals. 
Administration of saline (control group) did not affect 
(p=0.373) the basal concentration of glutamate during 24 h 
after the i.v. administration (Table 7 and Figure 20A), 
demonstrating that the surgical procedure did not interfere 
with the serum glutamate concentration. Injection of 
glutamate (15 mM) induced a significant (p<0.05) increase in 
serum glutamate concentration 1 h after administration 
(Table 7 and Figure 20B). Basal concentration was 
normalized 3 h after treatment administration. This effect 
shows that the administration of glutamate in healthy 
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animals could be used to simulate the increase in serum 
glutamate, a hallmark biochemical parameter after ischemia. 
 Saline (A) Glutamate 15mM (B) 
Basal 160±15 150±23 
1h 155±23 196±27 
2h 151±30 168±22 
4h 158±18 152±17 
6h 162±22 145±23 
24h 150±20 156±14 
Table 7: Blood glutamate levels after i.v. administration of (A) saline and (B) 
Glutamate (15mM).  
 
Figure 20: Blood glutamate levels after i.v. administration of (A) saline and 
(B) Glutamate (15mM). 
On the basis of previous reports where rGOT1 has been used 
to study other pathologies, we started with a dose of 6.44 
µg/100g to analyze the capacity of the enzyme to metabolize 
serum glutamate. Administration of 6.44 µg/100g of rGOT1 
induced a reduction (p<0.01) (Table 8 and Figure 21A) in 
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serum glutamate concentration with respect to the maximum 
increase observed after glutamate injection. The maximum 
effect appeared between 2 and 4 h after administration of 
treatment. A higher dose of 12.88 µg/100g rGOT1 induced a 
robust reduction (p<0.01) in serum glutamate concentration 
(Table 8 and Figure 21B). Similar to the previous dose, the 
maximum lowering effect appeared between 2 and 4 h after 
administration of treatment; however, in this case, the 
capacity to reduce serum glutamate concentration was much 
higher. Administration of rGOT1 25.76 µg/100g induced a 
significant (p=0.007) reduction in serum glutamate 
concentration (Table 8 and Figure 21C). The maximum effect 
appeared between 2 and 4 h after administration of the 
treatment; however, the capacity of this dose to reduce 
serum glutamate concentration was similar to the 12.88 
µg/100g dose. These findings showed that 12.88 µg/100g 
seems to be the most appropriate dose of rGOT1 to achieve a 
significant reduction in the serum glutamate concentration in 
the animals. Of note, serum glutamate concentrations were 
normalized 4–6 h after rGOT1 administration, demonstrating 
that the effect of the enzymatic treatment is transient. 
In order to determine whether the effect of the enzyme could 
be potentiated by oxaloacetate (co-substrate of the 
enzymatic reaction), the dose of rGOT1 (12.88 µg/100g) was 
supplemented with a non-effective dose of oxaloacetate (1.5 
mg/100g). In our previous study (already published6), we 
had described that a dose of 1.5 mg/100g of oxaloacetate did 
not affect the serum glutamate levels. Similar results were 
observed again in this study (Table 8 and Figure 21D). 
Administration of rGOT1 12.88 µg/100g with oxaloacetate 
(1.5 mg/100g) induced an immediate and significant 
(p<0.01) lowering of serum glutamate concentration, which is 
the gold standard approach for reducing increased glutamate 
levels after brain ischemia. The decrease in glutamate 
appeared 30 min (with respect to the basal values) after 
treatment administration and remained during at least 3 h 
(Table 8 and Figure 21E); however, no significant differences 
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with respect to rGOT1 12.88 µg/100g alone were observed. 
These results led us to examine whether the protective 
efficacy of rGOT1 (12.88 µg/100g) or rGOT1 (12.88 
µg/100g) supplemented with oxaloacetate (1.5 mg/100g) in 
ischemic animals was higher than that observed previously 
with oxaloacetate 3.5 mg/100g.6 
 
Untreat 
rGOT 
6.44 
mg/100g 
rGOT 
12.88 
mg/100g 
rGOT 
25.76 
mg/100gr 
rGOT 12.88 
mg/100g 
+Oxal 1.5 
mg/100g 
Oxal 
1.5 
mg/100g 
Basal 150±23 145±34 156±42 147±25 145±34 145±21 
1h 196±27 140±14 123±31 114±56 96±12 185±32 
2h 168±22 110±23 98±19 100±63 74±12 170±24 
4h 152±17 107±20 75±23 74±34 68±21 165±29 
6h 145±23 148±18 150±31 158±20 132±34 155±14 
24h 156±14 159±27 152±23 161±34 144±24 145±20 
Table 8: Effect of rGOT and oxaloacetate (Oxal) on serum glutamate levels 
in healthy rats. Glutamate 15mM was injected i.v. 30 min prior to 
treatments. (A) Comparison between rats treated with glutamate 15mM 
(blue line) and rats treated with glutamate 15mM and rGOT1 6.44 µg/100g 
(black line).(B) Comparison between rats treated with glutamate 15mM 
(blue line) and rats treated with glutamate 15mM and rGOT1 µg/100g (black 
line).(C) Comparison between rats treated with glutamate (15 mM) (blue 
line) and rats treated with glutamate (15 mM) and with rGOT1 (25.76 
µg/100g).(D) Comparison between rats treated with glutamate 15mM (blue 
line) and rats treated with glutamate (15 mM) and oxaloacetate (Oxal) (1.5 
mg/100g).(E) Comparison between rats treated with glutamate (15 mM) 
(blue line) and rats treated with glutamate (15 mM) and rGOT1 (12.88 
µg/100g) plus oxaloacetate (Oxal) (1.5 mg/100g). 
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Figure 21: Effect of rGOT and oxaloacetate (Oxal) on serum glutamate levels 
in healthy rats. Glutamate 15mM was injected i.v. 30 min prior to 
treatments. (A) Comparison between rats treated with glutamate 15mM 
(blue line) and rats treated with glutamate 15mM and rGOT1 6.44 µg/100g 
(black line).(B) Comparison between rats treated with glutamate 15mM 
(blue line) and rats treated with glutamate 15mM and rGOT1 µg/100g (black 
line).(C) Comparison between rats treated with glutamate (15 mM) (blue 
line) and rats treated with glutamate (15 mM) and with rGOT1 (25.76 
µg/100g).(D) Comparison between rats treated with glutamate 15mM (blue 
line) and rats treated with glutamate (15 mM) and oxaloacetate (Oxal) (1.5 
mg/100g).(E) Comparison between rats treated with glutamate (15 mM) 
(blue line) and rats treated with glutamate (15 mM) and rGOT1 (12.88 
µg/100g) plus oxaloacetate (Oxal) (1.5 mg/100g). 
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7.3. Protective study 
7.3.1. Study of the protective effect of rGOT1 with 
or without supplementation of oxaloacetate on 
ischemic animals 
MCAO induced an increase of 30% of serum glutamate 
concentration 1 h after reperfusion (Table 9 and Figure 22), 
returning to normal levels 3 h later. In sham operated rats in 
which MCA was not occluded, no changes in serum glutamate 
concentration were detected (data not shown). 
 Saline Oxal rGOT 1 Oxal+rGOT1 
Basal 149,7 ±25,7 149,7±45,8 153,2±21,9 132,3±37,8 
0 172,0±60,4 166,1±64,6 168,3±29,9 154,8±43,1 
60 min 190,5±37,8 113,4±46,4 100,5±21,1 101,3±41,9 
120 min 188,5±20,9 130,4±33,1 111,2±52,7 124,6±39,0 
180 min 163,7±24,3 130,5±23,1 106,5±56,1 134,7±43,2 
Table 9: Serum glutamate concentration (µM) in MCAO rats. MCAO rats were 
treated with saline (control group) (n=6), oxaloacetate (Oxal) 3.5 mg/100g 
(n¼6), rGOT1 12.88 µg/100g (n=6) and rGOT1 12.88 µg/100g plus 
oxaloacetate 1.5 mg/100g (n=6).  
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Figure 22: Time course of serum glutamate concentration (µM) in MCAO 
rats. MCAO rats were treated with saline (control group) (n=6), oxaloacetate 
(Oxal) 3.5 mg/100g (n¼6), rGOT1 12.88 µg/100g (n=6) and rGOT1 12.88 
µg/100g plus oxaloacetate 1.5 mg/100g (n=6). Solid arrow indicates the 
time of treatment injection, administered at the moment of reperfusion (80 
min after occlusion). Serum glutamate concentration was measured under 
basal conditions (before surgery), at the moment of the reperfusion (before 
treatment administration), and 1, 2 and 3 h after reperfusion. Data are 
shown as mean±S.E.M.*p<0.05, **p<0.01 compared with control group. 
The increase in serum glutamate concentration after cerebral 
ischemia was inhibited (p<0.05) by each one of the three 
treatments; rGOT1 (12.88 µg/100g), oxaloacetate (3.5 
mg/100g) and rGOT1 plus oxaloacetate (12.88 µg/100g and 
1.5 mg/100g, respectively) (Table 9 and Figure 22). The 
small differences observed between the treatments were not 
statistically significant. 
To confirm that treatment with rGOT1 induced an increase in 
systemic GOT1 activity, their levels were measured at 
different time points (Table 10 and Figure 23). GOT1 
activities in the control and oxaloacetate groups were not 
altered after treatment, whereas rGOT1 treatments induced a 
significant (p<0.01) increase in serum GOT activity 1 h after 
administration, which returned close to normal levels 24 h 
after treatment administration. 
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 Saline Oxal rGOT 1 Oxal+rGOT1 
Basal 80 ±13 75±10 79±8 82±9 
1 h 75 ± 10 78±8 1400±45 1555±35 
3 h 110±12 130±10 1367±67 1600±78 
24 h 120±15 150±20 300±25 350±30 
Table 10: Time course of serum GOT activity in MCAO rats. MCAO rats were 
treated with saline (control group) (n=6), oxaloacetate (Oxal) 3.5 mg/100g 
(n=6), rGOT1 12.88 µg/100g (n=6) and rGOT1 12.88 µg/100g plus 
oxaloacetate 1.5 mg/100g (n=6). Treatments were administered at the 
moment of reperfusion (80 min after occlusion). GOT activity was measured 
under basal conditions (before surgery), and 1, 3 and 24 h after reperfusion. 
Data are shown as percentage compared with basal levels±S.E.M. 
 
Figure 23: Time course of serum GOT activity in MCAO rats. MCAO rats were 
treated with saline (control group) (n=6), oxaloacetate (Oxal) 3.5 mg/100g 
(n=6), rGOT1 12.88 µg/100g (n=6) and rGOT1 12.88 µg/100g plus 
oxaloacetate 1.5 mg/100g (n=6). Treatments were administered at the 
moment of reperfusion (80 min after occlusion). GOT activity was measured 
under basal conditions (before surgery), and 1, 3 and 24 h after reperfusion. 
Data are shown as percentage compared with basal levels±S.E.M. **p <0.01 
with respect to control group. 
To confirm that serum glutamate reduction caused by the 
three treatments led a reduction of brain glutamate, MRS 
was performed on brain ischemic animals. Quantitative 
analysis of MRS revealed a persistent increase in brain 
glutamate levels after the occlusion of MCA in the control 
group. Glutamate levels in the brain parenchyma were 
significantly decreased (p<0.05 relative to the control 
animals), with each of the three treatments tested (Table 11, 
Figure 24 and Figure 25). 
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 Saline Oxal rGOT 1 Oxal+rGOT1 
25 min 1,4±0,3 1,4±0,1 1,6±0,4 1,5±0,3 
50 min 1,5±0,3 1,6±0,3 1,6±0,4 1,6±0,4 
80 min 1,8±0,2 1,7±0,3 1,7±0,1 1,8±0,2 
25 min 1,8±0,4 1,6±0,5 1,3±0,1 1,4±0,2 
50 min 1,7±0,5 1,2±0,1 0,9±0,1 1,1±0,1 
75 min 1,6±0,4 1,1±0,4 1,0±0,1 1,0±0,1 
100 min 1,7±0,4 1,0±0,4 0,8±0,1 0,8±0,1 
125 min 1,6±0,3 0,8±0,2 0,8±0,2 0,9±0,1 
150 min 1,5±0,3 0,9±0,2 0,8±0,1 0,9±0,1 
175 min 1,3±0,5 1,0±0,1 1,0±0,1 1,1±0,2 
Table 11: Magnetic resonance spectroscopy of the time course of brain 
glutamate levels in MCAO rats treated with saline (control group) (n=6), 
oxaloacetate (Oxal) 3.5 mg/100 g (n=6), rGOT1 12.88 µg/100g (n=6) and 
rGOT1 12.88 µg/100g plus oxaloacetate 1.5 mg/100g (n=6). 
 
Figure 24: MRS analysis. Quantitative analysis of glutamate signals were 
normalized to creatine (Cr) peaks for each single spectra. Brain glutamate 
levels were analyzed during the occlusion (80 min) and during reperfusion 
(180 min). Brain glutamate levels were similar in treated (before treatment) 
and control (treated with saline) ischemic animals during occlusion. 
However, during reperfusion glutamate levels were lower in treated animals 
compared with the control. 
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Figure 25: MRS analysis. Time course of brain glutamate levels in MCAO rats 
treated with saline (control group) (n=6), oxaloacetate (Oxal) 3.5 mg/100 g 
(n=6), rGOT1 12.88 µg/100g (n=6) and rGOT1 12.88 µg/100g plus 
oxaloacetate 1.5 mg/100g (n=6). Solid arrow indicates the moment of i.v 
treatment. Cerebral glutamate levels were measured during occlusion (80 
min) and reperfusion (180 min). MRS analysis was performed in an 
independent group of animals. Data are shown as the mean of cerebral 
glutamate levels relative to the contralateral region±S.E.M. Blue dashed line 
indicates the levels of brain glutamate in the contralateral region.*p<0.05, 
**p<0.01 compared with control group. 
In order to demonstrate that the reduction in serum and 
brain glutamate levels observed after treatment 
administration produced a protective effect in our animal 
model of cerebral ischemia, infarct volumes were measured 
at 24 h and 7 days after ischemia and were compared with 
the control group. Table 13 and Figure 26 show that, 
although all treatments were able to induce a significant 
(p<0.05) protection against the ischemic damage both 24 h 
and 7 days after the onset of ischemia, rGOT1+oxaloacetate 
revealed to be the more effective treatment (p<0.01, with 
respect to the control group). Analysis of infarct volumes 
adjusted to the ipsilateral hemisphere showed a similar 
protective profile (data not shown). Infarct volumes 
measured in those animals subjected to the spectroscopy 
protocol (Table 12 and Figure 27) showed the same 
protective results for the 3 treatments. Diffusion images 
revealed that all animals subjected to spectroscopy 
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presented the same ischemic damage before the treatment 
administration. 
 Saline Oxal rGOT 1 Oxal+rGOT1 
Basal 100 100 100 100 
24d 98±17 77±16 74±11 47±15 
7d  66±19 52±11 42±7 29±19 
Table 12: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with saline (control group), oxaloacetate (Oxal) 3.5 mg/100g, 
rGOT1 12.88 µg/100g and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 
mg/100g. Treatments were administered at the moment of the reperfusion. 
Infarct size was assessed in ischemic rats subjected to spectroscopy 
analysis. Infarct sizes were measured at 24 h and 7 days after ischemia. 
ADC basal volumes were determined before the administration of treatment. 
Data is shown as the percentage relative to the basal infarct volume.  
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Figure 26: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with saline (control group), oxaloacetate (Oxal) 3.5 mg/100g, 
rGOT1 12.88 µg/100g and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 
mg/100g. Treatments were administered at the moment of the reperfusion. 
Infarct size was assessed in ischemic rats not subjected to spectrocopy 
analysis. Infarct sizes were measured at 24 h and 7 days after ischemia. 
Data are shown as the mean of infarct volume (mm3) ± S.E.M.*p<0.05, 
**p<0.01 with respect to the control group at 24 h; #p<0.05, ##p<0.01 as 
well as on day 7. 
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 Saline Oxal rGOT 1 Oxal+rGOT1 
24h 283±47 192±56 165±62 147±61 
7d 192±79 142±68 106±54 95±62 
Table 13: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with saline (control group), oxaloacetate (Oxal) 3.5 mg/100g, 
rGOT1 12.88 µg/100g and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 
mg/100g. Treatments were administered at the moment of the reperfusion. 
Infarct size was assessed in ischemic rats not subjected to spectrocopy 
analysis. Data is shown as the mean of infarct volume (mm3) ± S.E.M. 
 
Figure 27: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with saline (control group), oxaloacetate (Oxal) 3.5 mg/100g, 
rGOT1 12.88 µg/100g and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 
mg/100g. Treatments were administered at the moment of the reperfusion. 
Infarct size was assessed in ischemic rats not subjected to spectrocopy 
analysis. Infarct sizes were measured at 24 h and 7 days after ischemia. 
Data are shown as the percentage relative to the basal volume.*p<0.05, 
**p<0.01 with respect to the control group at 24 h; #p<0.05, ##p<0.01 as 
well as on day 7. 
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To determine the therapeutic window of rGOT1 treatments, 2 
groups of animals were treated 1 h after reperfusion (140 
min after occlusion). Analysis of serum glutamate 
concentration in animals treated with rGOT1 (12.88 µg/100g) 
or rGOT1 plus oxaloacetate (12.88 µg/100g and 1.5 
mg/100g, respectively) showed that both treatments caused 
a significant (p<0.05) inhibition of the increase in glutamate 
observed in the control group (Table 14 and Figure 28). 
 Saline rGOT1 (+1h) Oxal+rGOT1 (+1h) 
Basal 149,7±25,7 153,2±21,9 132,3±37,8 
0 172,0±60,4 168,3±29,9 154,8±43,1 
60 190,5±37,8 189,0±21,1 197,0±41,9 
120 188,5±20,9 111,2±52,7 124,6±39,0 
180 163,7±24,3 112,0±67,0 134,7±43,2 
Table 14: Serum glutamate concentration (µM) in MCAO rats. MCAO rats 
were treated with saline (control group) (n=6), rGOT1 12.88 µg/100g (n=6) 
and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 mg/100g (n=6) 1 h after 
reperfusion. Serum glutamate concentration was measured under basal 
conditions (before surgery), at the time of reperfusion (before treatment 
administration), and 1, 2 and 3 h after reperfusion. Data are shown as 
mean±S.E.M. 
 
Figure 28: Time course of serum glutamate concentration (µM) in MCAO 
rats. MCAO rats were treated with saline (control group) (n=6), rGOT1 12.88 
µg/100g (n=6) and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 mg/100g 
(n=6) 1 h after reperfusion. Solid arrow indicates the time of the i.v. 
treatments. Serum glutamate concentration was measured under basal 
conditions (before surgery), at the time of reperfusion (before treatment 
administration), and 1, 2 and 3 h after reperfusion. Data are shown as 
mean±S.E.M.*p<0.05, **p<0.01 with respect to the control group. 
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Analysis of infarct volume determined that both treatments 
displayed similar infarct volume reduction at 24 h when 
administered immediately after reperfusion (Table 15, Table 
16, Figure 29 and Figure 30), however, while the protective 
effect induced for rGOT1 disappears when this treatment is 
given 1 h after reperfusion on day 7; when rGOT1 is 
administered in combination with oxaloacetate, the effect 
persists beyond 1 h after reperfusion (p<0.05, with respect to 
the control). 
 Saline rGOT 1 rGOT1 (+1h) 
24h 283±47 165±62 176±56 
7d 192±79 106±54 153±27 
Table 15: Infarct size measured by MRI in MCAO rats. MCAO rats were 
treated at 2 different times, at the moment of reperfusion and 1 h after 
reperfusion.(A) Saline (control group) (n=6), rGOT1 12.88 µg/100g (rGOT1) 
(n=6) at the moment of reperfusion, and rGOT1 12.88 µg/100g (rGOT1+1 
h) (n=6) 1 h after reperfusion. Data are shown as the mean of infarct 
volume (mm3) ±S.E.M. 
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Figure 29:Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated at 2 different times, at the moment of reperfusion and 1 h after 
reperfusion.(A) Saline (control group) (n=6), rGOT1 12.88 µg/100g (rGOT1) 
(n=6) at the moment of reperfusion, and rGOT1 12.88 µg/100g (rGOT1+1 
h) (n=6) 1 h after reperfusion. Data are shown as the mean of infarct 
volume (mm3) ±S.E.M.*p<0.05, **p<0.01 compared with control group at 
24 h; #p<0.05, ##p<0.01 with respect to control group at day 7. 
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 Saline rGOT 1 rGOT1 (+1h) 
24h 283±47 147±61 152±35 
7d 192±79 95±62 133±32 
Table 16: Infarct size determined by MRI in MCAO rats. MCAO rats were 
treated at 2 different times, at the moment of reperfusion and 1 h after 
reperfusion. Saline (control group) (n=6), rGOT1 12.88 µg/100g plus 
oxaloacetate 1.5 mg/100g (Oxal+rGOT1) (n=6) at the time of the 
reperfusion and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 mg/100g 
(Oxal+rGOT1 +1 h) (n=6) 1 h after reperfusion. Data are shown as the 
mean of infarct volume (mm3) ±S.E.M. 
 
Figure 30: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated at 2 different times, at the moment of reperfusion and 1 h after 
reperfusion. Saline (control group) (n=6), rGOT1 12.88 µg/100g plus 
oxaloacetate 1.5 mg/100g (Oxal+rGOT1) (n=6) at the time of the 
reperfusion and rGOT1 12.88 µg/100g plus oxaloacetate 1.5 mg/100g 
(Oxal+rGOT1 +1 h) (n=6) 1 h after reperfusion. Data are shown as the 
mean of infarct volume (mm3) ±S.E.M.*p<0.05, **p<0.01 compared with 
control group at 24 h; #p<0.05, ##p<0.01 with respect to control group at 
day 7.  
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Somatosensory test, an important end point assay of drug 
screening in stroke, confirmed that reduction in infarct 
volume observed with each of the 3 treatments was 
associated with a better neurological outcome measured 7 
days after ischemia, showing the treatment rGOT1 
oxaloacetate to be a superior effect (p<0.01, with respect to 
the control) (Table 17 and Figure 31). 
Group Laterality index (7days) 
Baseline 48,99±0,06 
Saline 94,29±0,12 
Oxal 74,17±0,20 
rGOT1 63,77±0,13 
Oxal+rGOT1 56,67±0,16 
rGOT1 (+1h) 70,00±0,23 
Oxal+rGOT1(+1h) 65,00±0,15 
Table 17: Effect of treatments on somatosensory test. Sensorimotor deficits 
after an ischemic insult were assessed using the cylinder test and quantified 
by laterality index. +1 h denotes that those treatments were administered 1 
h after reperfusion. Other treatments were administered at the moment of 
the reperfusion. Somatosensory tests were performed 1 day before surgery 
(baseline) and on day 7 after MCAO. Values represent the mean±S.E.M, 
n=6. 
 
Figure 31: Effect of treatments on somatosensory test. Sensorimotor deficits 
after an ischemic insult were assessed using the cylinder test and quantified 
by laterality index. +1 h denotes that those treatments were administered 1 
h after reperfusion. Other treatments were administered at the moment of 
the reperfusion. Somatosensory tests were performed 1 day before surgery 
(baseline) and on day 7 after MCAO. Values represent the mean±S.E.M, 
n=6.*p<0.05, **p<0.01 relative to control group. 
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8.Section II: Effect of glutamate 
grabbers cells on ischemic 
damage. 
8.1. Plasmid EAAT2 production for virus cell 
infection. 
Previously, in this section, it will be explained those results 
regarding to the plasmid EAAT2 production used for virus cell 
infection. 
• Long construct production: YFP-EAAT2 
The sequence YFP-EAAT2 was obtained from the digestion of 
the original plasmid pRcCMVmYFPEAAT2 with the restriction 
enzyme EcoRI (Figure 32A). The digested DNA was 
electrophoresed on agarose gels and 3 fragments were 
obtained. In Figure 32B we can observe the fragments of the 
YPF-EAAT2 sequence (~2500 bp) and other 2 sequences 
(~5000 bp and ~900 bp) after enzymatic digestion, which 
belongs to the backbone of the plasmid.  
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Figure 32: (A) Digestion of the plasmid pRcCMVmYFPEAAT2 with EcoRI, that 
should originate 3 fragments: One sequence of ~5000 pb other of ~900 pb 
corresponding to backbone of the plasmid and 1 sequence of ~2500pb 
belongs to the YFP-EAAT2, long construct.(B)The result of the electrophoresis 
of the digested plasmid showed 3 fragments, which corresponding with the 
expected sequences.  
Once obtained the YFP-EAAT2 sequence, this was inserted in 
the viral vector to be used in the production of rAAV virus. 
The viral vector used was csCMV, which was subjected to 
EcoRI digestion process for its linearization. Next, the vector 
was electrophoresed and the fragment obtained was excised 
and purified. In addition, the linearizated vector was 
dephosphorylated for preventing the circulation. Once the 
vector was ready, it was carried out the ligation process 
(Figure 33). 
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Figure 33: (A) The long construct YFP-EAAT2 was obtained by the restriction 
of the plasmid pRcCMVmYFP-EAAT2 with EcoRI. (B)The viral vector 
(sCCMVm) was submitted to restriction with EcoRI for linearization; C) YFP-
EAAT2 inserted in the viral vector. 
After ligation process (insertion of YFP-EAAT2 sequence in 
viral vector), 18 colonies were grown and picked in LB 
medium. The isolation of plasmid DNA, which consists of the 
insert YFP-EAAT2 and the viral vector, was done with the kit 
NucleoSpin Plasmid. The DNA obtained was subjected to the 
following restriction controls (EcoRI, SmaI and AhdI) to 
ensure that the insert was cloned successfully in the viral 
vector. 
The result of the restriction with EcoRI (Figure 35) should 
generate 2 fragments (the insert YFP-EAAT2 ~2500pb and 
the backbone of the viral vector ~5000 bp) (Figure 34). The 
electrophoresis of digested DNA demonstrated that the DNA 
isolated from 16 independent colonies containing the insert 
cloned into the viral vector, however 2 of them showed 
incorrect ligation as it is indicated in the Figure 35. 
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Figure 34: Restriction with EcoRI enzyme of the viral vector that contained 
the insert YFP-EAAT2 resulted in 2 fragments: the insert YFP-EAAT2 
(~2500pb) and the backbone of the viral vector (~5000 bp). 
Figure 35: Electrophoresis of digested DNA demonstrated that the DNA 
isolated from 16 independent colonies containing the insert cloned into the 
viral vector. Only 2 colonies, 3 and 5, showed incorrect ligation as the size of 
the band did not correspond with 2 and 5 Kb. 
The 14 clones selected were subjected to restriction with 
HindIII to certify that the insert was attached in the right 
direction. This restriction control with HindIII should generate 
2 fragments corresponding with the sequence of YFP-EAAT2 
(2500pb) and the backbone of the viral vector (5000pb) 
(Figure 36). As it can see in Figure 37, the clones 4, 8 and 10 
contained the insert (YFP-EAAT2), but unfortunately the 
insert was not in the correct direction, because of the 2 
fragments obtained corresponds to the fragment of 5000 bp 
(backbone of the viral vector), however the fragment had 
1000bp, when the correct size of the insert should be around 
2500pb. 
ITR CMV ITR AmpR
1 181 205 793 799 807 EcoRI 817 2153 5030
YFP-EAAT2
EcoRI
YFP-EAAT2 
2500pb
scCMVm
~ 5000 pb
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Figure 36: Restriction control with HindIII should generate 2 fragments 
corresponding with the sequence of YFP-EAAT2 (2500pb) and the backbone 
of the viral vector (5000pb). 
 
Figure 37: Plasmid DNA containing the viral vector and YFP-EAAT2 was cut 
with HindIII enzyme restriction. Only colonies 4, 8 and 10 showed 2 
fragments, one corresponded to the fragment of 5000 bp (backbone of the 
viral vector) and other of 1000 bp. 
To solve this problem, the clone 4 (that was analyzed by DNA 
sequencing to verify that the YFP-EAAT2 was correct) that 
contained the insert YFP-EAAT2 in the wrong direction into 
the viral vector csCMVm was used to isolate the insert. For 
that, the clone 4 was submitted to restriction with EcoRI, 
electrophoresis and purification process. The DNA of the 
insert was ligated again with the viral vector (csCMVm) and 
the ligation mixture was used to transform competent cells. 
After ligation, 10 colonies were grown and picked in LB 
medium, following the protocol described above. Once, the 
plasmid DNA was isolated and submitted to the same control 
restriction with EcoRI, HindIII, SmaI and AhdI. 
ITR CMV ITR AmpR
1 181 205 793 799 5500
HindIII
2153 50307324
HindIII
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Analyses of EcoRI and HindIII were successful (data not 
show). Then AhdI and SmaI digestion were performed. The 
digestion of the viral vector (csCMV) with the same enzymes 
was carried out as a control restriction. The restriction of the 
viral vector with SmaI should generate 4 fragments (~ 3702 
pb, ~1300 pb and 2 of 11pb) (Figure 38A). While the same 
digestion for the clones (from clone 4) should produce 5 
fragments (with sizes of ~3758 pb, ~2000 pb, ~767 pb and 
2 of 11pb) (Figure 38B). The digestion with AhdI of the viral 
vector should generate 3 fragments (~1239pb, ~2629 pb 
and ~1128 pb) (Figure 39A) and the restriction with AhdI for 
the clones should be 3 fragments (~3700pb, ~2629 pb and 
~1128 pb) (Figure 39B). 
 
Figure 38: (A) Restriction of the viral vector with SmaI should generate 4 
fragments (~ 3702 pb, ~1300 pb and 2 of 11pb).(B) Digestion with SmaI for 
the different clones (from clone 4) should produce 5 fragments (with sizes of 
~3758 pb, ~2000 pb, ~767 pb and 2 of 11pb) 
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Figure 39: (A) The digestion with AhdI of the viral vector should generate 3 
fragments (~1239pb, ~2629 pb and ~1128 pb). (B) The restriction with 
AhdI for the clones should produce 3 fragments (~3700pb, ~2629 pb and 
~1128 pb). 
The results of restrictions with SmaI showed that the viral 
vector was digested correctly, as the number and the sizes of 
the fragments were expected. The restriction was right for all 
the clones (3 fragments with the size correct) (Figure 40A). 
Regarding to the restriction with AhdI, the viral vectors 
generated the expected fragments. However, the digestion of 
the clones showed that only the clones 3, 5 and 6 originated 
the 3 fragments (~3700pb, ~2629pb and ~1128 pb) (Figure 
50B). 
 
Figure 40: (A) Restriction with SmaI. (B) Restriction with AhdI. Only the 
clones 3, 5 and 6 had the insert YFP-EAAT2 cloned in the right direction. 
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Then, the clones 3, 5 and 6 had the insert YFP-EAAT2 cloned 
in the right direction. This final result indicated that this 
plasmid-DNA (viral vector and YFP-EAAT2) was ready for viral 
encapsulation. 
8.1.1. Short construct: Ha-tag-EAAT2 
Due to the viral packaging limitation (see Material and 
Methods), besides of to produce YFP-EAAT2 for viral 
encapsulation, a shorter sequence with EAAT2 (Ha-tag-
EAAT2) was also produced. 
To obtain the Ha-tag-EAAT2 insert, previously the sequence 
YFP-EAAT2 was isolated from the clone 4 (already tested in 
the YFP-EAAT2 production) through the restriction with EcoRI, 
electrophoresis and purification. 
 
Figure 41: Isolation of the sequence YFP-EAAT2 from the clone 4 with EcoRI. 
Then the fragment of interest (EAAT2) was amplificated by 
means of PCR in combination with the probe Ha-tag and 2 
restriction sites for EcoRI and XbaI, indicated in the Figure 
42. 
ITR CMV ITR AmpR
1 181 205 793 799 807 EcoRI 817 2153 5030
YFP-EAAT2
EcoRI
YFP-EAAT2 
2500pb
scCMVm
~ 5000 pb
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Figure 42: Representation of the sequence Ha-tag-EAAT2. 
The PCR-fragment was composed of EAAT2-gen bound to the 
probe Ha-tag and to the restriction sites for EcoRI and XbaI. 
Then, this fragment was purified, digested with EcoRI and 
XbaI, submitted to electrophoresis and purificated again 
(Figure 43A). Later, the insert Ha-tag-EAAT2 was obtained 
and it was ready for cloning in the viral vector (scCMV). 
Previously to the clonation, the viral vector was linearized 
with EcoRI and XbaI (Figure 43 B). Then, the appropriate 
ligation reaction mixtures were done (Figure 44) and used to 
the transformation of competent cells, which were grown in 
selective medium with ampicillin (see Material and Methods). 
 
Figure 43: (A) Electrophoresis of PCR fragment composed of EAAT2-gen 
bound to the probe Ha-tag and to the restriction sites for EcoRI and XbaI. 
(B) scCMV vector linearized by restriction with EcoRI and XbaI. 
Ha-tag-EAAT2
XbaI EcoRI
María Pérez Mato  Results 
170 
 
 
Figure 44:(A)The sequence of XbaI-Ha-tag-EAAT2-EcoRI was created by 
means PCR amplification.(B)Linearization of the viral vector with XbaI and 
EcoRI.(C)Ligation process in which the Ha-Tag-EAAT2 was inserted in the 
scCMVm. 
Apparently those colonies that grew as a result of the ligation 
(100 colonies) had the insert Ha-Tag-EAAT2 cloned in the 
viral vector scCMV. Fourteen colonies were picked and 
seemed in LB medium. Later, the plasmid DNA from the 
different colonies were isoleted and digested with the 
following restriction enzymes: EcoRI, XbaI, SmaI and AhdI. 
The restriction with XbaI and EcoRI should created 2 
fragments: ~1500pb (Hag-tag-EAAT2) and ~5000pb 
(backbone of the viral vector) (Figure 45). The result of the 
digestion with EcoRI and XbaI showed that all the clones had 
the sequence Ha-Tag-EAAT2 (except the clones 8, 10 and 12) 
(Figure 46). 
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Figure 45: The restriction with XbaI and EcoRI should create 2 
fragments:~1500pb (Hag-tag-EAAT2) and ~5000pb (backbone of the viral 
vector). 
 
Figure 46: Resctriction with EcoRI and XbaI showed that all the clones had 
the sequence Ha-Tag-EAAT2 (except the clones 8, 10 and 12). 
Then, the selected clones, which contained the insert Ha-tag-
EAAT2, were submitted to digestion with SmaI and AhdI to 
verify that the insert was in the right direction. Again the 
viral vector was digested with the same enzymes as a control 
restriction. The restriction with SmaI for scCMVm should 
originate the same fragments mentioned in section 0. SmaI 
should produce fragments with a size of ~2772pb, ~3758pb 
and 2 fragments of 11 pb for the clone digestion (Figure 47:  
ITR CMV ITR AmpR
1 181 205 793 799 807 EcoRI 817 2153 5030
YFP-EAAT2
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YFP-EAAT2 
1500pb
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Figure 47: (A)The restriction of the vector with SmaI should generate 4 
fragments (~ 3702 pb, ~1300 pb and 2 of 11pb).(B)Digestion with SmaI for 
the different clones should produce 4 fragments (which sizes were ~3758 
pb, ~2772 pb and 2 of 11pb). 
The digestion of the viral vector with AhdI produced the 
same fragments that were mentioned above. Three 
fragments were generated (~2739pb, ~2629pb and 
~1128pb) (Figure 48 and 18). 
ITR CMV ITR AmpR
181 205 793 799 807 811 503028
SmaI
1311
SmaI
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Figure 48: (A) The digestion with AhdI of the viral vector should generate 3 
fragments (~1239pb, ~2629 pb and ~1128 pb).(B)The restriction with AhdI 
for the clones should produce 3 fragments (~2739pb, ~2629 pb and ~1128 
pb). 
The results of restrictions with AhdI showed that the viral 
vector was digested correctly, because the number and size 
of the fragments were the expected. The restriction was right 
for the clones 3, 5, 6, 9 and 11 (Figure 49A). 
In case of SmaI enzymatic analysis, the viral vectors 
generated the expected fragments (~3758pb, ~2772pb). All 
clones studied contained both fragments (Figure 49B). 
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Figure 49: (A) Restriction with AhdI showed that clones 3, 5, 6, 9 and 11 
originated the expected fragments.(B) The result of the restriction with SmaI 
exhibit that all the clones produced the correct fragments. 
The results indicated that the clones 3, 5, 6, 9 and 11 had 
the insert in the right position (Figure 49). Again, this final 
result indicated that this plasmid-DNA (viral vector and Hag-
tag-EAAT2) was prepared for viral encapsulation. 
 
8.2. Infection of MSC with different 
serotypes of virus rAAV-GFP  
In this point, we have plasmid-DNA (viral vector with YFP-
EAAT2 or with Hag-tag-EAAT2) available for viral 
encapsulation, however it was previously necessary to know 
the viral capside to get the cell infection (important in case 
MCSs). 
With this aim, six viral serotypes (1, 2, 4, 5, 6 and 8) from 
rAAV-GFP were tested on cells (MCSs). Microscopy analysis 
showed that serotypes 2 and serotype 6 were the only ones 
that could infect the MCSs as it can be observe in the Figure 
50. Therefore serotypes 2 and 6 were used for subsequently 
production. 
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Figure 50: Transduction of MCSs with 6 different types of serotypes (rAAV-
YFP), 1, 2, 4, 5, 6, 8. Serotype 2 and 6 were the ones which could infect the 
MSC. 
8.3. Production and purification of 
recombinant adeno-associated viruses 
(rAAVs) 
Based on the previous results of transduction with different 
serotypes in MSCs, serotypes 2 and 6 were chosen for the 
production of rAAV virus, which should incorporate the 
sequence Ha-tag-EAAT2 and YFP-EAAT2. Therefore 4 types of 
virus were generated: rAAV-YFP-EAAT2 serotype 6, rAAV-Ha-
tag-EAAT2 serotype 6, rAAV-YFP-EAAT2 serotype 2 and rAAV-
Ha-tag serotype 2, according to the protocol described in 
Materials and Methods. Real-time PCR was used for the viral 
tittering as appear indicated in the Table 18. 
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 Serotype 6 Serotype 2 
YFP-EAAT2 1.227x107pv/ µl 6.538x107 pv/ µl 
Ha-tag-EAAT2 3.666x108pv/ µl 1.842x108pv/ µl 
Table 18: Titer of virus. 
8.4. Exogenous expression of EAAT2 on 
MSCs cells through viral infection 
In order to induce the exogenous EAAT2 expression in MSCs, 
viral infection was performed as it is described in Material 
and Methods. Toxicity and efficiency of infection were also 
tested. 
8.4.1. Infection with rAAV-YFP-EAAT2 (serotypes 2, 
6) and rAAV-Ha-Tag-EAAT2 (serotypes 2, 6) of 
MSCs  
The MSCs were infected with virus rAAV-YFP-EAAT2 
(serotypes 2, 6) and rAAV-Ha-Tag-EAAT2 (serotypes 2, 6) 
and the toxicity was evaluated by LDH assay. 
Infection of MCSs with rAAV6-YFP-EAAT2 did not show 
toxicity effect respect to the control groups (% respect to 
control group) (Table 19 and Figure 51A).  
rAAV6-YFP-EAAT2 24h 48h 72h 
Control 100±5 100±6 100±5 
Vehicle 101±8 98±10 100±5 
MOI: 1x1010 101±3 96±6 98±16 
MOI: 5x109 101±1 99±5 98±4 
MOI: 1x109 99±9 100±11 99±6 
Table 19: Toxicity analysis induced for different MOI of rAAV6-YFP-EAAT2, 
determined by means of LDH assay. Data are represented as % respect to 
the control values (n=3) 
The same result was obtained when the rAAV6-Ha-tag-EAAT2 
was used (Table 20 and Figure 51B). 
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rAAV6-Ha-tag -EAAT2 24h 48h 72h 
Control 100±5 100±6 100±5 
Vehicle 89±10 88±12 92±7 
MOI: 1x1010 93±6 92±7 97±10 
MOI: 5x109 92±6 93±3 96±8 
Table 20: Toxicity analysis induced for different MOI of  rAAV6-Ha-tag-EAAT2 
on MSCs, determined by means of LDH assay. Data are represented as % 
respect to the control values (n=3). 
 
Figure 51: Toxicity analysis induced for different MOI of (A) rAAV6-YFP-
EAAT2 and (B) rAAV6-Ha-tag-EAAT2 on MSCs, determined by means of LDH 
assay. Data are represented as % respect to the control values (n=3). 
Analysis of the toxicity effect on MSCs induced for virus 
rAAV2-YFP-EAAT2 (Table 21 and Figure 52A) and rAAV2-Ha-
tag-EAAT2 (Table 22 and Figure 52B) infection, showed that 
both infections did not cause toxicity respect to the control 
group. 
rAAV2-YFP-EAAT2 24h 48h 72h 
Control 100±5 100±8 100±3 
Vehicle 86,0±0,7 90,0±0,4 93±1 
MOI: 1x1010 90±4 89±11 90±13 
MOI: 5x109 93±5 92±6 98±16 
MOI: 1x109 118±9 100±3 101±6 
Table 21: Analysis of toxicity induced for different MOI of rAAV2-YFP-EAAT2 
on MSCs determined by means LDH assay. Data are represented as % 
respect to the control group (n=3). 
rAAV2-Ha-tag -EAAT2 24h 48h 72h 
Control 100±5 100±8 100±3 
Vehicle 90±9 92±15 96±3 
MOI: 1x1010 92±10 92±7 97±14 
MOI: 5x109 96±13 98±4 94±7 
Table 22: Analysis of toxicity induced for different MOI of rAAV2-Ha-Tag -
EAAT2 on MSCs determined by means LDH assay. Data are represented as % 
respect to the control group (n=3). 
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Figure 52: Analysis of toxicity induced for different MOI of (A) rAAV2-YFP-
EAAT2 and (B) rAAV2-Ha-Tag -EAAT2 on MSCs determined by means LDH 
assay. Data are represented as % respect to the control group (n=3). 
The three MOI tested in the experiments of toxicity were 
used on MSCs to induce the EAAT2 expression. Unfortunately, 
all viruses probed, rAAV-YFP-EAAT2 (serotypes 2 and 6) and 
rAAV-Ha-Tag-EAAT2 (serotypes 2 and 6), did not show an 
efficient expression of the protein (YFP or Ha-Tag) analyzed 
by fluorescence microscopy (results not shown). Resume of 
the viral production and MSCs infection is represented in the 
Figure 53. 
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Figure 53: Resume of the viral production and MSCs infection. (1) Synthesis 
of constructors and viral production. (2) MSCs viral infection. (3) Analysis of 
viral toxicity (LDH). (4) Analysis of gen-reporter expression (microscopy 
analysis). 
8.5. Exogenous expression of EAAT2 on 
MSCs cells through transfection 
techniques 
Due to the viral infection used to induce the EAAT2 
expression did not showed successful result, the following 
transfection techniques were probed: phosphate calcium 
transfection, lipofectamine transfection and electroporation 
transfection. The phosphate calcium technique was discarded 
because of the elevated toxicity and the low efficiency of 
transfection (data not shown), lipofectamine transfection had 
also to be discarded due to the low efficiency of transfection, 
therefore electroporation transfection was chosen. 
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8.5.1. Electroporation of MSCs 
MSCs were submitted to electroporation procedure according 
the protocol described in Materials and Methods. Briefly, 4 µg 
of pRcCMVm-YFP-EAAT2 plasmid per 1x106 MSCs were used 
in the electroporation procedure. Microscopy analysis showed 
YFP- positive cells (yellow fluorescence) demonstrating the 
efficacy of this transfection procedure (Figure 54). 
Figure 54: Microscopy analysis of the MSCs electroporation transfection. (A) 
Phase contrast image of MSCs.(B) MSC transfected positive YFP (scale bar 
100µm). 
To evaluate the harmful effect of the technique on the cells, 
the proliferation ratio and toxicity (LDH assay) were 
evaluated. Table 23 and Figure 55 show that the transfection 
produces a significant (p<0.05) reduction of proliferation rate 
48h after assay, however this effect is reverted after 72 h. 
 24h 48h 72h 
Non-transfected MSCs 100±13 100±6 100±16 
Transfected MSCs 69±5 71±11 89±12 
Table 23: Analysis of the transfection on MSCs proliferation rate. Data are 
expressed as % respect to the non-transfected at 24 h. Data are compared 
at each time-point respect to the non-transfected cells.(n=3). 
A B
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Figure 55: Analysis of the transfection on MSCs proliferation rate. Data was 
expressed as % respect to the un-transfected at 24 h. Data was compared 
at each time-point respect to the un-transfected cells. (n=3). 
However, as it can be observed in Table 24 and Figure 56, 
there were not significant differences between non-
transfected MSC (MSC-) and transfected MSC (MSC+) in 
terms toxicity (referred to control %) measured by LDH 
assay.  
 24h 48h 72h 
Non-transfected MSCs 100±13 100±11 100±9 
Transfected MSCs 78±9 82±13 85±16 
Table 24: Toxicity measured by means LDH assay demonstrates that there 
were significant differences between MSC- and MSC+, (n=3). 
 
Figure 56: Toxicity measured by means LDH assay demonstrates that there 
were significant differences between MSC- and MSC+, (n=3). 
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8.5.2. Analysis of the reporter gen YFP in MSC 
Through of fluorescence microscopy it was determined that 
the electroporation transfection induced an efficient 
expression of the gen-reporter (YFP) in transfected MSCs. 
The next step was to determine the time-point where the 
expression of the gen-reporter was higher. For that, the gen 
YFP expression was analyzed in the MSC+ by flow cytometry 
at various time-points (Figure 57). Flow cytometry analysis 
showed that the transfection efficiency of the electroporation 
was 60%, being the maximum expression at 48h after the 
transfection. After this point, the percentage of transfected 
cells (MSC+) started to decrease. Analysis of non-transfected 
cells (MSC-) showed that they were negatives for YFP 
analysis. 
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Figure 57: Analysis of gene expression YFP by flow cytometry. The 
maximum expression of YFP was at 48 h after electroporation. After this 
point, the percentage of transfected cells (MSC+) started to decrease. 
Analysis of MSC- (non-transfected cells) showed that they were negatives 
for YFP analysis 
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8.5.3. Analysis of the expression of EAAT2 on MSC+ 
In order to assess the expression of EAAT2 in MSC+, 
immunostaining of EAAT2 and confocal microscopy were 
performed. The results showed in Figure 58 indicate that 
MSC+ was positive for YFP (Figure 58B) and EAAT2. MSCs- 
(Figure 58A), YFP-negative cells, were negative for EAAT2 
staining. These results demonstrated the expression of EAAT2 
on MSC+. 
 
Figure 58: Immunostaining of EAAT2.(A) MSCs- were negative for YFP 
expression and for EAAT2 staining.(B) MSC+ expressed YFP that colocalize 
with the EAAT2 staining. 
Colocalization of YFP and EAAT2 is showed in detail, in the 
Figure 59 and Figure 60. 
 
 
 
María Pérez Mato  Results 
185 
 
 
 
 
 
Figure 59: Colocalization of EAAT2 and YFP on MSC+ 
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Figure 60: Detail of colocalization of EAAT2 and YFP on MSC+ 
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8.5.4. Characterization of the functionality of the 
EAAT2 in MSC+ 
To verify the functionality of the EAAT2 expressed in MSCs, 
glutamate uptake experiments were carried out. Previously, 
to optimize the experimental protocol, this assay was 
performed in astrocytes, cells that express endogenously the 
EAATs. We found that glutamate uptake in astrocytes was 
reduced significantly in the presence of excess of unlabeled 
glutamate (1mM) that demonstrated a specific uptake of 
glutamate (Table 25 and Figure 61). The uptake of glutamate 
was also measured in the presence of specific EAAT 
inhibitors, DHK and TBOA. DHK (dihydrokainic acid) is a 
selective inhibitor of EAAT2, and TBOA (DL-threo-beta-
Benzyloxyaspartate) a nonspecific inhibitor of EAAT1, 2, and 
3. We found that 500µM DHK and 300µM TBOA inhibit the 
glutamate uptake into astrocytes. 
Glutamate Concentration Astrocytes Astrocytes (DHK&TBOA) 
1µM 100±1,4 4,0±0,70 
10µM 93±3 3,0±0,8 
50µM 67±15 3,0±0,3 
100µM 26±5 2,0±0,5 
250µM 15±4 2,0±0,6 
500µM 7±1 2,0±0,3 
1mM 4,0±1,8 2,0±0,3 
10mM 2,0±0,6 1,0±0,4 
Table 25: Glutamate uptake in astrocytes. 
 
Figure 61: Glutamate uptake in astrocytes. 
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Analysis of glutamate uptake in MSC+, showed that the 
MSC+ were able to uptake glutamate specifically considering 
that the uptake was saturated at elevated concentrations of 
unlabeled glutamate (1mM) and the MSC- did not present an 
specific glutamate uptake (Table 26 and Figure 62). 
Glutamate concentration MSC+ MSC- 
1µM 100±2 29±24 
10µM 97± 3 25±21 
50µM 128±21 24±20 
100µM 74±44 19±16 
250µM 51±38 17±14 
500µM 35±21 15±12 
1mM 24±17 14±12 
10mM 22±19 15±13 
Table 26: Glutamate uptake in MSC- and MSC+. Glutamate uptake observed 
in MSC+ is reduced at 1mM glutamate concentration (n=6). 
 
Figure 62: Glutamate uptake in MSC- and MSC+. Glutamate uptake 
observed in MSC+ is reduced at 1mM glutamate concentration (n=6). 
To further characterize the glutamate uptake in MSC+ and 
determine whether the uptake was mediated by the EAAT2 
present on MSC+, glutamate uptake was measured in 
combination with specific EAATs inhibitors, DHK and TBOA. 
The results showed that when the assay was performed with 
500µM DHK and 300µM TBOA, the glutamate uptake was 
abolished (Table 27 and Figure 63). 
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Glutamate concentration MSC+ MSC+(DHK&TBOA) 
1µM 100±2 37±7 
10µM 97± 3 24,0±0,7 
50µM 128±21 30±4 
100µM 74±44 35±21 
250µM 51±38 30±8 
500µM 35±21 21±9 
1mM 24±17 23±3 
10mM 22±19 19±7 
Table 27: Selective inhibition of uptake glutamate mediated by DHK and 
TOBA in MSC+, (n=6). 
 
Figure 63: Selective inhibition of uptake glutamate mediated by DHK and 
TOBA in MSC+, (n=6). 
The effect of DHK and TOBA were also evaluated individually 
on glutamate uptake. In Table 28 and Figure 64 it can be 
observed that glutamate uptake was inhibited (p<0.05) when 
DHK (500µM) alone or in combination TBOA (300µM) were 
used. However the glutamate uptake reduction observed with 
TBOA (300µM) alone was not significant. 
Group 10µM 
MSC+ 13±5 
MSC+ (DHK) 4,9±0,8 
MSC+ (TBOA) 9,4±1,6 
MSC+ (DHK&TBOA) 4,4±0,6 
Table 28: Uptake assay of glutamate using specific inhibitors together and 
individually. 
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Figure 64: Uptake assay of glutamate using specific inhibitors together and 
individually. 
8.6. Analysis of MSC+ 
The MSCs have endogenous characteristics that can be 
altered after transfection process. Therefore specific markers 
of MSCs phenotype, angiogenic capacity and secretion of 
VEGF were analyzed in MSC- and MSC+. 
8.6.1. Flow cytometry 
In order to evaluate phenotypic changes after transfection, 
CD45, CD90 and CD73 (membrane markers) were studied by 
means of flow cytometry in MSC- and MSC+. In Figure 65, it 
can observe CD90+, CD73+ and CD45- appear expressed in 
MSC- (that confirm the mesenchymal phenotype of the cells 
used). Analysis of MSC+ confirmed similar mesenchymal 
phenotype than MSC- after transfection. 
María Pérez Mato  Results 
191 
 
 
Figure 65: (A) Flow cytometry graphs of MSC- showed that the typical 
phenotype CD90+, CD73+ and CD45+. (B) Flow cytometry graphs of MSC+ 
demonstrated that the electroporation did not affected to the phenotype due 
to MSC+ were positive for CD90 and CD73 and negative for CD45. 
8.6.2. Matrigel angiogenesis assay 
The angiogenic capacity of MSC+ was also studied. In Figure 
66B it can appreciate that MSC+ maintained the angiogenic 
properties without significant differences respect to MSC- 
(Figure 66A). 
 
Figure 66: Microscopy contrast phase image of matrigel angiogenic assay 
with (A) MSC- and (B) MSC+, (scale bar 100µm). 
The number of rings (an objective parameter of angiogenic 
activity) it was also analyzed and the results showed that 
there were not differences observed between MSC- and 
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MSC+ after the transfection, according with the microscopy 
image (Table 29 and Figure 67). 
 Number of rings 
MSC- 19,5±3,5 
MSC+ 18,5±0,7 
Table 29: Number of rings formation of MSC- and MSC+ were analyzed by 
means of matrigel angiogenic assay with the aim to determine the influence 
of transfection of cell angiogenic activity, (n=3). 
 
Figure 67: Number of rings formation of MSC- and MSC+ were analyzed by 
means of matrigel angiogenic assay with the aim to determine the influence 
of transfection of cell angiogenic activity, (n=3). 
8.6.3. VEGF assay 
VEGF, a growth factor released for MSCs were also 
measured. Levels of VEGF corrected for protein showed that 
there were not differences between MSC- and MSC+ at 
different time-points (Table 30 and Figure 68). 
 24h 48h 
MSC- 7,43±0,33 8,44±0,22 
MSC+ 7,98±0,43 8,13±0,15 
Table 30: VEGF release (pg/ml per µg protein) were determined at different 
time-points in MSC- and MSC+, (n=6). 
 
0
5
10
15
20
25
MSC-
MSC+
Nu
m
be
r o
f r
in
gs
María Pérez Mato  Results 
193 
 
 
Figure 68: VEGF release (pg/ml per µg protein) were determined at different 
time-points in MSC- and MSC+, (n=6). 
In Figure 69 it can be observed the resume of all employed 
techniques to express the EAAT2 in MSCs. Only the 
electroporation turned out useful to induce the expression of 
EAAT2 on MSCs. 
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Figure 69: Resume of the procedures used to induce the expression of EAAT2 
in MSCs. (1) Synthesis of constructors and viral production. (2) MSCs 
transfection. (3) Analysis of transfection toxicity (LDH assay). (4) Analysis of 
gen-reporter expression (microscopy fluoresce and flow cytometry). (5) 
analysis of EAAT2 expression (confocal microscopy).(6) analysis of EAAT2 
functionality ([3H] glutamate uptake. (7) Analysis mesenchymal phenotype 
(microscopy fluoresce and flow cytometry and VEGF release). Only the 
electroporation protocol could be used induce the expression of EAAT2 on 
MSCs with the aim to test the effect of EEAT2-cell on (8) blood glutamate 
and (9) in ischemic animal model. 
María Pérez Mato  Results 
195 
 
8.7. Expression of EAAT2 on HEK cells 
across viral infection 
In addition to MSCs, exogenous expression of EAAT2 was also 
tested in other type of cells without described effect on blood 
glutamate level and ischemic lesion. 
With this purpose, HEK cells were chosen to induce the EAAT2 
exogenous expression by means of virus infection. Similar 
than MSCs, viral toxicity and infection efficiency were 
evaluated and EAAT2 expression and the functionality of were 
studied. 
8.7.1. Infection with rAAV-YFP-EAAT2 (serotypes 2, 
6) of HEK cells 
HEK cells were infected with the virus rAAV6-YFP-EAAT2 and 
rAAV2-YFP-EAAT2 according to the protocol mentioned in 
section Materials and Methods and used for MSCs. After cell 
infection, cell toxicity was determined by LDH assay. Results 
showed that there was a not significant difference between 
the control and the groups after infection with rAAV2-YFP-
EAAT2 (Table 31 and Figure 70A) and rAAV6-YFP-EAAT2 
(Table 32 and Figure 70B). 
rAAV2-YFP-EAAT2 24h 48h 72h 
Control 100±32 100±13 100±17 
Vehicle 979 96±8 97±14 
MOI: 1x1010 95±12 96±14 95±16 
MOI: 5x109 104±20 92±15 101±13 
MOI: 1x109 103±7 103±18 101±9 
Table 31: Toxicity analysis induced for different MOI of rAAV6-EAAT2 on HEK 
determined by means of LDH assay. Data are represented as % respect to 
the control values (n=3). 
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rAAV6-YFP-EAAT2 24h 48h 72h 
Control 100±7 100±9 100±5 
Vehicle 88±8,90 81±3,50 90±9 
MOI: 1x1010 92±8 82±7 92±10 
MOI: 5x109 99±5 98±8 96±9 
MOI: 1x109 100±7 100±9 100±5 
Table 32: Toxicity analysis induced for different MOI of rAAV6-YFP-EAAT2 on 
HEK determined by means of LDH assay. Data are represented as % respect 
to the control values (n=3). 
 
Figure 70: Toxicity analysis induced for different MOI of (A) rAAV6-EAAT2 
and (B) rAAV6-YFP-EAAT2 on HEK determined by means of LDH assay. Data 
are represented as % respect to the control values (n=3). 
8.7.2. Analysis of the reporter gene YFP in infected 
HEK cells 
To analyze the YFP expression in HEK cells infected with the 
virus rAAV2-YFP-EAAT2 was determined with fluorescence 
microscopy. The Figure 71A showed an image of phase 
contrast image of culture of HEK cells and in Figure 71B 
shows the same cell positive for YFP protein, which indicates 
the YFP-EAAT2 plasmid expression. YFP protein expression 
was only observed with rAAV2-YFP-EAAT2 virus but not with 
rAAV6-YFP-EAAT2 (data not shown). 
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Figure 71: (A) Phase contrast image of culture of HEK cells. (B) HEK cells 
which expressed the YFP (scale bar 100µm) previously infected with rAAV2-
YFP-EAAT2. Infection with rAAV6-YFP-EAAT2 did not showed YFP expression. 
Flow cytometry analysis used to determine the infection 
efficacy of rAAV2-YFP-EAAT2 demonstrated that the 
percentage of efficiency was around 0.5% after 7 days of 
infection, that shows the low efficiency of the virus used 
(Figure 72). 
 
Figure 72: (A) Flow cytometry analysis of non-infected HEK cells and (B) 
Flow cytometry analysis of HEK cells infected with AAV2-YFP-EAAT2. Only 
0.5% of cells infected were positive for YFP expression. 
Although the infection efficiency was very low, the culture 
could be purified and obtain a high percentage of HEK cells 
positive for YFP by sorting technique. Consequently, after 
A
B
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performing of sorting, the culture was purified to achieve a 
purity of 90%, which was analyzed by fluorescence 
microscopy (Figure 73) and flow cytometry (Figure 74). 
 
Figure 73: (A) Phase contrast image of HEK cells. (B) Fluorescence image of 
HEK cells that were submitted to sorting (scale bar 100µm) 
 
Figure 74: (A) Flow cytometry analysis of non-infected HEK cells and (B) 
flow cytometry analysis of infected HEK cells after sorting, positive for YFP 
expression 
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8.7.3. Analysis of expression of EAAT2 in HEK cells 
positive for YFP 
Sorted HEK cells, positive for YFP expression, infected with 
AAV2-YFP-EAAT2, were analyzed to determine the expression 
of EAAT2 by immunofluorescence. Figure 75, showed it could 
not be detect a clear positive staining for EAAT2. 
Figure 75: (A) Immunostaining for EAAT2 in HEK negative for YFP. (B) 
Immunostaining for EAAT2 HEK positive for YFP. 
8.7.4. Characterization of the functionality of the 
EAAT2 in HEK cells positive for YFP 
Despite the fact that a clear signal of staining for EAAT2 in 
HEK positive for YFP was not detected, the functionality of 
EAAT2 was analyzed by glutamate uptake assay. In line with 
the previous stating results, HEK cells, positive for YFP, 
showed an unspecific glutamate uptake, as glutamate uptake 
was not reduced with higher glutamate concentrations (Table 
33 and Figure 76). 
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Glutamate concentration HEK-AAV2 HEK+AAV2 
1µM 106±50 100±55 
10µM 52±10 97±24 
50µM 56±3 89±35 
100µM 35±14 92±37 
250µM 85±40 65±34 
500µM 37±9 56±24 
1mM 38±6 48±23 
10mM 26±3 34±14 
Table 33: Glutamate uptake assay with un-infected HEK cells (HEK-AAV2) 
and infected with virus AAV2-YFP-EAAT2 (HEK+AAV2). 
 
Figure 76: Glutamate uptake assay with un-infected HEK cells (HEK-AAV2) 
and infected with virus AAV2-YFP-EAAT2 (HEK+AAV2). 
Althought the virus did not produce a good results in terms 
of infection process, employing sorting techniques was 
achieved purify the culture until a very high percentage of 
HEK cells were positive for YFP. However, 
immunofluorescence techniques and glutamate uptake assay 
showed that the transporter EAAT2 was not correctly 
expressed, thefore viral infection with AAV2-YFP-EAAT2 used 
to induce the EAAT2 expression in HEK cells was discarded. 
In the Figure 77 it can be observed a summary of the 
procedures used to achieve expression of EAAT2 by viral 
infection in HEK cells. 
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Figure 77: Summary of the procedures used to achieve expression of EAAT2 
by viral infection in HEK cells. (1) Synthesis of constructors and viral 
production. (2) HEK cells viral infection (3) Analysis of viral toxicity (LDH). 
(4) Analysis of gen-reporter expression (flow cytometry and microcopy). (5) 
Analysis of EAAT expression (confocal microscopy). (6) [3H] glutamate 
uptake assay. 
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8.8. Calcium phosphate transfection of 
HEK cells 
The calcium phosphate transfection with plasmid 
pRcCMVmYFPEAAT2 was used as alternative technique to 
induce the expression of EAAT2 in HEK cells. Other 
transfection technique (lipofectamine or eletroporation) were 
not cosidered as calcium phosphate was the most used for 
HEK cells trasnfection. 
Microscopy analysis of transfected HEK cells (HEK+) with 
calcium phosphate transfection showed that they were 
express the gen-reporter (YFP) (Figure 78). 
 
Figure 78: (A) Contrast phases image of HEK cells. (B) Culture of transfected 
HEK cells with calcium phosphate transfection (scale bar 100µm). Green 
cells indicate the successful expression of the gen-reporter (YFP). 
To test the possible adverse effects of the calcium phosphate 
transfection on HEK cells, toxicity analysis by means of LDH 
assay was performed. In addition, the proliferation rate was 
evaluated. The LDH assay (Table 34 and Figure 79) showed 
that there was no significant difference between HEK– and 
HEK+, indicating low the toxicity of the transfection method 
used. There were not also significant differences between 
HEK- and HEK+ regarding to proliferation rate (Table 35 and 
Figure 80). 
 
 
B
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 24h 48h 72h 
HEK- 100±24 100±16 100±18 
HEK+ 97±26 95±14 98±21 
Table 34: Toxicity analysis of calcium phosphate transfection on HEK cells 
determined by means of LDH assay. Data are represented as % respect to 
the control values (n=3). 
 
Figure 79: Toxicity analysis of calcium phosphate transfection on HEK cells 
determined by means of LDH assay. Data are represented as % respect to 
the control values (n=3). 
 24h 48h 72h 
HEK- 100±22 100±19 100±16 
HEK+ 97±15 98±22 99±10 
Table 35: Proliferation rate analysis of calcium phosphate transfection on 
HEK cells (n=3). 
 
Figure 80: Proliferation rate analysis of calcium phosphate transfection on 
HEK cells (n=3). 
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8.8.1. Analysis of the reporter gen YFP in HEK+ 
transfected with calcium phosphate 
Analysis of the percentage of efficiency of phosphate calcium 
in HEK cells, determined by means of flow cytometry, was 
around 50%. In the Figure 81, it can appreciate that the 
HEK-did not expresses YFP, while around 50% of the 
transfected cells were positive for YFP. 
 
Figure 81: Analysis of YFP expression in of HEK- and HEK+ with calcium 
phosphate determined by flow cytometry. 
The calcium phosphate technique for transfection of HEK cells 
proved to be very efficient for a highest number of 
transfected cells. In addition, many of the YFP-positive cells 
can be seleted based on their resistence to gentamicin 
(gentamicin resistence gene are included in the plasmid 
used) which allowed to separate. This procedure allowed to 
HEK+ 24h
HEK- 24h
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select cells with plasmid integrated in the genome of the 
cells, therefore YFP (and subsecuently EAAT2) are expressed 
constitutively. In the Figure 82, it can be observed a colony 
of HEK+ which expressed the gene YFP constitutively. This 
colony was picked and expanded in the optimum conditions. 
 
Figure 82: (A) Phase-contrast image of a colony of HEK+ selected with 
gentamincin. (B) Fluorescence microscopy image of a colony of HEK cells 
that express the gene YFP constitutively (HEK+) that selected with 
gentamicin. 
 
 
 
 
 
 
 
 
 
 
 
A B
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8.8.2. Analysis of expression of EAAT2 in HEK+  
The expression of EAAT2 in HEK+ was evaluated by 
immunostaining of EAAT2 and confocal microscopy. The 
results are showed in Figure 83B, in which it can be observed 
that YFP positive cells were also positive for the expression of 
EAAT2 and both labels colocalized Figure 83A). 
 
Figure 83: Immunostaining of EAAT2 in (A) HEK- and in (B) HEK+. 
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8.8.3. Characterization of the functionality of the 
EAAT2 in HEK+ 
Glutamate uptake assays were performed with the aim to 
determine the functionality of the EAAT2 in HEK+. The results 
showed (Table 36 and Figure 84) that HEK+ are able to 
uptake glutamate in a specific way as the uptake was 
reduced when elevated concentrations of unlabeled 
glutamate were used (1mM). Specific glutamate uptake was 
not observer in HEK-. 
Glutamate concentration HEK- HEK+ 
1µM 13±3 100±14 
10µM 15±3 98±13 
50µM 10±2 97±12 
100µM 8±1 65±12 
250µM 6±2 41±15 
500µM 5±2 28±6 
1mM 5±1 21±3 
10mM 5±2 13±3 
Table 36: Glutamate uptake assay for HEK- and HEK+. 
 
Figure 84: Glutamate uptake assay for HEK- and HEK+. 
To be sure that glutamate uptake was mediated by EAAT2, 
two selective inhibitors (DHK and TBOA) of the transporter 
were used. In Table 37 and Figure 6, it can observe that the 
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uptake of glutamate by HEK+ was blocked when both EAAT2-
blockers were used. 
Glutamate concentration HEK+ HEK+(TBOA+DHK) 
1µM 100±14 8±3 
10µM 98±13 8±3 
50µM 97±12 9,0±0,9 
100µM 65±12 8±2 
250µM 41±15 9±2 
500µM 28±6 7±2 
1mM 21±3 5±0,5 
10mM 13±3 6±0,7 
Table 37: Selective inhibition of uptake glutamate mediated by DHK 
(500µM) and TBOA (300µM) in HEK+. 
 
Figure 85: Selective inhibition of uptake glutamate mediated by DHK 
(500µM) and TBOA (300µM) in HEK+. 
DHK and TBOA were tested independently (Table 38 and 
Figure 86). Glutamate uptake was inhibited (p<0.05), when 
both transporters inhibitors were used separately, the 
indicated the specific glutamate uptake observed. 
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 Group 10µM 
HEK+ 98±12 
HEK+ (DHK) 2,6±0,5 
HEK+ (TBOA) 1,7±0,5 
HEK+ (DHK&TBOA) 8,6±0,9 
Table 38: Selective inhibition of uptake glutamate mediated by DHK and 
TBOA used in combination and separately HEK transfected cells (HEK+), 
(n=6). 
 
Figure 86: Selective inhibition of uptake glutamate mediated by DHK and 
TBOA used in combination and separately HEK transfected cells (HEK+), 
*(p<0.05, n=6) 
Therefore, we can conclude that calcium phosphate 
transfection with pRcCMVmYFPEAAT2, represents the optimal 
technique to obtain HEK cells with functional EAAT2. In Figure 
87 it is summarized the results obtained for HEK cells. 
In the Figure 88 is represented all results and procedures 
involved in EAAT2 gene expression in HEK cells and MSCs. 
Cells obtained were used to test their effect blood glutamate 
reduction in healthy animals and then their protective in 
ischemic animals. 
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Figure 87: Resume of the procedures used to induce the expression of EAAT2 
in HEK cells by means of calcium phosphate transfection. (1) Synthesis of 
constructors and viral production. (2) HEK cells transfection. (3) Analysis of 
transfection toxicity (LDH assay). (4) Analysis of gen-reporter expression 
(microscopy fluoresce and flow cytometry). (5) Analysis of EAAT2 expression 
(confocal microscopy). (6) Analysis of EAAT2 functionality [3H] glutamate 
uptake. (7) Analysis mesenchymal phenotype (microscopy fluoresce and 
flow cytometry and VEGF release). Calcium phosphate transfection was the 
optimal protocol to induce the expression of EAAT2 on HEK cells with the aim 
to test the effect of EAAT2-cell on blood glutamate (8) and in ischemic model 
(9). 
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Figure 88: Procedures involved in EAAT2 gene expression in HEK cells and 
MSCs. 
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8.9. Protective effect of HEK+ and MSC+ 
on ischemic animals model 
8.9.1. Serum glutamate concentration in healthy 
animals 
To determine the protective effect of HEK+ and MSC+, a 
previous dose-response assay in healthy animals was 
performed to determine the appropriate number of cells 
needed to induce a blood glutamate reduction. 
The following experimental groups were studied: Vehicle 
(control group, treated with saline), oxaloacetate (3.5 
mg/100g), 3x106HEK- cells, 3x106HEK+ cells, 3x106MSCs- 
and 3x106MSCs+. The serum glutamate was measured prior 
to administration of treatment (basal) and 1, 3 and 4h after. 
The oxaloacetate was used as positive control of blood 
glutamate grabber. 
The results showed a reduction of glutamate in the animals 
treated with oxaloacetate at 1h (p<0.05) and 4h (p<0.05) 
after the administration compared with the vehicle. According 
with the EAAT2 induced expression, administration of 
3x106HEK+ produced a reduction of glutamate levels at 1h 
(p<0.05) after administration, while 3x106MSC+ decreased 
the glutamate levels at 1h (p<0.01) and 3h (p<0.05) after of 
the administration compared with the vehicle. The decrease 
of glutamate was maintained at least 3h after administration. 
In those animals treated with 3x106HEK- and 3x106MSC-, a 
reduction of glutamate was not observed (Table 38 and 
Figure 89). 
In order to achieve a greater reduction of glutamate, in the 
second phase of the study, a dose of 9x106 MSC- and 9x106 
MSC+ were also tested. The results demonstrated that a 
dose of 9x106MSC+ could reduce the glutamate significantly 
(p<0.05) during 3 h compared with the vehicle, however this 
effect was not higher than 3x106MSC+ dose. The dose of 
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9x106MSC- did not cause any effect on glutamate (Table 38 
and Figure 89). 
 Basal 1h 3h 4h 
Vehicle 100±19 107±34 118±22 101±39 
Oxal 100±6 64±24 84±55 54±2 
3x106 HEK- 100±12 101±47 87±29 117±40 
3x106 HEK+ 100±8 88±4 72±7 97±28 
3x106 MSC- 100±5 113±14 126±23 96±33 
3x106 MSC+ 100±20 56±13 73±30 104±57 
9x106 MSC- 100±13 97±6 108±24 136±52 
9x106 MSC+ 100±5 64±9 70±7 82±12 
Table 39: Effect of vehicle (control group, treated with saline), oxaloacetate 
(3.5 mg/100g), 3x106HEK- cells, 3x106HEK+ cells, 3x106MSCs-, 
3x106MSCs+, 9x106MSCs- and 9x106MSCs+ on serum glutamate in healthy 
animals. Glutamate was determined in basal conditions (before treatment 
administration), and 1, 3 and 4 h after treatment. Data are shown as % 
respect to the basal levels (n=6).   
 
Figure 89: Effect of vehicle (control group, treated with saline), oxaloacetate 
(3.5 mg/100g), 3x106HEK- cells, 3x106HEK+ cells, 3x106MSCs-, 
3x106MSCs+, 9x106MSCs- and 9x106MSCs+ on serum glutamate in healthy 
animals. Glutamate was determined in basal conditions (before treatment 
administration), and 1, 3 and 4 h after treatment. Data are shown as % 
respect to the basal levels (*p<0.05, **p<0.001, (n=6). Dashed line 
indicates the reference respect to basal levels. 
8.9.2. Serum glutamate concentration in ischemic 
animals 
Once determined their effect on blood glutamate reduction, 
their protective effect were analyzed in ischemic animals 
(Table 40 and Figure 90). The following groups were 
performed: Vehicle (control group, treated with saline), 
oxaloacetate (3.5 mg/100g), 3x106HEK- cells, 3x106HEK+ 
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cells, 3x106MSCs-, 3x106MSCs+, 9x106MSCs- and 
9x106MSCs+. Treatments were injected after the reperfusion 
(45 min). The analysis of serum glutamate was performed 
prior to MCAO (pre-ischemia), reperfussion and 1, 3, 4 and 
24h after the administration of treatment. In Figure 90, it 
can be observed that in the animals treated with 
oxaloacetate and transfected cells (3x106HEK+, 3x106MSC+ 
and 9x106MSC+), all treatments caused a reduction 
(p<0.05) of blood glutamate 1h after the administration of 
treatment compared with the vehicle. None effect on blood 
glutamate levels were observed during the first 4 h after 
administration in those animals treated with non transfected 
cells (3x106HEK-, 3x106MSC- and 9x106MSC). 
 Basal Reperf 1h 3h 4h 24h 
Vehicle 100±22 101±25 105±28 99±35 113±30 124±27 
Oxal 100±32 97±31 73±14 84±36 84±29 91±30 
3x106 HEK- 100±17 99±5 88±29 110±36 98±54 94±38 
3x106 HEK+ 100±8 115±34 76±11 89±18 105±20 105±14 
3x106 MSC- 100±12 86±29 96±14 91±19 107±44 61±10 
3x106 MSC+ 100±16 91±45 74±23 63±27 74±22 69±29 
9x106 MSC- 100±25 107±28 122±70 110±72 106±70 145±10 
9x106 MSC+ 100±9 107±12 73±5 67±6 78±11 119±45 
Table 40: Serum glutamate in ischemic animals. Data are shown as the 
percentage relative to the basal level (*p<0.05, **p<0.01, ***p<0.001, 
n=6).
 
 
Figure 90: Serum glutamate in ischemic animals. Data are shown as the 
percentage relative to the basal level (*p<0.05, **p<0.01, ***p<0.001, 
n=6). Dashed line indicates the reference respect to basal levels. 
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8.9.3. Effects on ischemic lesion volume 
Infarct volume sizes were measured on ADC maps, 
calculated from MR DWI, acquired during the occlusion (t=0), 
and on T2 maps, obtained from T2 weighted images at 1, 7 
and 14 after the induction of the ischemia.  
In Figure 91 it can be observed a representative MRI of each 
group at different time points. In Table 41 and Figure 92, 
infarct volume sizes are expressed in percentage respect the 
hemisphere volume corrected by edema factor. No 
statistically significant differences were found on infarct 
volumes of all groups at t=0. In those groups that were 
treated, except the animals injected with 3x106 HEK-, the 
infarct volumes experiment a decrease compared to vehicle 
at 1, 7 and 14 days. These results were statistically 
significant only for animals which were administrated with 
oxaloacetate at 14days (p<0.05), 3x106 MSC- at 7 and 14 
days (p<0.05) and 9x106 MSC- at 1, 7 and 14 days 
(p<0.01). 
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Figure 91: Representative MRI of each group at different time points. tMCAO 
corresponds to ADC maps and 1,7 and 14 days to T2 weighed images. 
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 ADC 24h 7d 14d 
Vehicle 43±3 41±7 33±8 30±10 
Oxal 41±2 35±9 28±7 24±6 
3x106HEK- 38±3 37±6 34±17 30±16 
3x106HEK+ 44±2 36±9 32±8 27±7 
3x106MSC- 42±3 32±5 23±8 22±4 
3x106MSC+ 43±2 36±4 28±9 25±3 
9x106MSC- 40±4 22±11 15±12 13±12 
9x106MSC+ 41±5 33±12 25±12 22±13 
Table 41: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with vehicle (control group, treated with saline), oxaloacetate 
(3.5 mg/100g), 3x106HEK- cells, 3x106HEK+ cells, 3x106MSCs-, 
3x106MSCs+, 9x106MSCs- and 9x106MSCs+. Treatments were injected after 
the reperfusion (45 min). Infarct sizes were measured at 24 h, 7 and 14 
days after ischemia. ADC map were used to determine the basal ischemic 
lesion before treatment administration. Data are shown as % ± S.E.M 
respect to the hemisphere volume corrected by edema factor (n=6). 
 
Figure 92: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with vehicle (control group, treated with saline), oxaloacetate 
(3.5 mg/100g), 3x106HEK- cells, 3x106HEK+ cells, 3x106MSCs-, 
3x106MSCs+, 9x106MSCs- and 9x106MSCs+. Treatments were injected after 
the reperfusion (45 min). Infarct sizes were measured at 24 h, 7 and 14 
days after ischemia. ADC map were used to determine the basal ischemic 
lesion before treatment administration. Data are shown as % ± S.E.M 
respect to the hemisphere volume corrected by edema factor.*p<0.05, 
**p<0.01 with respect to the control group at the same time point (n=6). 
Higher difference between groups was observed at 14 days (indicated with 
the dashed line). 
Infarct volume was also analyzed considering the infarct size 
relative to the basal volume, with the aim to eliminate the 
basal difference between groups. The statistical analysis 
showed similar results than the previous analysis. In this 
case, higher protective effect seems to be observed in the 
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3x106HEK+ compared to 3x106HEK- respect to control group, 
however this differences are not significant (Figure 93).  
 ADC 24h 7d 14d 
Vehicle 100±7 95±17 77±19 71±24 
Oxal 100±5 84±22 67±16 58±14 
3x106HEK- 100±8 97±16 90±45 78±40 
3x106HEK+ 100±6 81±21 73±18 62±15 
3x106MSC- 100±7 76±13 54±19 53±8 
3x106MSC+ 100±5 83±8 66±20 58±8 
9x106MSC- 100±10 55±28 37±29 32±29 
9x106MSC+ 100±12 80±28 60±29 53±32 
Table 42: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with vehicle (control group, treated with saline), oxaloacetate 
(3.5 mg/100g), 3x106HEK- cells, 3x106HEK+ cells, 3x106MSCs-, 
3x106MSCs+, 9x106MSCs- and 9x106MSCs+. Treatments were injected after 
the reperfusion (45 min). Infarct sizes were measured at 24 h, 7 and 14 
days after ischemia. ADC maps were used to determine the basal ischemic 
lesion before treatment administration. Data are shown as % ± S.E.M 
respect to the basal volume (n=6).  
 
Figure 93: Infarct size assessed by means of MRI in MCAO rats. MCAO rats 
were treated with vehicle (control group, treated with saline), oxaloacetate 
(3.5 mg/100g), 3x106HEK- cells, 3x106HEK+ cells, 3x106MSCs-, 
3x106MSCs+, 9x106MSCs- and 9x106MSCs+. Treatments were injected after 
the reperfusion (45 min). Infarct sizes were measured at 24 h, 7 and 14 
days after ischemia. ADC maps were used to determine the basal ischemic 
lesion before treatment administration. Data are shown as % ± S.E.M 
respect to the basal volume.*p<0.05, **p<0.01 with respect to the control 
group at the same time point (n=6). Higher difference between groups was 
observed at 14 days (indicated with the dashed line). 
8.9.4. Functional test 
The overall effects on functional recovery were evaluated for 
cylinder and mNSS tests. Both tests were performed prior to 
tMCAO (pre-ischemia) and 7 and 14 days after the ischemia. 
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The cylinder test was done by counting the number of 
forelimb contacts. The number of impaired and non-impaired 
forelimb contacts was calculated as a percentage of total 
contacts. Attending to the obtained results (Table 43 and 
Figure 94), the administration of oxaloacetate, 3x106HEK+, 
3x106MSC-, 3x106MSC+, 9x106MSC- and 9x106MSC+ 
showed a reduction on the use of impaired forelimb 
compared with the vehicle at 7 and 14 days. But only there 
were significant differences at 7days in animals treated with 
3x106MSC- (p<0.05). At 14 days there were significant 
differences in the next animals: treated with oxoalocetate 
(p<0.05) 3x106HEK+ (p<0.05), 3x106MSC- (p<0.01) and 
9x106MSC-(p<0.01). The effect on the cylinder test was 
detected for the treatment with 3x106HEK- at 14 days, but 
the beneficial effect was less than the mentioned groups. 
 Basal 7d 14d 
Vehicle 48±4 25±13 26±12 
Oxal 45±8 27±13 33±8 
3x106HEK- 48±5 23±3 29±3 
3x106HEK+ 50±9 25±3 34±3 
3x106MSC- 47±7 34±12 38±12 
3x106MSC+ 50±4 29±8 34±4 
9x106MSC- 48±7 30±18 39±12 
9x106MSC+ 43±4 29±13 32±16 
Table 43: Use of impaired forelimb (%) in the cylinder test. 
 
Figure 94: Use of impaired forelimb (%) in the cylinder test. 
 
B
as
al
7 
da
ys
14
 d
ya
s
B
as
al
7 
da
ys
14
 d
ya
s
B
as
al
7 
da
ys
14
 d
ya
s
B
as
al
7 
da
ys
14
 d
ya
s
B
as
al
7 
da
ys
14
 d
ya
s
B
as
al
7 
da
ys
14
 d
ya
s
B
as
al
7 
da
ys
14
 d
ya
s
B
as
al
7 
da
ys
14
 d
ya
s
0
20
40
60 Vehicle Oxal 3x106HEK- 3x106HEK+ 3x106MSC- 3x106MSC+ 9x106MSC- 9x106MSC+
 U
se
 o
f i
m
pa
ire
d 
fo
re
lim
b(
%
)
* *
* ** *
**
María Pérez Mato  Results 
220 
 
The results of the mNSS test are showed in Table 44 and 
Figure 95. It can be observed that there was a tendency to 
improve of the functional recovery for all groups at time 
points measured, being the differences between theirs 
minimal. The groups treated with oxaloacetate and 
9x106MSC- showed the best result regarding to functional 
recovery. 
 Basal 7d 14d 
Vehicle 0,00±0,04 9,7±1,5 8±3 
Oxal 0,00±0,03 8,0±1,4 7,0±1,1 
3x106HEK- 0,00±0,02 8±2 8,0±1,3 
3x106HEK+ 0,00±0,05 10±2 9±2 
3x106MSC- 0,00±0,03 8,0±1,1 6±2 
3x106MSC+ 0,00±0,01 9,0±1,4 8±2 
9x106MSC- 0,00±0,06 8±2 6±2 
9x106MSC+ 0,00±0,03 8±2 7,0±1,3 
Table 44: Points in the mNSS. 
 
Figure 95: Points in the mNSS. 
  
Basal 7d 14d
0
5
10
15
Vehicle
OXAL
3x106HEK-
3x106HEK+
3x106MSC-
3x106MSC+
9x106MSC-
9x106MSC+
Po
in
ts
María Pérez Mato  Discussion 
221 
 
 
 
 
Discussion 
María Pérez Mato  Discussion 
222 
 
  
María Pérez Mato  Discussion 
223 
 
9.Section I: Analysis of protective 
effect of rGOT in ischemia 
Nowadays, the concept of blood/brain glutamate scavenging 
is well recognized as a novel and attractive protective 
strategy to reduce the excitotoxic effect of excess 
extracellular glutamate that accumulates in the brain 
following an ischemic stroke. The efficacy of this strategy has 
been demonstrated in different types of ischemic animal 
models, and it has also been tested in other pathologies 
associated with an increase in brain glutamate levels, such as 
traumatic brain injury (TBI)312 or glioma170 with successful 
results.  
GOT activation by means of exogenous administration of 
oxaloacetate has been used as the most common approach 
to reduce the serum glutamate concentration. In this study, 
we found that the i.v. administration of rGOT1 was also able 
to induce a reduction in serum and brain glutamate levels, 
which also resulted in a significant reduction in the infarct 
volume and improvement in the sensorimotor deficit after 
ischemia. These effects were similar to those observed with 
the higher doses of oxaloacetate116. Importantly, the 
protective effect of rGOT1 was more evident when it was 
administered in combination with a low concentration of 
oxaloacetate that had no effect by itself, indicating that the 
combined administration of rGOT1 and oxaloacetate could be 
an efficient serum glutamate-grabbing approach. The i.v. 
administration of an endogenous serum enzyme such as 
GOT1 as a new protective treatment against ischemia is an 
interesting strategy because it is unlikely that the 
administration of rGOT1 can induce toxic effects in humans 
as the levels of this enzyme varies among healthy human 
subjects (7–45 U/l), and has been shown to increase 10-fold 
in patients with liver damage. 313 On the other hand, the 
increase in the enzyme activity after the treatment is not 
much longer than 24 h, and serum glutamate concentrations 
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come back to normal within the first 6 h, which reduces long-
term potential adverse effects. However, the effective dose 
of GOT (12.88 µg/100g) used in the animals cannot be 
extrapolated to humans, as GOT levels in rats are almost 10-
fold higher than those in humans (10 U/l in humans versus 95 
U/l in rats). In this regard, further (pre)-clinical studies 
based on the administration of GOT should be conducted in 
humans to determine the effective therapeutic dose of GOT 
able to induce a significant reduction in serum glutamate in 
humans. In line with this, we have previously observed that 
stroke patients who had high GOT activity (average of 17 
U/l) at admission had reduced serum glutamate 
concentrations and a significantly better neurological 
outcome than patients with lower average activity of GOT of 
11 U/l. 118, 314 Therefore, it can be hypothesized that the 
administration of rGOT1 doses able to increase the systemic 
GOT activity, at least two or three-fold, are necessary for 
clinical studies in stroke patients.  
Regarding the use of oxaloacetate as a serum glutamate 
scavenging treatment, such a treatment could present some 
limitations associated with the high dose likely to be 
necessary in patients to achieve the same effects than those 
observed in experimental animals.86 However, although to 
date there are no consistent data in humans confirming this 
toxic effect, a study published in the 60’s,315 in which 
oxaloacetate was used to treat diabetic patients (from 200 to 
1000mg per day in three divided doses given orally) did not 
report any effect on liver function tests and blood acetone 
and cholesterol levels at the doses administered. Oral 
administration is not comparable to i.v. administration used 
in this study; nevertheless, this clinical study represents 
evidence for the relative safety of the administration of this 
molecule in humans. In this line, we also observed that 
oxaloacetate does not affect the viability of the neuronal 
culture, which is used as a current assay for neurotoxicity. 316 
The protective effects of oxaloacetate have also been 
discussed. 114 As this molecule participates in the energy 
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metabolism and provides an antioxidant protection of cells 
subjected to stress, such as hydrogen peroxide, it has been 
suggested that the protective role of oxaloacetate could be 
related to other mechanisms different from serum glutamate 
reduction. Studies in a TBI model showed that the protective 
effect of oxaloacetate was abolished in the presence of 
excess glutamate in serum or when it was administered in 
combination with maleate (a GOT inhibitor),136 which 
effectively demonstrate its serum glutamate-scavenging 
action.  
Interestingly, the protective effect of rGOT1 (12.88 µg per 
100 g) was potentiated when it was administered in 
combination with a non-effective low dose of oxaloacetate 
(1.5mg per 100 g) but not with higher doses of the enzyme 
(25.76 µg per 100 g). These findings are in agreement with a 
previous glioblastoma study reporting that the combination 
of rGOT1 with low amounts of oxaloacetate together with 
temozolodine significantly extends the lifespan of tumor-
bearing animals. The therapeutic synergistic effect observed 
between oxaloacetate and GOT can be attributed to the fact 
that the endogenous oxaloacetate concentration can become 
a limiting factor of the enzymatic reaction when GOT activity 
is increased after treatment. Therefore, attending to the 
rapid and maintained reduction in serum glutamate 
concentration, treatments based on the combined 
administration of rGOT1 supplemented with a low 
concentration of oxaloacetate could be optimal to reach the 
maximum protective effect in ischemia. Of note, the low dose 
of oxaloacetate is sufficient to increase the glutamate-
scavenging activity of rGOT1, which reduces the potential 
complications associated with a high dose of this molecule. 
 It is crucial to develop treatment approaches capable of 
overcoming the narrow therapeutic window in stroke in order 
to mitigate the detrimental effects of the excess of brain 
glutamate after ischemia, which represents a stumbling-block 
from a clinical point of view. Owing to this limitation, only 
those treatments (mainly, NMDA antagonists) with protective 
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effects beyond the first 1–2 h after the onset of ischemia 
have shown clinical interest. 317 In our ischemic experimental 
model, we have observed that brain and serum glutamate 
levels appear to be increased in the first 2 h after 
reperfusion. We observed that lowering of glutamate by 
means of GOT treatments had protective effects even when 
the treatment was delayed until 1 h after reperfusion. 
Further experiments need to be carried out to determine the 
length of the therapeutic window; however, based on our 
results, it may be speculated that the therapeutic window for 
the administration of rGOT1 could be up to 2 h after the 
onset of ischemia. As this treatment does not require a prior 
computerized tomography scan, it could be given as early as 
possible, perhaps even as ambulatory treatment suggesting 
potential clinical application. In this line, in a recently 
published model of brain hemorrhage, glutamate grabbers 
were shown to decrease the blood glutamate levels but did 
not affect the hemorrhagic hematoma, confirming that this 
treatment can be given without neuroimaging, in case of 
suspected stroke, which may potentially increases the 
number of patients treated within the therapeutic window. 121  
All preclinical studies on different models and the clinical 
observational analysis reported about the effect of rGOT 
and/or oxaloacetate, guarantee the therapeutic efficacy of 
the reduction of blood glutamate as well as the glutamate 
grabber drugs; however, translation to clinical practice has 
critical steps before their use in humans. These critical steps 
are those necessary to develop a clinical trial, which will 
involve high financial support and risk of investment for the 
sponsors interested in the study. In addition, the repeated 
failure of protective drugs against glutamate excitotoxicity in 
clinical trials has reduced the trust of pharmaceutical 
companies and other sponsors in stroke studies. 
Aiming to demonstrate the clinical efficacy glutamate 
grabbers in humans and reduce the risk of investment in the 
study, a novel pharmacological strategy known as drug 
repositioning was used for our group one year ago to find 
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new grabbing drugs. This allowed researchers to search 
drugs already known and used for other pathologies and in 
which the clinical phase I and phase II were already 
completed, reducing the risk of investment for sponsors in 
case the clinical study result failed. Following this 
pharmacological strategy and, as purpose of other project 
ongoing in our group, we analyzed more than one thousand 
known drugs with the aim to determine whether any of them 
could act on GOT activity reducing glutamate levels, similar 
to treatment with OxAc. In this analysis, one drug (coded as 
CBG000592) was found with a high affinity for GOT (EC50 = 
4.04 μM, Emax = 30 μM). A proof of concept (EudraCT 
Number: 2014-003123-22) in progress will allow us to check 
the protective efficacy of this drug and this mechanism. 
In conclusion, in this study we show that oxaloacetate 
potentiates the protective effect of intravenously 
administered rGOT1 after ischemia. This effect is mediated 
through a reduction in serum and brain glutamate levels. The 
protective effect was observed even when the treatments 
were initiated as soon as 2 h after the onset of ischemia. The 
robust protection shown by the combination of rGOT1 and 
low doses of oxaloacetate proposes that this strategy may 
represent a valid approach for a successful acute-phase 
stroke treatment. Successful results with CBG000592 in the 
clinical proof of concept will allow us to get financial support 
to start a new clinical study based in the use if this enzymatic 
treatment, rGOT. 
These data are already published in Cell Death Dis. 2014; 
9;5:e992. 
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10. Section II: Effect of glutamate 
grabbers cells on ischemic 
damage. 
Glutamate is an essential excitatory neurotransmitter 
regulating brain functions. Excitatory amino acid transporter 
(EAAT2) is one of the major glutamate transporters 
expressed predominantly in astroglial cells and responsible 
for 90% of total glutamate uptake. Glutamate transporters 
tightly regulate glutamate concentration in the synaptic cleft. 
In fact, dysfunction of EAAT2 leads to an accumulation of 
excessive extracellular glutamate implicated in the 
development of several neurodegenerative diseases including 
Alzheimer’s disease, Huntington’s disease, and amyotrophic 
lateral sclerosis. Analysis of the EAAT2 promoter showed that 
the expression of this protein can be increased by means of 
transcriptional activators. Indeed, screening of approximately 
1,040 FDA approved compounds and nutritionals led to the 
discovery that many β-lactam antibiotics are transcriptional 
activators of EAAT2 resulting in increased EAAT2 protein 
levels. Therefore, treatment with ceftriaxone (CEF) in 
animals, a β-lactam antibiotic, led to an increase of EAAT2 
expression and glutamate transport activity in the brain. 
Subsequent experimental studies showed that CEF has 
neuroprotective effects in both in vitro and in vivo models 
based on its ability to inhibit neuronal cell death by 
preventing glutamate excitotoxicity.76  
Based on these previous studies where over-expression of 
EAAT2 in astrocytes cells led a protection against glutamate 
excitotoxicity, we thought that if we could induce an 
expression of EAAT2 in cells we could originate blood cell 
grabbers, potentially more efficient than the current 
treatments already tested, oxaloacetate or enzymes (rGOT). 
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On the other hand, mesenchymal stem cells (MSCs) 
represent the most common neurodegenerative experimental 
strategy in cerebral ischemia. Application MSCs resulted in an 
improved functional recovery and infarct reduction in 
experimental animals. The underlying precise mechanisms of 
this phenomenon remain elusive, although MSC 
transplantation is considered to affect many diverse events, 
e.g., by modulating the inflammatory milieu, stimulating 
endogenous neurogenesis and angiogenesis, and reducing 
glial scar formation. Because of these preclinical studies, first 
clinical trials confirmed improved functional recovery in 
patients who had received MSCs systemically.318  
Therefore, given the high affinity of EAAT2 for glutamate and 
the high beneficial effect of MSCs in stroke pathology, in this 
study we planned to combine both mechanisms with the aim 
to obtain a cellular therapy against stroke with 
neuroprotective and neurorecovery effect. 
With this purpose, EAAT2 protein expression was induced in 
MSCs and the functionality of these transporters to uptake 
glutamate was determined by means of in vitro assays and 
their capacity to reduce glutamate from blood in vivo 
experiments. The effect of EAAT2-trasfected MSCs were also 
compared with a well know blood glutamate grabber, 
oxaloacetate, and with EAAT2-trasfected HEK cells to 
eliminate the intrinsic beneficial effect of MSCs.  
The in vitro experimental results showed that the 
transfection protocols used to induce the EAAT2 expression in 
MSCs (electroporation transfection) and in HEK cells 
(phosphate calcium transfection) were efficient. Microscopy 
analysis and [3H] glutamate uptake assay confirmed the 
expression and the functionality of the protein, while 
phenotypic analysis indicated that, apparently, the 
mesenchymal properties were not change after transfection 
However, although, the transfection protocols used were 
successful to the EAAT2 expression, viral infection strategy 
María Pérez Mato  Discussion 
230 
 
used for the same purpose did not showed good results, as 
MSCs did not present expression of both gen-reporter, YFP , 
in case of the rAAV-YFP-EAAT2 and Ha-tag, in case of rAAV-
Ha-tag-EAAT2. In this sense, there are numerous reports 
indicating the success of these vectors in transduction of 
MSCs from other species, but there seems to be no 
convincing evidence to suggest that AAV can effectively 
transduce rat MSCs at high levels. The reason for this species 
transduction efficiency difference is unclear at present, but it 
seems unlikely to be due to low expression of necessary cell-
surface receptors, given that the low efficiency was seen with 
all the serotypes. It is possible, however, that it is the result 
of inefficient transport to the nucleus and limited second 
strand synthesis, since previous studies have shown that this 
is the major limiting factor in efficient gene expression after 
AAV transduction. 319  
In case of HEK cells, it was possible to observe the 
expression of the gen reporter YFP after viral transduction 
(infected with rAAV-YFP-EAAT2) however, microscopy 
analysis and [3H] glutamate uptake assay did not 
demonstrate a clear expression and functionality of the 
transporter. Although, sequence analysis should be perform 
to confirm this idea, we speculate that scission of the EAAT2 
from the plasmid could explain this results.  
Our major interest to obtain EAAT2-trasnducted cells by 
means of AVV infections was due to, this strategy allow to 
incorporate the EAAT2-gen to the cell genome, and therefore 
the protein (EAAT2) would be expressed constitutively, while 
the transfection procedure used to induce the protein 
expression made necessary to repeat the same protocol 
before to use the transfected in case of MSCs.  
In line with the in vitro [3H] glutamate uptake assay, 
administration of EAAT2-transfected MSCs (MSCs+) and 
EAAT2-transfected HEK cells (HEK+) induced a reduction of 
blood glutamate in healthy animals, that it was not observed 
in case of un-transfected cells. Therefore these results, 
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confirmed our original hypothesis, that the expression of 
EAAT2 in cells originates cell grabbers of blood glutamate. 
With the aim to increase the effect of transfected MSCs on 
blood glutamate reduction, a higher dose of MSCs+ (9x106 
cells) was also tested; however, we could not observe that 
the effect increased. We speculate that the dose used (9x106 
cells), it was a really high dose (i.v. cell doses higher than 
3x106 cells is not commonly used in experimental studies 
with rats), therefore many cells could be trapped in the lung 
or the spleen, reducing their effect. In fact, future studies will 
be also necessary to perform in order to determinate the 
final destination of the administered cells.  
It could be also tentative to speculate that, to increase the 
expression of the numbers of EAAT2 per cell could be an 
alternative to increase the glutamate grabbing efficacy, 
however, as it was already explained in Material and 
Methods, the maximum amount of plasmid optimized for 
transfection protocol was already used to get the maximum 
expression of the protein per cell.  
Analysis of the same treatments on ischemic animals showed 
that, in line with those results observed previously in healthy 
rats, oxaloacetate and transfected cells caused a significant 
reduction of blood glutamate levels after administration; 
however, this effect was not correlated with the infarct 
volume reduction. Thus, higher protective effect was 
observed with untransfected MSCs (MCSs-). Only, in case of 
HEK cells treatment, functional analysis measured by means 
of cylinder test, showed that HEK+ had better functional 
recovery than HEK- in agreement with the blood glutamate 
reduction observed.  
We believe that MSCs have multiple intrinsic beneficial 
effects on ischemic stroke that can be altered after 
transfection procedure. This could explain why the protective 
effect of MCS- is better than MSC+. Thus, although MSC+ is 
able to reduce the glutamate excitotoxicity, the alteration of 
beneficial properties of MSCs is possibly much more relevant 
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in terms of protection. Phenotype analysis of MSCs 
(membrane markers, VEGF release and ring formation) did 
not showed deference respect MCS- after transfection, 
however although these properties are the most used to 
characterize the MSCs, other multiple protective molecular 
mechanism associated to these cells can be affected after 
transfection. 
Interestingly, when HEK cells, a type of cells without 
described effect on cerebral ischemic lesion, express EAAT2, 
they are able to reduce the blood glutamate levels and 
induce a functional improvement 14 days after ischemia. 
Once, this confirm by means of an alternative strategy, the 
effect of blood glutamate reduction as an efficient protective 
strategy against ischemic stroke.   
In addition of cell glutamate grabbers here described, the 
use of grabbing drugs (oxaloacetate or rGOT) already tested, 
other alternatives to induce a reduction of blood glutamate 
has also been evaluated as blood glutamate grabbers with 
beneficial effects in ischemia. In this regard, the use of 
dialysis to filter the blood and remove excess glutamate has 
been suggested as an interesting and potentially useful 
method for reducing blood glutamate concentrations. Thus, 
compared with healthy controls, patients with end-stage 
renal failure on hemodialysis had higher concentrations of 
blood glutamate, and it has been described that, during 
hemodialysis (especially in the first hour), glutamate 
concentrations decreased regardless of the size of filter 
pores, blood flow rate, or gender.320 Similarly, peritoneal 
dialysis resulted in decreases in blood glutamate with a 
corresponding increase of glutamate in the dialysis 
solution.120 In agreement with these findings, in a rat model 
of ischemia, the reduction of blood glutamate levels observed 
with peritoneal dialysis was associated with a decrease in 
infarct area. In fact, this hypothesis is currently being tested 
in clinical trials in phase IIa (EudraCT Number: 2012-
000791-42). 
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We have to note, that one important limitation of this study 
was that we did not analyzed the neurorecovery effect of 
MSC+ with the aim to determine its neuroprotective and 
neurorecovery effect. Since MSC- presented higher protective 
effect than MSC+, we considered not relevant to perform this 
analysis.  
In conclusion, these results showed that the induced 
expression of EAATs on cells represents other novel an 
interesting alternative to reduce blood glutamate with 
potential beneficial effect after ischemia. However, blood 
glutamate cell grabbing did not present better beneficial 
effect trespect to other glutamate grabbers already well 
described, as their protective effect was not higher than 
oxaloacetate.  
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11. Conclusions 
Based on the objectives cited at the beginning of this Thesis, 
and once completed the experiments and analyzed the 
results obtained; we can conclude that: 
Section I: Analysis of protective effect of rGOT in ischemia 
1. The administration of rGOT1 alone induces a reduction 
in serum and brain glutamate levels, which also 
resulted in a significant reduction in the infarct 
volume and improvement in the sensorimotor deficit 
after ischemia. 
2. The beneficial effects mediated by rGOT1 were similar 
to those observed with the higher doses of 
oxaloacetate. 
3. Combination of rGOT1 with a low dose of oxaloacetate 
potentiates the therapeutic effect of intravenously 
rGOT1 after ischemia. 
4. The protective effect mediated by administration of 
rGOT1 was observed even when the treatments were 
initiated as soon as 2h after the onset of ischemia. 
5. The robust protection shown by the combination of 
rGOT1 and low doses of oxaloacetate proposes that 
this strategy may represent a valid approach for a 
successful acute-phase stroke treatment. 
 
Section II: Effect of glutamate grabbers cells on ischemic 
damage. 
1. We have optimized a protocol to induce the 
exogenous expression of EAAT2 in mesenchymal stem 
cells and HEK cells. 
2.  We have demonstrated the expression and 
functionality of EAAT2 in mesenchymal stem cells and 
HEK cells. 
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3.  The transfection of mesenchymal stem cells does not 
affect the membrane markers analyzed, angiogenic 
capacity or secretion of VEGF. 
4. The administration of transfected cells with EAAT2 is 
able to induce a lowering of serum glutamate levels in 
vivo.  
5. The beneficial effect of mesenchymal stem cells is 
reduced after exogenous expression of EAAT2, which 
limit the use of these cells like a cell grabber. 
6. Blood glutamate cell grabbing do not present better 
benefit than other glutamate grabbers already well 
described, as their protective effect is not higher than 
oxaloacetate. 
7. Results with EAAT2 transfected cells have confirmed 
the effect of blood glutamate reduction as an efficient 
alternative protective strategy against ischemic 
stroke. 
8. Our results demonstrate that the transfection of 
mesenchymal stem cells with functional EAAT2 may 
confer their a dual therapeutic action: neuroprotection 
and neurorepair. 
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12. Conclusiones  
Basándonos en los objetivos citados al comienzo de esta 
Tesis, y una vez completados los experimentos y analizados 
los resultados obtenidos; podemos concluir que: 
Sección I: Análisis del efecto protector de la rGOT1 en la 
isquemia 
1. La administración de rGOT1 produce una reducción de 
los niveles de glutamato en suero y en cerebro, lo 
cual está asociado a una disminución del volumen de 
infarto y una mejora del déficit sensoriomotor 
después de la isquemia. 
2. Los efectos beneficios mediados por rGOT1 fueron 
similares a los observados con el oxaloacetato a dosis 
elevadas. 
3. La combinación de rGOT1 con una dosis baja de 
oxaloacetato, potencia los efectos terapéuticos de la 
rGOT1 intravenosa tras la isquemia. 
4. El efecto protector mediado por la administración de 
la rGOT1 se observa incluso cuando los tratamientos 
se inician 2h después del comienzo de la isquemia. 
5. La destacada protección mostrada por la combinación 
de rGOT1 y dosis bajas de oxaloacetato sugiere que 
esta estrategia puede representar una aproximación 
válida para el tratamiento exitoso del ictus en fase 
aguda. 
 
Sección II: Efecto de los atrapadores celulares de glutamato 
en el daño isquémico 
1. Hemos optimizado un protocolo para inducir la 
expresión exógena del EAAT2 en células madre 
mesenquimales y células HEK. 
2. Hemos demostrado la expresión y funcionalidad del 
EAAT2 en células madre mesenquimales y células 
HEK. 
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3. La transfección de células madre mesenquimales no 
afecta a los marcadores de membrana analizados, a la 
capacidad angiogénica o a la secreción de VEGF. 
4. La administración de células transfectadas con EAAT2 
induce una disminución de los niveles de glutamato 
sérico in vivo. 
5. El efecto beneficioso de las células madre 
mesenquimales es reducido tras la expresión exógena 
del EAAT2, lo cual limita el uso de estas células como 
un atrapador celular. 
6. Los atrapadores celulares de glutamato sanguíneo no 
presentan un mayor beneficio que los otros 
atrapadores de glutamato ya descritos, así como su 
efecto protector no es mayor que el del oxaloacetato. 
7. Los resultados con células transfectadas con EAAT2 
confirman que, por medio de un procedimiento 
alternativo, la reducción del glutamato sanguíneo es 
una estrategia protectora eficiente en el ictus 
isquémico. 
8. Nuestros resultados demuestran que la tranfección de 
células madre mesenquimales con un EAAT2 funcional 
puede conferirles una acción terapéutica dual: 
neuroprotección y neurorreparación. 
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13. Resumen 
Las enfermedades cerebrovasculares son la segunda causa 
de muerte y la primera de discapacidad en países 
desarrollados. Sin embargo, a pesar de su importancia socio-
económica, las terapias disponibles son limitadas. La 
etiología más frecuente del ictus, el ictus isquémico, consiste 
en la reducción localizada del flujo cerebral tras la oclusión 
de una arteria cerebral. Este proceso desencadena una serie 
de eventos a nivel molecular y celular que culminan con un 
fallo energético en el área cerebral afectada, seguida de un 
proceso de muerte celular por necrosis. Esta área recibe el 
nombre de core isquémico. La región circundante al core, 
denominada penumbra isquémica, está constituida por tejido 
hipoperfundido pero todavía viable. Sin embargo, esta área 
está condicionada a una serie de procesos moleculares de 
excitotoxicidad, estrés oxidativo y respuesta inflamatoria que 
constituyen las dianas terapéuticas principales de 
neuroprotección en la isquemia cerebral.  
Las terapias de reperfusión, bien por trombólisis 
farmacológica con el activador tisular del plasminógeno 
recombinante (rt-PA) o por trombectomía mecánica, 
constituyen las estrategias terapéuticas que logran mejores 
beneficios en los pacientes que sufren un ictus isquémico. Sin 
embargo, la estrecha ventana terapéutica (4.5 h tras el 
comienzo de los síntomas para la trombólisis farmacológica) 
los efectos secundarios asociados a esta terapia 
farmacológica y la necesidad de equipos altamente 
cualificados e infraestructuras de vanguardia para la 
trombectomía mecánica hacen que únicamente entre el 3 y el 
7% de los pacientes con infarto cerebral pueden beneficiarse 
de esta terapia en los países más desarrollados. Por ello, 
urge la necesidad de desarrollar nuevas estrategias 
terapéuticas basadas en neuroprotección o neurorreparación. 
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La neuroprotección es un término que incluye todas las 
terapias dirigidas a reducir la muerte celular tras un proceso 
isquémico sin ejercer ningún tipo de influencia en la 
reperfusión del tejido durante la fase aguda del ictus. Los 
fármacos neuroprotectores se clasifican, en cuanto a sus 
mecanismos de acción, en los siguientes grupos: 
antagonistas de los canales de Ca2+, antagonistas de los 
receptores de glutamato, antioxidantes, precursores 
fosfolipídicos, inhibidores de la liberación de glutamato, 
agonistas del GABA y anti-inflamatorios. Hasta ahora, 
algunos fármacos han mostrado resultados prometedores en 
estudios experimentales, pero una vez trasladados a ensayos 
clínicos no han demostrado eficacia. 
Por otro lado, las estrategias neurorreparadoras presentan 
una ventana terapéutica mayor que la fase aguda del ictus. 
Estas estrategias incluyen la restauración de la función 
cerebral, ya sea bien por regeneración del tejido cerebral 
dañado (neurorregeneración) o bien por la creación de 
nuevas conexiones neuronales o sinapsis (plasticidad 
cerebral). El fin de las terapias de neurorreparación es la 
restauración de la unidad neurovascular mediante estrategias 
farmacológicas o de terapia celular, enfocadas a la 
potenciación de la neurogénesis, angiogénesis y 
sinaptogénesis.  
El glutamato constituye una de las principales dianas de 
neuroprotección en la isquemia cerebral. El glutamato es el 
principal neurotransmisor del sistema nervioso central. En el 
cerebro, el glutamato se encuentra compartimentado 
intracelularmente en neuronas y astrocitos; siendo una 
pequeña fracción del mismo extracelular. Esta homeostasis 
del glutamato es muy sensible a cambios de energía y está 
regulada principalmente por los transportadores de 
aminoácidos excitatorios (EAATs), presentes en astrocitos, 
neuronas y las células endoteliales que forman la barrera 
hematoencefálica; siendo el EAAT2 el responsable del 90% de 
la recaptación de glutamato extracelular. La perturbación del 
equilibrio del glutamato está relacionada con daño del 
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sistema nervioso central, tal como ocurre en el ictus 
isquémico, el traumatismo craneoencefálico, la Esclerosis 
Lateral Amiotrófica (ELA) o la Enfermedad de Parkinson, 
entre otras.  
Durante la isquemia cerebral, la despolarización de la 
membrana celular debido al fallo energético produce un 
incremento de glutamato en el espacio extracelular. Este 
exceso de glutamato induce un complejo proceso de 
mecanismos patogénicos, que conducen a la 
neuroexcitotoxicidad. Con el fin de mitigar los efectos 
deletéreos de la excitotoxicidad, se desarrollaron nuevos 
fármacos neuroprotectores para bloquear los receptores del 
glutamato o inhibir la liberación de glutamato a través del 
bloqueo de los canales presinápticos. Dichos tratamientos 
farmacológicos no mostraron eficacia en clínica humana, por 
lo que urge la necesidad de desarrollar nuevas estrategias 
terapéuticas contra la excitotoxicidad mediada por 
glutamato. Con este fin, surgieron los estudios que describen 
la existencia de un gradiente de concentración de glutamato 
entre las células endoteliales que forman la barrera 
hematoencefálica del cerebro y el torrente sanguíneo. 
Cuando la concentración de glutamato de las células 
endoteliales cerebrales es mayor que la concentración de 
glutamato sanguíneo, este es transportado desde el cerebro 
hacia el torrente sanguíneo. Debido a ello, surge la hipótesis 
de que la reducción de los niveles de glutamato sanguíneo 
incrementaría el gradiente de concentración entre el 
endotelio cerebral y la sangre; favoreciendo de este modo la 
eliminación de glutamato cerebral. Este mecanismo potencial 
de neuroprotección se denomina atrapamiento de glutamato 
sanguíneo. Así, el tratamiento de la isquemia cerebral con 
atrapadores de glutamato sanguíneo, podría generar una 
reducción del glutamato cerebral, lo que podría conllevar 
implicaciones terapéuticas tras la isquemia cerebral. En este 
sentido, diferentes estudios han descrito que la reacción 
metabólica mediada por la transaminasa glutámico 
oxalacética (GOT) podría constituir una importante diana 
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neuroprotectora en la isquemia cerebral. El potencial 
terapéutico asociado a la GOT se debe al hecho de que esta 
enzima, usando el oxalacetato como co-substrato, es capaz 
de metabolizar el glutamato a α-cetoglutarato y aspartato, 
conllevando a una disminución de los niveles de glutamato 
en sangre. Basándose en esta premisa, nuestro grupo 
demostró que la administración de oxalacetato induce una 
reducción de los niveles de glutamato sanguíneo, por medio 
de la activación de la GOT, lo cual media efectos 
neuroprotectores en un modelo animal en rata de isquemia 
cerebral. Sin embargo, desde un punto de vista clínico, el uso 
de oxalacetato como atrapador de glutamato puede tener 
importantes limitaciones como son sus potenciales efectos 
secundarios, debido a que el oxalacetato participa en el Ciclo 
de Krebs, su elevada dosis terapéutica y su estrecha ventana 
terapéutica. 
La terapia celular ha surgido como una estrategia 
prometedora frente a tratamientos farmacológicos 
convencionales debido a sus múltiples y potenciales 
mecanismos de acción, entre los cuales destacan la 
integración de las células administradas en los tejidos, 
procesos de inmunomodulación o secreción de factores de 
crecimiento. Varias estirpes celulares han demostrado 
efectos beneficiosos en estudios preclínicos de isquemia 
cerebral, incluyendo células madre embrionarias, células 
madre neurales, células madre pluripotentes inducidas y 
células madre mesenquimales (MSCs), entre otras. De todas 
ellas, las MSCs han sido descritas como las más idóneas. 
Esto se debe, no solo a que son multipotentes, sino también 
a sus capacidades inmunomoduladoras y de secreción de 
factores de crecimiento, lo que les confiere mecanismos 
pleiotrópicos de acción entre los que destacan:   
diferenciación a células de estirpe neural; inducción de la 
neurogénesis, angiogénesis y sinaptogénesis; activación de 
procesos endógenos de plasticidad cerebral; regulación del 
flujo sanguíneo cerebral; reducción de la apoptosis; 
inmunomodulación de la inflamación; e incremento de la 
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supervivencia celular, entre otros. Además, diversos estudios 
preclínicos de isquemia cerebral en roedores han encontrado 
recuperación funcional y reducción del volumen de infarto.  
Por todo lo anteriormente mencionado, la combinación de 
mecanismos de neuroprotección (por atrapadores de 
glutamato sanguíneo), y de neurorreparación (mediados por 
MSCs) constituiría una estrategia terapéutica prometedora en 
la isquemia cerebral. Por ello, el objetivo de este trabajo 
consistió en el desarrollo de nuevas alternativas de 
atrapadores de glutamato sanguíneo para su uso en el ictus 
isquémico. Para ello hemos utilizado dos estrategias: 
enzimática y celular. La estrategia enzimática se basó en el 
uso de la rGOT1 administrada individualmente y combinada 
con una dosis no terapéutica de oxaloacetato. La estrategia 
celular, consistió en expresar, por transfección celular, el 
transportador EAAT2 en estirpes celulares. Para este fin, se 
usaron dos tipos celulares: células HEK (se busca el efecto 
neuroprotector por capatación de glutamato sanguíneo por 
EAAT2) y las MSCs (efecto dual: neuroprotector, por 
captación de glutamato sanguíneo por EAAT2, y 
neurorreparador, por sus propiedades endógenas de célula 
madre).  
Para testar la eficacia de la rGOT1 en la disminución del 
glutamato sanguíneo y cerebral, y posteriormente determinar 
el efecto protector de la enzima, el estudio fue dividido en 
dos partes. En primer lugar, se realizó un estudio dosis-
respuesta en animales sanos con el objetivo de determinar la 
dosis más efectiva de rGOT1 en la disminución de glutamato 
sanguíneo. Para simular el incremento de glutamato 
observado después de la isquemia cerebral, inyectamos 
glutamato, a una dosis de 15mM, en la yugular de ratas SD. 
Se ensayaron las siguientes dosis de rGOT1: 6.44 µg/100g, 
12.88 µg/100g y 25.76 µg/100g. Para analizar las 
concentraciones de glutamato se obtuvieron muestras 
sanguíneas de la vena de la cola antes de la inyección de 
glutamato y a las 1, 2, 4, 6 y 24 h después de la inyección de 
glutamato. Los niveles de glutamato sérico se midieron 
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mediante técnicas de ELISA. Los resultados mostraron que la 
dosis de 12.88 µg/100g de rGOT1 fue la más efectiva en la 
reducción del glutamato sanguíneo (p<0.01). Con el objetivo 
de determinar si el efecto de la enzima podría ser potenciado 
por el oxalacetato, la dosis rGOT1 12.88 µg/100g se combinó 
con una dosis no terapéutica de oxalacetato (1.5mg/100g). 
La administración de dicha combinación indujo una mayor 
disminución del glutamato en sangre (p<0.01).  
El siguiente paso fue examinar el efecto protector de la 
rGOT1 (12.88 µg/100g) y rGOT1 (12.88 µg/100g) 
suplementada con oxalacetato (1.5 mg/100g) en ratas SD, 
sometidas a isquemia cerebral mediante filamento 
intraluminal, comparado con animales tratados con 
oxalacetato a una dosis de 3.5 mg/100g (dosis terapéutica). 
Para determinar la capacidad terapéutica de los tratamientos, 
los cuales fueron administrados justo después de la 
reperfusión, se avaluó el volumen de infarto por imagen de 
Resonacia Magnética (MRI) y el déficit funcional por el Test 
del Cilindro. Asimismo, se midió la reducción del glutamato 
sanguíneo por técnicas de ELISa y la actividad de GOT fue 
determinada por Reflotron GOT, y la reducción de glutamato 
cerebral por espectroscopia de MRI. Los resultados 
mostraron que el incremento del glutamato sérico tras la 
isquemia cerebral fue reducido por los tratamientos: rGOT1 
(12.88 µg/100g), oxaloacetato (3.5 mg/100g) y rGOT1 más 
oxaloacetato (12.88 µg/100g y 1.5 mg/100g, 
respectivamente), sin haber diferencias significativas entre 
ellos. Esta disminución de glutamato sérico causada por los 
tratamientos se asoció a una reducción del glutamato 
cerebral (p<0.05). Todos los tratamientos indujeron una 
disminución del volumen de infarto a las 24 h y a los 7 d 
después de la isquemia (p<0.05), siendo este efecto mayor 
en los animales tratados con rGOT1+oxaloacetato (p<0.05). 
En los animales a los cuales se les administró rGOT1, la 
actividad enzimática de la misma estaba aumentada 
(p<0.01). 
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Con el fin de determinar la ventana terapéutica óptima para 
la administración de la rGOT1, las ratas isquémicas fueron 
tratadas también 1 h después de la reperfusión. Los grupos 
de tratamientos fueron: rGOT1 (12.88 µg/100g) y 
rGOT1+oxaloacetato (12.88 µg/100g y 1.5 mg/100g, 
respectivamente). Ambos tratamientos causaron una 
reducción significativa (p<0.05) de los niveles de glutamato 
sanguíneo. Sin embargo, el análisis del volumen de infarto 
reveló que la administración de los tratamientos 1 hora 
después de la reperfusión tiene un menor efecto protector 
que la administración justo después de la reperfusión. 
En cuanto a los test somatosensoriales, el tratamiento 
combinado de rGOT1 con oxaloacetato está asociado a un 
mejor pronóstico funcional a los 7 días (p<0.05). 
Por otro lado, para inducir la expresión de EAAT2 en diversas 
estirpes celulares empleamos diferentes técnicas de 
transfección. Mediante microscopía de fluorescencia y 
citometría de flujo, se analizó la presencia del gen reporter 
YFP, que confirmaba la eficiencia del proceso de transfección 
del EAAT2. En un primer paso, se utilizaron diferentes 
vectores virales para tratar de expresar el EAAT2 en células 
HEK y MSCs. Los resultados de la infección no mostraron una 
expresión del YFP en dichas células. Debido a ello, se 
emplearon otras técnicas de transfección. Por un lado, en las 
MSCs se ensayaron las siguientes técnicas: fosfato cálcico, 
lipofección y electroporación; siendo esta última la que 
ofreció resultados positivos para la expresión de EAAT2 y el 
YFP asociado. En lo que se refiere a las células HEK, se 
consiguió expresar EAAT2 y el YFP asociado mediante la 
transfección con fosfato cálcico. La posterior selección con 
gentamicina permitió seleccionar aquellas células HEK que 
habían integrado el EAAT2 en su genoma. 
Mediante técnicas de inmunofluorescencia y microscopía 
confocal, se observó que tanto las HEK como la MSCs co-
expresaban el gen reporter YFP y EAAT2. Además, se 
determinó la funcionalidad del gen EAAT2 en las células 
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transfectadas mediante experimentos de captación de 
glutamato tritiado. Los resultados de estos experimentos 
demostraron que las células transfectadas eran capaces de 
captar glutamato de una forma eficiente. Para confirmar que 
dicha captación estaba mediada por EAAT2, se determinó la 
captación del glutamato en combinación con inhibidores 
específicos del EAAT2, DHK y TBOA. Los resultados de estos 
experimentos demostraron que la utilización de los 
inhibidores impedía la captación de glutamato en las células 
transfectadas, confirmando que dicha captación estaba 
mediada por EAAT2.  
Debido a que las MSCs presentan propiedades endógenas 
neurorreparadoras, fue necesario determinar que dicho 
fenotipo celular no fue modificado tras el proceso de 
electroporación. Para ello se analizaron, por citometría de 
flujo, la expresión de marcadores específicos del fenotipo de 
MSCs (CD90+, CD45- y CD73+), la capacidad angiogénica 
por matrigel y la secreción de VEGF por técnicas de ELISA. 
Los resultados mostraron que no existen diferencias entre las 
MSC+ y MSC-, en cuanto a las propiedades mencionadas 
anteriormente. 
Una vez demostrada la capacidad de las células transfectadas 
para captar glutamato in vitro, fue necesario determinar su 
efecto in vivo. Para ello, previamente a la utilización de las 
células transfectadas en ratas Wistar sometidas a isquemia 
cerebral, se determinó la dosis celular adecuada para inducir 
una reducción de los niveles de glutamato plasmático. Con 
esta finalidad, los siguientes grupos experimentales fueron 
analizados en ratas sanas: 3.5 mg/100g de oxalacetato 
(dosis terapéutica, control positivo), 3x106 HEK-, 3x106 
HEK+, 3x106 MSC- y 3x106 MSC+. La concentración de 
glutamato sérico fue medida mediante técnicas de ELISA, 
previamente a la administración del tratamiento y a las 1, 3 
y 4 h después de la administración del tratamiento. Los 
resultados mostraron una reducción de glutamato sérico en 
los animales tratados con oxalacetato a 1 y 4 h después de la 
administración. En cuanto a los grupos tratados con células, 
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la administración de 3x106 HEK+ indujo una disminución de 
los niveles de glutamato 1 h después, mientras que el grupo 
tratado con 3x106 MSC+ disminuyó los niveles de glutamato 
sérico 1 y 3 h después de la administración del tratamiento 
(todas las p<0.05). Con el objetivo de conseguir una mayor 
reducción de glutamato, se analizaron 2 grupos más, 9x106 
MSC- y 9x106 MSC+. Los resultados mostraron que en el 
grupo tratado con 9x106 MSC+ disminuye los niveles de 
glutamato a las 3 h (p<0.05) respecto al grupo control, pero 
dicha disminución no era mayor a la inducida por la dosis de 
3x106 MSC+. 
Finalmente, se estudió el efecto terapéutico de las estirpes 
celulares transfectadas con EAAT2, administradas 
intravenosamente, en ratas Wistar sometidas a isquemia 
cerebral mediante filamento intraluminal. Para determinar los 
efectos beneficiosos de esta terapia se avaluó el volumen de 
infarto por imagen de Resonacia Magnética (MRI) y el déficit 
funcional. Asimismo, se analizaron los niveles de glutamato 
sistémico mediante ELISA. Se realizaron los siguientes 
grupos de estudio: vehículo (PBS), oxalacetato (3.5 
mg/100g), 3x106 HEK-, 3x106 HEK+, 3x106 MSC-, 3x106 
MSC+, 9x106 MSC- y 9x106 MSC+. Los tratamientos fueron 
inyectados en yugular justo después de la reperfusión. El 
análisis de glutamato sérico fue realizado previamente a la 
cirugía, inmediatamente tras la reperfusión y a las 1, 3, 4 y 
24 h después de la administración del tratamiento. Los 
resultados mostraron una reducción del glutamato sérico, a 1 
hora tras la administración del tratamiento, en los grupos 
tratados con oxalacetato y células transfectadas (p<0.05). 
Sin embargo, de estos grupos que indujeron una reducción 
del glutamato sanguíneo, únicamente el grupo tratado con 
oxalacetato mostró una reducción del volumen del infarto 
(p<0.05). Otros grupos que indujeron una reducción del 
volumen del infarto al día 7 fueron 3x106 MSC- y 9x106 MSC-
. En cuanto a los test funcionales, los animales tratados con 
oxalacetato, 3x106 HEK+, 3x106 MSC- y 9x106 MSC- 
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mostraron una mejoría funcional a los 14 días tras la 
isquemia. 
En base a todos los resultados anteriormente indicados, 
concluimos que: 
- La administración de rGOT1 produce una reducción de 
los niveles de glutamato en suero y en cerebro, lo cual está 
asociado a una disminución del volumen de infarto y una 
mejora del déficit sensoriomotor después de la isquemia. 
- Los efectos beneficios mediados por rGOT1 fueron 
similares a los observados con el oxaloacetato a dosis 
elevadas. 
- La combinación de rGOT1 con una dosis baja de 
oxaloacetato, potencia los efectos terapéuticos de la rGOT1 
intravenosa tras la isquemia. 
- El efecto protector mediado por la administración de 
la rGOT1 se observa incluso cuando los tratamientos se 
inician 2h después del comienzo de la isquemia. 
- La destacada protección mostrada por la combinación 
de rGOT1 y dosis bajas de oxaloacetato sugiere que esta 
estrategia puede representar una aproximación válida para el 
tratamiento exitoso del ictus en fase aguda. 
- Hemos optimizado un protocolo para inducir la 
expresión exógena del EAAT2 en células madre 
mesenquimales y células HEK. 
- Hemos demostrado la expresión y funcionalidad del 
EAAT2 en células madre mesenquimales y células HEK. 
- La transfección de células madre mesenquimales no 
afecta a los marcadores de membrana analizados, a la 
capacidad angiogénica o a la secreción de VEGF. 
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- La administración de células transfectadas con EAAT2 
induce una disminución de los niveles de glutamato sérico in 
vivo. 
- El efecto beneficioso de las células madre 
mesenquimales es reducido tras la expresión exógena del 
EAAT2, lo cual limita el uso de estas células como un 
atrapador celular. 
- Los atrapadores celulares de glutamato sanguíneo no 
presentan un mayor beneficio que los otros atrapadores de 
glutamato ya descritos, así como su efecto protector no es 
mayor que el del oxaloacetato. 
- Los resultados con células transfectadas con EAAT2 
confirman que, por medio de un procedimiento alternativo, la 
reducción del glutamato sanguíneo es una estrategia 
protectora eficiente en el ictus isquémico. 
- Nuestros resultados demuestran que la tranfección de 
células madre mesenquimales con un EAAT2 funcional puede 
conferirles una acción terapéutica dual: neuroprotección y 
neurorreparación. 
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14. Summary 
Cerebrovascular disease is the second leading cause of death 
and disability in the first developed countries. However, 
despite its socio-economic importance, available therapies 
are limited. The most common etiology of stroke, ischemic 
stroke, is localized reduction of cerebral blood flow following 
cerebral artery occlusion. This process triggers a series of 
events at the molecular and cellular level that culminate with 
a power failure in the area of the brain affected, followed by 
a process of cell death by necrosis. This area is called the 
ischemic core. The region surrounding the core, called the 
ischemic penumbra, consists hypoperfused tissue but still 
viable tissue. However, this area is subject to a number of 
molecular processes excitotoxicity, oxidative stress and 
inflammatory response are the main therapeutic targets for 
neuroprotection in cerebral ischemia. 
Reperfusion therapies, by pharmacologic thrombolysis with 
tissue recombinant plasminogen activator (rt-PA) or 
mechanical thrombectomy, are the treatment strategies that 
achieve better benefits in patients suffering ischemic stroke. 
However, the narrow therapeutic window (4.5 h after onset 
of symptoms you for pharmacological thrombolysis), the side 
effects associated with this drug therapy and the need for 
highly qualified equipment and infrastructure for mechanical 
thrombectomy make only between 3 and 7% of patients with 
cerebral infarction may benefit from this therapy in most 
developed countries. Therefore, there is urgent need to 
develop new therapeutic strategies based on neuroprotection 
or neurorepair. 
Neuroprotection is a term that includes all therapies aimed at 
reducing death after ischemia without exerting any influence 
on tissue reperfusion during the acute phase of stroke. 
Neuroprotective drugs are classified in terms of their 
mechanisms actions in the following groups: antagonists of 
Ca2+ channel, antagonists of glutamate receptor, 
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antioxidants, phospholipid precursors, inhibitors of the 
release of glutamate, GABA agonists and anti -inflammatory. 
So far, some drugs have shown promising results in 
experimental studies, taken once per clinical trials have not 
demonstrated efficacy. 
Furthermore, the neurorepair strategies present a 
therapeutic window larger than the acute phase of stroke. 
These strategies include the restoration of brain function, 
whether good by regeneration of brain tissue damaged 
(neuroregeneration) or by creating new neural connections or 
synapses (brain plasticity). The purpose of the neurorepair 
therapies is the restoration of the neurovascular unit using 
pharmacological or cell therapy strategies, focused on 
enhancing neurogenesis, angiogenesis and synaptogenesis. 
Glutamate is one of the major targets of neuroprotection in 
cerebral ischemia. Glutamate is the primary neurotransmitter 
of the central nervous system. In the brain, glutamate is 
compartmentalized intracellularly in neurons and astrocytes, 
as a small extracellular fraction thereof. This glutamate 
homeostasis is very sensitive to energy changes and is 
mainly regulated by excitatory amino acid transporters 
(EAATs) present in astrocytes, neurons and endothelial cells 
which form the blood brain barrier; EAAT being responsible 
for 90% of the reuptake of extracellular glutamate. The 
disturbance of equilibrium of glutamate is related central 
nervous system damage, such as occurs in ischemic stroke, 
head injury, amyotrophic lateral sclerosis (ALS) and 
Parkinson's Disease, among others. 
During cerebral ischemia, depolarization of the cell 
membrane due to power failure causes an increase of 
glutamate into the extracellular space. This excess glutamate 
induces a complex process pathogenic mechanisms leading 
to neuroexcitotoxicity. To mitigate the deleterious effects of 
excitotoxicity, novel neuroprotective drugs developed to 
block glutamate receptors or inhibit glutamate release by 
blocking presynaptic channels. These drug treatments did not 
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show efficacy in human clinical, because of this urgent need 
to develop new therapeutic strategies against excitotoxicity 
mediated by glutamate. To this end, different studies 
described the existence of glutamate concentration gradient 
between the endothelial cells that form the blood-brain 
barrier and the bloodstream. When glutamate concentration 
of the brain endothelial cells is greater than the concentration 
of blood glutamate, this is carried from the brain to the 
bloodstream. Because of that a new hypothesis arise, which 
postulate that the reducing blood levels of glutamate would 
increase the concentration gradient between brain 
endothelium and blood; thereby favoring the elimination of 
cerebral glutamate. This potential mechanism of 
neuroprotection is called grabbing of blood glutamate. Thus, 
treatment of cerebral ischemia with blood glutamate 
grabbers, could lead to a reduction of cerebral glutamate, 
which could lead to therapeutic implications after cerebral 
ischemia. In this regard, various studies have reported that 
the metabolic reaction mediated by glutamic oxaloacetic 
transaminase (GOT) could be an important neuroprotective 
target in cerebral ischemia. The therapeutic potential 
associated with the GOT is due to the fact that this enzyme, 
using oxaloacetate as co-substrate, is able to metabolize 
glutamate to α-ketoglutarate and aspartate, leading to a 
decrease in blood levels of glutamate. Based on this premise, 
our group demonstrated that administration of oxaloacetate 
induces a reduction in blood glutamate levels through the 
activation of the GOT, which average neuroprotective effects 
in an animal model of cerebral ischemia in rat. However, 
from a clinical point of view, the use of oxaloacetate as a 
glutamate grabber can have important limitations due to 
their potential side effects, because the oxaloacetate 
participates in the Krebs cycle, its high therapeutic dose and 
narrow therapeutic window. 
Cell therapy has emerged as a promising strategy against 
conventional medical treatments because of its many 
potential mechanisms of action, among which the integration 
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of the administered cells in tissues, immunomodulation 
processes or secretion of growth factors. Several cell lines 
have shown beneficial effects in preclinical studies of cerebral 
ischemia, including embryonic stem cells, neural stem cells, 
induced pluripotent stem cells and mesenchymal stem cells 
(MSCs), among others. Of these, MSCs have been described 
as the most suitable. This is because not only they are 
multipotent, but also their immunomodulatory abilities and 
secretion of growth factors, giving them pleiotropic 
mechanisms of action, among them: differentiation into 
neural lineage cells; induction of neurogenesis, angiogenesis 
and synaptogenesis; activation of endogenous processes of 
brain plasticity; regulation of cerebral blood flow; reduced 
apoptosis; immunomodulation of inflammation; and 
increased cell survival, among others. Moreover, several 
preclinical studies of cerebral ischemia in rodents found 
functional recovery and reduced infarct volume. 
For all the above, the combination of mechanisms of 
neuroprotection (by blood glutamate grabbing) and 
neurorepair (mediated by MSCs) constitute a promising 
therapeutic strategy in cerebral ischemia. Therefore, the 
objective of this work was the development of new 
alternatives of blood glutamate grabbers for use in ischemic 
stroke. So we have used two strategies: enzymatic and 
cellular. The enzymatic strategy was based on the use of 
rGOT1 administered individually and combined with a non-
therapeutic dose of oxaloacetate. The cell strategy was to 
express, through cell transfection, the transporter EAAT2 in 
cell lines. For this purpose, two cell lines were used: HEK 
cells (it seeks the neuroprotective effect for blood glutamate 
uptake by EAAT2) and MSCs (dual effect: neuroprotective, by 
uptake of blood glutamate by EAAT2 and neurorepair, by 
endogenous properties of mesenchymal stem cells).  
To test the effectiveness of rGOT1 in decreased of blood 
glutamate and brain glutamate, and then determine the 
protective effect of the enzyme, the study was divided into 
two parts. First, a dose response study in healthy animals 
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was performed in order to determine the most effective dose 
of rGOT1 in reducing blood glutamate. To simulate of 
increase of glutamate observed after cerebral ischemia, 
glutamate was injected, at a dose of 15 mM, in the jugular of 
SD rats. The following doses were tested rGOT1: 6.44 µg/ 
100g, 12.88 µg /100g and 25.76 µg /100g. To determine the 
concentrations of glutamate, the blood samples were 
obtained from the tail vein before glutamate injection and at 
1, 2, 4, 6 and 24 h after glutamate injection. Serum levels 
glutamate were measured by ELISA. The results showed that 
the dose of 12.88 µg /100g rGOT1 was the most effective in 
reducing blood glutamate (p <0.01). In order to determine 
whether the effect of the enzyme could be powered by 
oxaloacetate, rGOT1 dose 12.88 µg /100g was combined 
with a non-therapeutic dose of oxaloacetate (1.5mg /100g). 
The administration of such combination induced a larger 
decrease in blood glutamate (p <0.01). 
The next step was to examine the protective effect of rGOT1 
(12.88 µg/100g) and rGOT1 (12.88 µg /100g) supplemented 
with oxaloacetate (1.5 mg/100g) in SD rats subjected to 
cerebral ischemia by intraluminal filament, compared with 
animals treated oxaloacetate with a dose of 3.5 mg/100g 
(therapeutic dose). To determine the therapeutic capacity of 
the treatments, which were administered immediately after 
reperfusion, the infarct volume was valued by Magnetic 
Resonance image (MRI) and the functional deficit by Cylinder 
Test. Likewise, the reduction of blood glutamate was 
measured by ELISA and GOT activity was determined by 
means of Reflotron GOT, and the reduction of cerebral 
glutamate was measured MRI spectroscopy. The results 
showed that the increase in serum glutamate following 
cerebral ischemia was reduced by treatments: rGOT1 (12.88 
µg/100g), oxaloacetate (3.5 mg/100g) and rGOT1 more 
oxaloacetate (12.88 µg/100g and 1.5mg/100g respectively), 
without significant differences between them. This decrease 
in serum glutamate caused by treatment was associated with 
a reduction in brain glutamate (p <0.05). All treatments 
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induced a decrease in infarct volume at 24 h and 7 d after 
ischemia (p <0.05), with the greatest effect in animals 
treated with rGOT1 + oxaloacetate (p <0.05). In animals 
which were administered rGOT1, the enzymatic activity 
thereof was increased (p <0.01). 
In order to determine the optimal therapeutic window for the 
administration of rGOT1, ischemic rats were also treated 1 h 
after reperfusion. The treatment groups were: rGOT1 (12.88 
µg/100g) and rGOT1 + oxaloacetate (12.88 µg/100 g and 
1.5 mg/100g, respectively). Both treatments caused a 
significant reduction (p <0.05) of blood glutamate levels. 
However, the infarct volume analysis revealed that the 
administration of treatment 1 h after reperfusion has less 
protective effect that the administration right after 
reperfusion. 
As somatosensory test, combination therapy of rGOT1 with 
oxaloacetate is associated with better functional outcome 7 d 
(p <0.05). 
Moreover, to induce expression of EAAT2 in various cell lines 
employ different transfection techniques. By fluorescence 
microscopy and flow cytometry the presence of the YFP 
reporter gene was analyzed to test the efficiency of the 
transfection process of EAAT2. In a first step, different viral 
vectors to try to express the EAAT2 in HEK cells and MSCs 
were used. The results of infection did not show expression 
of YFP in such cells. As a result, other transfection techniques 
were used. On one hand, in MSCs the following techniques 
were tested: calcium phosphate, lipofection and 
electroporation; the latter being offered positive results for 
the expression of EAAT2 and associated YFP. As it regards the 
HEK cells, the expression of EAAT2 and YFP was achieved by 
calcium phosphate transfection. The subsequent selection 
with gentamicin allowed to select those HEK cells that had 
integrated the EAAT2 in its genome. 
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By immunofluorescence and confocal microscopy, we found 
that both HEK as MSCs co-expressing the YFP reporter gene 
and EAAT2. Furthermore, the functionality of EAAT2 gene in 
transfected cells was determined by experiments of 
glutamate uptake. The results of these experiments showed 
that the transfected cells were able to uptake glutamate 
efficiently. To confirm that the uptake was mediated by 
EAAT2, glutamate uptake in combination with specific 
inhibitors of EAAT2, DHK and TBOA, was determined. The 
results of these experiments demonstrated that the use of 
the inhibitors prevented the glutamate uptake in transfected 
cells, confirming that this uptake was mediated by EAAT2. 
Because of MSCs exhibit endogenous neurorepairs properties 
was necessary to determine that the electroporation process 
not change the characteristic of MSCs. To this, the 
expression of specific markers of the phenotype of MSCs 
(CD90 +, CD45- and CD73 +) were analyzed by flow 
cytometry, the angiogenic capacity by matrigel and VEGF 
secretion by ELISA. The results showed no differences 
between the MSC- and MSC+, regarding the above 
mentioned properties. 
Having demonstrated the ability of transfected cells to uptake 
glutamate in vitro, it was necessary to determine their effect 
in vivo. For this, prior to the use of transfected cells in Wistar 
rats subjected to cerebral ischemia, adequate cell dose was 
determined to induce a reduction of blood glutamate. To this 
end, the following experimental groups were analyzed in 
healthy rats: 3.5 mg/100g of oxaloacetate (therapeutic dose, 
positive control), 3x106 HEK-, 3x106 HEK+, 3x106 MSC- and 
3x106 MSC +. Serum glutamate concentration was measured 
by ELISA prior to the administration of treatment and at 1, 3 
and 4 h after administration of the treatment. The results 
showed a reduction in serum glutamate in animals treated 
with oxaloacetate at 1 and 4 h after administration. As for 
the groups treated with cells, administration of 3x106 HEK+ 
induced a decrease in glutamate levels 1 hour after, while 
3x106 MSC+ treated group decreased serum glutamate levels 
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1 and 3 h after administration (all p <0.05). With the aim of 
achieving greater reductions glutamate, two more groups, 
9x106 MSC- and 9x106 MSC+, were analyzed. The results 
showed that in the group treated with 9x106 MSC+ reduces 
glutamate levels at 3 h (p <0.05) respect to the control 
group, but this reduction was not greater than the dose of 
3x106 MSC+. 
Finally, the therapeutic effect of cell lines transfected with 
EAAT2, administered intravenously, in Wistar rats subjected 
to cerebral ischemia by intraluminal filament was studied. To 
determine the beneficial effects of this therapy, infarct 
volume was valued by Magnetic Resonance image (MRI) and 
functional deficits by functional test. Likewise, blood 
glutamate levels were analyzed by ELISA. The following 
study groups were conducted: Vehicle (PBS), oxaloacetate 
(3.5 mg/100g), 3x106 HEK-, 3x106 HEK+, 3x106 MSC-, 3x106 
MSC+, 9x106 MSC- and 9x106 MSC+. Treatments were 
injected into right jugular after reperfussion. Analysis of 
serum glutamate was conducted prior to surgery, 
immediately after reperfusion and 1, 3, 4 and 24 h after 
treatment administration. The results showed a reduction in 
serum glutamate, 1 h after treatment administration, in the 
groups treated with oxaloacetate and transfected cells (p 
<0.05). However, the animals treated with oxaloacetate 
showed a reduction of infarct volume (p <0.05). Other 
groups that induced a reduction of infarct volume were 3x106 
MSC- and 9x106 MSC+ at 7d. As for the functional test, the 
animals treated with oxaloacetate, 3x106 HEK+, 3x106 MSC- 
and 9x106 MSC- functional improvement showed 14 d after 
ischemia. 
Based on all the above results, we conclude that: 
Section I: Analysis of protective effect of rGOT in ischemia 
6. The administration of rGOT1 alone induces a reduction 
in serum and brain glutamate levels, which also 
resulted in a significant reduction in the infarct 
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volume and improvement in the sensorimotor deficit 
after ischemia. 
7. The beneficial effects mediated by rGOT1 were similar 
to those observed with the higher doses of 
oxaloacetate. 
8. Combination of rGOT1 with a low dose of oxaloacetate 
potentiates the therapeutic effect of intravenously 
rGOT1 after ischemia. 
9. The protective effect mediated by administration of 
rGOT1 was observed even when the treatments were 
initiated as soon as 2h after the onset of ischemia. 
10. The robust protection shown by the combination of 
rGOT1 and low doses of oxaloacetate proposes that 
this strategy may represent a valid approach for a 
successful acute-phase stroke treatment. 
 
Section II: Effect of glutamate grabbers cells on ischemic 
damage. 
9. We have optimized a protocol to induce the 
exogenous expression of EAAT2 in mesenchymal stem 
cells and HEK cells. 
10.  We have demonstrated the expression and 
functionality of EAAT2 in mesenchymal stem cells and 
HEK cells. 
11.  The transfection of mesenchymal stem cells does not 
affect the membrane markers analyzed, angiogenic 
capacity or secretion of VEGF. 
12. The administration of transfected cells with EAAT2 is 
able to induce a lowering of serum glutamate levels in 
vivo.  
13. The beneficial effect of mesenchymal stem cells is 
reduced after exogenous expression of EAAT2, which 
limit the use of these cells like a cell grabber. 
14. Blood glutamate cell grabbing do not present better 
benefit than other glutamate grabbers already well 
described, as their protective effect is not higher than 
oxaloacetate. 
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15. Results with EAAT2 transfected cells have confirmed 
the effect of blood glutamate reduction as an efficient 
alternative protective strategy against ischemic 
stroke. 
16. Our results demonstrate that the transfection of 
mesenchymal stem cells with functional EAAT2 may 
confer their a dual therapeutic action: neuroprotection 
and neurorepair. 
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